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 1. Einleitung 
1.1. Phenylketonurie und Defekt der Phenylalaninhydroxlase 
Die Phenylketonurie (PKU; OMIM #261600) ist mit einer Inzidenz von 1:5.062 (Nennstiel-
Ratzel, U et al. 2010) bis heute die häufigste Aminosäure-Stoffwechselstörung der europä-
isch abstammenden Bevölkerung (Zschocke, J 2003). Der Erkrankung liegt eine Störung der 
Hydroxylierungsreaktion der essentiellen Aminosäure Phenylalanin zu Tyrosin durch die 
Phenylalaninhydroxylase (PAH) zu Grunde. Bereits in den 30er Jahren des vergangenen 
Jahrhunderts konnte Dr. Asbjørn Følling durch eine einfache Methode zum Nachweis von 
Ketonkörpern im Urin bei Patienten mit mentaler Entwicklungsretardierung das Ausschei-
dungsprodukt Phenylbrenztraubensäure nachweisen (Følling, A 1934). Hiermit wurde nicht 
nur eine Veränderung im Phenylalaninstoffwechsel, sondern auch die Ursache der menta-
len Retardierung dieser Patienten aufgeklärt und damit die Phenylketonurie entdeckt 
(Jervis, GA 1953). Unbehandelt äußert sich die Erkrankung in schweren neurologischen 
Störungen mit psychomotorischer Retardierung, Intelligenzverlust und Autoaggression. Dr. 
Horst Bickel konnte 1952 zeigen, dass die Durchführung einer streng phenylalaninarmen 
Diät zu einer Besserung der Symptome, bzw. bei präsymptomatischer Durchführung zu 
einem Ausbleiben des Intelligenzverlustes führt (Bickel, H et al. 1953; Bickel, H et al. 1954). 
Aus dieser Beobachtung entstand die Idee zur Entwicklung einer Neugeborenenreihenun-
tersuchung zur Identifikation von Patienten mit Phenylketonurie bereits in den ersten Le-
benstagen. Diese wurde in den 60er Jahren umgesetzt, als Dr. Robert Guthrie auf der Basis 
eines bakteriologischen Hemmtestes eine einfache, universell anwendbare Methode zum 
Nachweis erhöhter Phenylalaninkonzentrationen im Blut entwickelte. Seither gilt die Phe-
nylketonurie als der Prototyp einer behandelbaren genetischen Erkrankung (Muntau, AC et 
al. 2010). 
Zwei Formen der Phenylketonurie werden unterschieden. 98 % der Patienten mit Hyper-
phenylalaninämie tragen eine Mutation im Phenylalaninhydroxylase (PAH)-Gen. In 2 % der 
Fälle liegt der Hyperphenylalaninämie ein Defekt der Biosynthese oder der Regeneration 
des natürlichen Kofaktors der PAH, 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4), zu 
Grunde (atypische Phenylketonurie) (Thöny, B et al. 2000; Scriver, CR et al. 2001). 
Heute sind 627 verschiedene krankheitsverursachende Mutationen im PAH-Gen bekannt 
(www.pahdb.mcgill.ca, www.hgmd.org)(Scriver, CR et al. 2000). Bei 80 % dieser Mutatio-
nen handelt es sich um missense Mutationen, darüber hinaus wurden Deletionen, Insertio-
nen, Stop-Mutationen, Splicing Varianten und Intron-Mutationen identifiziert. Die daraus 
resultierenden klinischen Phänotypen der Erkrankung werden auf der Grundlage der 
prätherapeutischen Phenylalaninkonzentrationen im Blut klassifiziert (Empfehlungen der 
Arbeitsgemeinschaft für Pädiatrische Stoffwechselerkrankungen (APS)): i) Klassische Phe-
nylketonurie (> 1200 µmol/l), ii) Milde Phenylketonurie (600-1200 µmol/l) und iii) Milde 
Hyperphenylalaninämie (120-600 µmol/l). Aus dieser Einteilung resultieren therapeutische 
Empfehlungen. Während Patienten mit einer Phenylalaninkonzentration im Blut > 600 
µmol/l, also einer milden oder klassischen Form der Phenylketonurie, lebensbegleitend eine 
streng phenylalaninarme Diät einhalten müssen, um Intelligenzeinbußen und das Auftreten 
neurologischer Symptome zu verhindern, können Patienten mit Milder Hyperphenylala-
ninämie auf eine eiweißarme Diät verzichten (Weglage, J et al. 2001). Etwa 69 % aller Pati-
enten in Deutschland sind Träger von Mutationen, die zu einer der beiden milderen Formen 
der Erkrankung führen. 
Im Jahr 1999 machte die Arbeitsgruppe um Kure et al. eine interessante Entdeckung. 
Pharmakologische Konzentrationen des natürlichen Kofaktors der Phenylalaninhydroxylase, 
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 BH4, führten bei vier Patienten mit Mutationen im PAH-Gen ohne Mangel des Kofaktors 
BH4 zu einer Reduktion der Phenylalaninkonzentration im Blut (Kure, S et al. 1999). Weite-
re Studien haben gezeigt, dass BH4 bei Patienten mit milderen Formen der PAH-Defizienz 
die Phenylalaninkonzentration im Blut senkt, die Enzymaktivität in vivo steigert und die 
diätetische Eiweißtoleranz deutlich erhöht (Muntau, AC et al. 2002). Damit wurde ein neuer 
klinischer Phänotyp der Phenylketonurie, der BH4-responsive Defekt der PAH, definiert. Im 
Rahmen weiterer klinischer Studien konnten Wirksamkeit und Sicherheit des Kofaktors 
nachgewiesen werden (Levy, HL et al. 2007; Lee, P et al. 2008; Trefz, FK et al. 2009) und 
2007 (FDA) und 2008 (EMEA) wurde Sapropterindihydrochlorid, die synthetisch hergestell-
te Form des Kofaktors, als orphan drug zur Therapie der Phenylketonurie durch BH4-
responsiven Defekt der PAH zugelassen (Muntau, AC et al. 2002; Levy, HL et al. 2007; 
Trefz, FK et al. 2009). 
 
1.2. Die Biochemie des Phenylalanin-Stoffwechsels 
Phenylalanin ist eine essentielle Aminosäure im menschlichen Stoffwechsel. Die aromati-
sche Aminosäure wird über eiweißhaltige Nahrungsmittel aufgenommen. Im weiteren 
Stoffwechsel wird Phenylalanin zur aromatische Aminosäure Tyrosin hydroxyliert, die zur 
Bildung des biogenen Amins Dopamin und der Katecholamine Noradrenalin und Adrenalin 
benötigt wird. Außerdem wird Tyrosin zur weiteren Synthese des Hautpigments Melanin 
benötigt (Abb. 1). 
 
Abb. 1. 
 
Abb. 1. Tyrosin wird in weiteren enzymatisch katalysierten Reaktionen zu Melanin und dem biogenen Amin Dopamin und der 
Katecholamine Noradrenalin und Adrenalin verstoffwechselt. 
 
Die Hydroxylierungsreaktion von Phenylalanin zu Tyrosin wird durch die Phenylalaninhyd-
roxylase katalysiert und ist der geschwindigkeitsbestimmende Schritt im Phenylalanin-
Metabolismus. Dabei werden ca. 75 % des durch die Nahrung und des Protein-
Katabolismus zur Verfügung gestellten Phenylalanins umgesetzt. Für diese Reaktion wer-
den der natürliche Kofaktor BH4 sowie molekularer Sauerstoff benötigt (Abb. 2).  
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 Abb. 2. 
 
Abb. 2. Die Phenylalaninhydroxylase katalysiert die Hydroxylierung von Phenylalanin zu Tyrosin. Für diese Reaktion wird der 
natürliche Kofaktor Tetrahydrobiopterin (BH4) sowie molekularer Sauerstoff benötigt. 
 
Eine Aktivitätsminderung des Enzyms PAH führt einerseits zum Anstieg der Phenylalanin-
konzentration im Blut, andererseits zu Symptomen des Tyrosin- und Melaninmangels. Dar-
aus ergeben sich die mit der Erkrankung assoziierten Symptome mit heller Hautfarbe, men-
taler und motorischer Entwicklungsretardierung, sowie Autoaggressionen. Im Rahmen der 
Phenylketonurie wird Tyrosin zur essentiellen Aminosäure.  
 
1.3 Enzymatische Funktion und Struktur der Phenylalaninhydroxylase  
Die Phenylalaninhydroxylase ist im Zytosol der Zelle lokalisiert und wird vorwiegend in der 
Leber sowie, in weit geringerem Ausmaß, auch in der Niere exprimiert. Sie gehört mit der 
Tyrosin- und Tryptophanhydroxlase zur Familie der aromatischen Aminosäurehydroxylasen 
(Udenfriend, S et al. 1952; Fitzpatrick, PF 2000). Hierbei handelt es sich um so genannte 
Monoxygenasen, die molekularen Sauerstoff zur Durchführung der katalytischen Reaktion 
benötigen (Kaufman, S et al. 1962). Die PAH ist ein eisenabhängiges Enzym. Wie bei allen 
aromatischen Aminosäurehydroxylasen ist das Eisen-Atom nicht an einen heterozyklischen 
Porphyrinring gebunden. Während der Hydroxylierungsreaktion wird Fe3+ zu Fe2+ reduziert. 
Die für diese Reaktion benötigten Elektronen werden von BH4 zur Verfügung gestellt, wobei 
ein Elektron zur Reduktion von Eisen und ein weiteres zur Bildung von Wasser aus Sauer-
stoff benötigt wird. 
Im Rahmen der Hydroxylierungsreaktion wird der Kofaktor der PAH BH4 zu Dihydrobiopte-
rin (BH2) oxidiert. An der Regeneration des Kofaktors sind die Enzyme Pterin-
Carbinolamin-Dehydratase (PCD) und Dihydropteridin-Reduktase (DHPR) beteiligt (Thöny, 
B et al. 2000; Werner, ER et al. 2011)(Abb. 3). Bei mangelnder DHPR-Aktivität wird chinoi-
des Dihydrobiopterin nicht-enzymatisch zu 7,8-Dihydrobiopterin umgewandelt, ein Substrat 
der Dihydrofolat-Reduktase (DHFR). 
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 Abb. 3. 
 
Abb. 3. 5,6,7,8-Tetrahydrobiopterin (BH4), der natürliche Kofaktor der PAH, wird im Rahmen der Hydroxylierungsreaktion 
über 4a-Hydroxy-Tetrahydrobiopterin durch die Pterin-Carbinolamin-Dehydratase (PCD) zu 6,7[8H]-Dihydrobiopterin umge-
wandelt. Die Dihydropteridin-Reduktase (DHPR) katalysiert die Reduktion von BH2 in Anwesenheit von NADH/H
+ zu BH4 
(Werner, ER et al. 2011). Bei mangelnder DHPR-Aktivität wird chinoides Dihydrobiopterin nicht-enzymatisch zu 7,8-
Dihydrobiopterin umgewandelt, ein Substrat der Dihydrofolat-Reduktase (DHFR).  
 
Strukturell handelt es sich bei der PAH um ein Homotetramer, das als Dimer aus Dimeren 
aufgebaut ist (Kaufman, S 1993) (Abb. 4). Es besteht ein Fließgleichgewicht zwischen Ho-
modimer und Homotetramer in einem Verhältnis von etwa 2/8 (Kappock, TJ et al. 1995). 
Das einzelne Monomer hat eine Größe von 52 kDa und besitzt drei funktionelle Domänen: 
eine N-terminal lokalisierte regulatorische Domäne (Aminosäuren 1-142), eine katalytische 
Domäne (Aminosäuren 143-410) mit den Bindungsstellen für Phenylalanin und BH4 sowie 
eine Oligomerisierungsdomäne (Aminosäuren 411-452). Strukturelle Untersuchungen ha-
ben gezeigt, dass zwischen den einzelnen Untereinheiten und Domänen ein hohes Maß an 
strukturellen Interaktionen besteht (Erlandsen, H et al. 1997; Fusetti, F et al. 1998; Kobe, B 
et al. 1999). 
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Abb. 4A      4B 
Abb. 4. Die PAH als Monomer und Tetramer. A, Das Monomer hat eine Größe von 52 kDa und besitzt drei funktionelle 
Domänen: eine N-terminal lokalisierte regulatorische Domäne (Aminosäuren 1-142, blau), eine katalystische Domäne 
(Aminosäuren 143-410, rot) mit den Bindungsstellen für Phenylalanin und BH4 (gelb) sowie eine Oligomerisierungsdomäne 
(Aminosäuren 411-452, grün) (Erlandsen, H et al. 1997). B, Die funktionelle PAH ist ein Tetramer zusammengesetzt aus vier 
einzelnen Monomeren, ein sogenanntes Dimer aus Dimeren (hellblau und grün sowie magenta und gelb).  
 
Die PAH wird komplex reguliert. Dabei ist die katalytische Aktivität des Enzyms einerseits 
von Phosphorylierungsreaktionen, andererseits von der Bindung des Substrats und des 
natürlichen Kofaktors abhängig (Shiman, R et al. 1994; Shiman, R et al. 1994; Xia, T et al. 
1994). Die Phosphorylierung des Enzyms an der Position Ser16 der regulatorischen Domäne 
wird u.a. über cAMP-abhängige Proteinkinasen gesteuert, wodurch die Aktivität auf das 
Dreifache gesteigert werden kann (Abita, JP et al. 1976). Während die Bindung des 
Substrats Phenylalanin an das Enzym zu einer Aktivierung führt, bewirkt die Bindung des 
natürlichen Kofaktors BH4 die Bildung eines inaktiven PAH-BH4-Komplexes (Shiman, R et al. 
1980; Shiman, R et al. 1982; Shiman, R et al. 1990; Mitnaul, LJ et al. 1995). Es ist bekannt, 
dass die Bindung des Substrats zu konformationellen Veränderungen über das gesamte 
Enzym führt, die Orientierung und Position von gebundenem BH4 (Andersen, OA et al. 2002, 
Andersen, OA et al. 2003) und der regulatorischen Domäne verändern (Stokka, AJ et al. 
2004). BH4 dagegen interagiert mit der N-terminalen autoregulatorischen Sequenz und der 
so genannten pterin binding loop, um einen binären Enzym-BH4-Komplex zu bilden (Solstad, 
T et al. 2003). All diese regulatorischen Mechanismen benötigen ein sehr flexibles Enzym 
und reversible konformationelle Veränderungen, die über das gesamte Enzym kommuniziert 
werden (Gersting, SW et al. 2010). 
 
1.4 Molekulare Mechanismen des Funktionsverlustes der PAH 
Die Entdeckung des neuen klinischen Phänotyps des BH4-responsiven PAH Defektes, bei 
dem pharmakologische Konzentrationen des natürlichen Kofaktors des defekten Enzyms die 
Phenylalaninkonzentration im Blut reduzieren und die Enzymaktivität normalisieren 
(Muntau, AC et al. 2002), führte zu einem Paradigmenwechsel in Bezug auf die klassische 
Sichtweise behandelbarer vererbbarer Stoffwechselerkrankungen und den damit 
verbundenen Funktionsverlust von Proteinen. Zum Zeitpunkt der Zulassung von 
Sapropterindihydrochlorid als orphan drug war die Wirksamkeit im Menschen zwar gut 
belegt, der Wirkmechanismus des neuen Medikamentes jedoch noch nicht verstanden. 
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Frühe Untersuchungen haben gezeigt, dass Mutationen im PAH-Gen zu Störungen der 
Oligomerisierung und zu einem beschleunigten Abbau varianter PAH-Proteine führen 
können (Knappskog, PM et al. 1996; Bjørgo, E et al. 1998; Waters, PJ et al. 1998; Waters, PJ 
et al. 2000; Erlandsen, H et al. 2004; Pey, AL et al. 2004). Diese Beobachtungen führten zu 
der Hypothese, dass die Wirkungsweise des Kofaktors in einer Korrektur der 
Proteinehlfaltung liegt und der Kofaktor somit als Pharmakologisches Chaperon die PAH 
stabilisiert. (Muntau, AC et al. 2002; Waters, PJ 2003; Erlandsen, H et al. 2004; Pey, AL et 
al. 2004). Eines der Ziele unserer Arbeitsgruppe bestand daher darin, den molekularen 
Mechanismus des Funktionsverlusts der PAH und die strukturellen Konsequenzen von 
missense Mutationen im PAH-Gen zu untersuchen, um so die Grundlagen für die 
Erforschung des Wirkmechanismus von BH4 als Pharmakologisches Chaperon zu legen. 
 
1.5. Bestimmung der Phenylalaninhydroxylase-Aktivität – Stand der Forschung 
Zur Bestimmung der PAH-Enzymaktivität stehen verschiedene Methoden zur Verfügung, die 
zumeist eine flüssigchromatographische Trennung des Substrats Phenylalanin vom Produkt 
Tyrosin erforderlich machen. Anschließend wird das Produkt über Radioaktivität oder 
Fluoreszenz detektiert. Ein anderer Ansatz detektiert die Oxidation von NADH bei der 
Regeneration des oxidierten Kofaktors durch Dihydropteridinreduktase und ist somit eine 
indirekte Methode (Andersen, OA et al. 2003). In der Annahme, dass hier sowohl Substrat 
und Kofaktor bei der Katalyse als auch Kofaktor und NAD bei der Kofaktorregeneration in 
stöchiometrischen Verhältnissen umgesetzt werden, kann aus dem NADH-Verbrauch auf die 
Tryrosinproduktion geschlossen werden. Insgesamt sind die bisher verfügbaren 
Messmethoden zeitraubend und ineffizient. Darüber hinaus verfolgen die meisten Methoden 
einen diskontinuierlichen Messansatz, d.h. Endpunktmessungen. Vorraussetzung dafür ist, 
dass eine Reaktion über einen bestimmten Zeitraum stets linear verläuft. Üblicherweise ist 
dies bis zu einem Verbrauch von 10 % des eingesetzten Substrats gewährleistet. Durch 
Veränderungen der experimentellen Bedingungen, z.B. der Substratkonzentration, der 
Temperatur oder des pH-Wertes, kann die Dauer des linearen Reaktionsmechanismus 
jedoch variieren (Copeland, RA 2000).  
Die Standardmethode zur Bestimmung der Aktivität rekombinanter PAH ist ein 
diskontinuierliches Messverfahren, bei der die Enzymaktivität der PAH über eine Minute bei 
verschiedenen Phenylalaninkonzentrationen und einer BH4-Konzentration sowie einer 
Phenylalanin- und verschiedenen BH4-Konzentrationen bestimmt wird. Bei der Analyse von 
Proben aus kultivierten Zellen oder Organen wird die Reaktionszeit des Versuchs auf 30-60 
Minuten ausgeweitet. Nach Ablauf der Reaktionszeit werden Substrat und Produkt über 
Flüssigchromatographie (High Performance Liquid Chromatography, HPLC) getrennt, 
anschließend wird das Produkt mittels Fluoreszenz bei einer Exzitationswellenlänge von 275 
nm und einer Emissionswellenlänge von 305 nm detektiert (Martinez, A et al. 1995; 
Miranda, FF et al. 2002). Diese Methode setzt jedoch voraus, dass die Reaktion auch unter 
veränderten Versuchsbedingungen mit Variation der Substrat- und Kofaktorkonzentrationen 
stets linear verläuft.  
 
 2. Ziele der Arbeit 
Eingehende Kenntnisse zur enzymatischen Funktion der PAH bei unterschiedlichen Sub-
strat- und Kofaktorkonzentrationen sind eine wichtige Voraussetzung für das Verständnis 
des fehlfaltungsbedingten Funktionsverlustes der PAH einerseits und der pharmakologi-
schen Korrektur der Enzymfunktion andererseits. Im Rahmen der durchgeführten Arbeiten 
sollte zunächst ein Standard-Aktivitätstest in unserer Arbeitsgruppe etabliert werden, um 
die enzymkinetischen Parameter der PAH bestimmen zu können. Diese umfassen die Aktivi-
tät (Vmax), die Affinität von Substrat und Kofaktor (S0.5 bzw. Km), die Kooperativität (h), die 
Substrataktivierung und die Substratinhibition. Mit diesem Verfahren sollte die Enzymakti-
vität rekombinant exprimierter und gereinigter Wildtyp-PAH und varianter PAH Proteine 
bestimmt werden, um den Einfluss von missense Mutationen auf die Parameter der spezifi-
schen Aktivität zu untersuchen. In einem nächsten Schritt sollte eine neue fluoreszenzba-
sierte Methode etabliert werden, die eine direkte kontinuierliche Messung der Enzymaktivi-
tät erlaubt. So sollte die PAH-Aktivität bei einem erheblich größeren Bereich an Substrat- 
und Kofaktorkonzentrationen als bisher bestimmt werden, um den optimalen Arbeitsbe-
reich des rekombinanten Proteins zu vermessen und den wechselseitigen Einfluss von Sub-
strat (aktivierend) und Kofaktor (inhibierend) zu analysieren. Darüber hinaus sollten das 
Bindungsverhalten des Enzyms gegenüber dem Kofaktor bei verschiedenen Substratkon-
zentrationen und somit der Einfluss des metabolischen Status auf die Wirkung des pharma-
kologischen Chaperons BH4 untersucht werden. Die an rekombinanten PAH-Proteinen er-
hobenen Ergebnisse sollten in einem weiteren Schritt mit Ergebnissen der Enzymaktivität 
nach stabiler Expression des Wildtyps und varianter PAH-Proteine in einem eukaryoten 
Zellkultursystem unter dem Einfluss verschiedener Substrat- und Kofaktorkonzentrationen 
verglichen und so der Einfluss auf die Menge funktionell aktiver PAH bestimmt werden. 
Schließlich sollten die gewonnenen Erkenntnisse durch Vergleich mit Daten aus BH4-
Belastungstest am Patienten in das humane System übersetzt werden, um so den Einfluss 
von Genotyp und physiologischem bzw. pathologischem metabolischen Status auf die the-
rapeutische Kofaktorwirkung in vivo untersuchen zu können.  
 
3. Ergebnisse eigener wissenschaftlicher Arbeiten 
3.1 Arbeiten zur kumulativen Promotionsleistung 
Gersting, S. W., Kemter, K. F., Staudigl, M., Messing, D. D., Danecka, M. K., Lagler, F. B., 
Sommerhoff, C. P., Roscher, A. A. and Muntau, A. C. (2008) Loss of function in phenylke-
tonuria is caused by impaired molecular motions and conformational instability. American 
Journal of Human Genetics 83(1): 5-17 
 
In dieser ersten Arbeit wurden die molekularen Auswirkungen von Mutationen im PAH-Gen 
auf Struktur und Funktion des rekombinanten PAH-Proteins eingehend untersucht. Das 
experimentelle Vorgehen umfasste die rekombinante Expression und Reinigung der PAH 
sowie die anschließende Analyse von Struktur, Stabilität und Funktion mittels biophysikali-
scher und biochemischer Methoden. Die PAH ist ein Homotetramer, das durch Bindung 
von Substrat und Kofaktor komplex reguliert wird (Mitnaul, LJ et al. 1995). Die Untereinhei-
ten können in drei funktionelle Domänen eingeteilt werden: regulatorische Domäne (Ami-
nosäuren 1-142), katalytische Domäne (143-410) und Oligomerisierungsdomäne (411-452). 
Es wurden 10 missense Mutationen im PAH-Gen ausgewählt, die bei Patienten mit einem 
Ansprechen auf pharmakologische Dosen des BH4-Kofaktors identifiziert wurden. Diese 
Mutationen führen zum Austausch von Aminosäuren in allen drei Domänen. 
10
 Die spezifische Restaktivität varianter PAH war im Vergleich zum Wildtyp-Protein in 6 von 
10 Fällen hoch, eine umfassende Charakterisierung der enzymkinetischen Parameter zeigte 
jedoch Veränderungen der Substrataktivierung und der Kooperativität. Dies deutete bereits 
auf eine veränderte Konformation mit gestörten molekularen Bewegungen hin. Durch Grö-
ßenausschlusschromatographie wurden Veränderungen der Quartärstruktur erfasst, wobei 
sowohl vermehrte Aggregation als auch Störungen im Aufbau des Tetramers beobachtet 
wurden. Bemerkenswert war, dass auch eine Mutation, welche die N-terminale regulatori-
sche Domäne betrifft, zu einer gestörten Oligomerisierung führte, obwohl eine deutliche 
räumliche Trennung zu Strukturen vorliegt, die dieser Funktion zugeordnet werden. Bei 4 
der varianten Enzyme zeigte sich eine reduzierte proteolytische Stabilität gegen Proteinase 
K, die als nicht sequenzspezifische Protease bevorzugt entfaltete strukturelle Bereiche an-
greift. Bei der Untersuchung der thermalen Stabilität mittels differential scanning fluori-
metry zeigten 5 Varianten eine beschleunigte Entfaltung der regulatorischen Domäne. Der 
Einfluss von thermalem Stress auf die Enzymfunktion wurde im Rahmen thermaler Inakti-
vierungsexperimente untersucht. Hier zeigten sich weniger stark ausgeprägte Effekte. Auf-
fällig war jedoch, dass 2 der 3 Varianten, die eine reduzierte Stabilität aufwiesen, nicht der 
katalytischen Domäne zugeordnet waren. 
Die mit biophysikalischen und biochemischen Methoden erhobenen Daten deuteten auf 
eine enge strukturelle Vernetzung der drei funktionellen Domänen der PAH hin. Um die 
beobachteten Fernwirkungen zwischen verschiedenen Domänen strukturell weiter aufzu-
klären, wurden die Aminosäureseitenketten an den von den Mutationen betroffenen Positi-
onen im 3D-Modell analysiert. Hierbei konnten Netzwerke von Aminosäureseitenketten 
identifiziert werden, über die eine Fehlfaltung innerhalb des Proteins, teilweise über alle 
drei Domänen hinweg, kommuniziert werden könnte.  
Zusammenfassend konnten wir mit dieser Arbeit Proteinfehlfaltung als Ursache des mole-
kularen Phänotyps bei PKU nachweisen. Dies führte zu der inzwischen international akzep-
tierten Sichtweise, dass es sich bei der durch missense Mutation induzierten Phenylketonu-
rie um eine Proteinfaltungserkrankung mit loss of function handelt. Von besonderer Bedeu-
tung war die Erkenntnis, dass lokale Austausche von Aminosäureseitenketten zu globalen 
Konformationsänderungen führen, die molekulare Bewegungen behindern, die für die en-
zymologische Funktion des Enzyms essentiell sind. 
Eigener Beitrag zum Artikel 
Im Rahmen dieser Publikation wurde zunächst der weltweit eingeführte state of the art as-
say zur Bestimmung der PAH-Aktivität mittels Flüssigkeitschromatographie und Fluores-
zenzmessung im eigenen Labor etabliert. In einem weiteren Schritt wurden die Enzymakti-
vitäten des rekombinant in E. coli exprimierten Wildtyp-Proteins und der zehn varianten 
Proteine bestimmt. Aus den erhobenen Daten erfolgte anschließend eine umfassende en-
zymkinetische Charakterisierung der PAH Proteine. Schließlich wurden die Ergebnisse in 
Hinblick auf den Einfluss von missense Mutationen auf Aktivität, Konformation und Alloste-
rie des Proteins interpretiert und publiziert.  
 
 
  
11
 Gersting, S. W.*, Staudigl, M.*, Truger, M. S., Messing, D. D., Danecka, M. K., Sommerhoff, 
C. P., Kemter, K. F. and Muntau, A. C. (2010) Activation of phenylalanine hydroxylase in-
duces positive cooperativity toward the natural cofactor. Journal of Biological Chemistry 
285(40): 30686-30697 
* contributed equally 
 
Die PAH unterliegt einer komplexen Regulierung, bei der das Verhältnis des Substrates L-
Phenylalanin zum Kofaktor BH4 über Aktivierung bzw. Inhibierung die Enzymaktivität steu-
ert (Mitnaul, LJ et al. 1995). Bei PKU-Patienten mit PAH-Defekt kommt es zu erhöhten Phe-
nylalaninkonzentrationen im Blut und iatrogen durch die Gabe pharmakologischer Dosen 
des Kofaktors zu Veränderungen der BH4-Konzentration. Mit dem Ziel, den wechselseitigen 
Einfluss von Substrat und Kofaktor auf die Enzymfunktion untersuchen zu können, haben 
wir einen fluoreszenzbasierten Echtzeit-Enzymaktivitätstest entwickelt und validiert, der 
einen hohen Durchsatz und damit die gleichzeitige Analyse verschiedener Einflussfaktoren 
erlaubt. Interessanterweise stellten wir für die kofaktorabhängige Kinetik des über das Sub-
strat aktivierten Enzyms ein kooperatives Verhalten fest, das dem Stand der Wissenschaft 
widersprach. Durch Analyse von mutationsbedingt präaktivierten natürlichen PAH-
Varianten haben wir die konformationelle Umlagerung bei Aktivierung durch das Substrat 
als strukturelle Voraussetzung der kooperativen Bindung des Kofaktors ermittelt. Damit 
konnten wir einen Einfluss der Substrataktivierung des PAH-Proteins auf die Affinität zum 
Kofaktor nachweisen. Diese Ergebnisse sind vor dem Hintergrund, dass PKU-Patienten 
auch unter einer diätetischen Therapie hochnormale bis erhöhte Phenylalaninkonzentratio-
nen im Blut aufweisen, von Bedeutung. Die Bindung und damit die Wirkung von BH4 als 
Pharmakologisches Chaperon ist also vom metabolischen Status abhängig und dieser sollte 
bei der Findung der optimalen Dosis für den Patienten individuell berücksichtigt werden. 
Eigener Beitrag zum Artikel 
Zur Bestimmung des wechselseitigen Einflusses von Substrat und Kofaktor auf die Enzym-
aktivität der PAH wurde im Rahmen dieser Arbeit eine neue fluoreszenbasierte Methode zur 
direkten kontinuierlichen Bestimmung der Enzymaktivität des Wildtyp-Proteins und präak-
tivierter varianter PAH Proteine entwickelt, etabliert und validiert. Nach Anwendung der 
Methode erfolgte für das Wildtyp-Protein und präaktivierte variante Proteine eine enzymki-
netische Charakterisierung. Dies ermöglichte die Analyse des Bindungsverhaltens des 
Kofaktors an das Protein und erlaubte zusätzliche Aussagen über strukturelle Unterschiede 
der Konformationen der PAH unter dem Einfluss von Substrat und Kofaktor. Dabei konnte 
der Effekt der Substrataktivierung der PAH auf die Affinität zum Kofaktor nachgewiesen 
werden.  
Somit wurde ein wichtiger Beitrag zum Verständnis der Auswirkungen der Bindung von 
BH4 unter dem Einfluss von Phenylalanin bzw. dem metabolischen Status auf das PAH-
Protein erbracht. 
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In einer weiteren Arbeit haben wir den wechselseitigen Einfluss von Phenylalanin und BH4 
auf die Funktion der PAH nicht nur am Wildtyp-Protein, sondern auch an PAH-Varianten 
und im Patienten untersucht. Der neu etablierte Enzymaktivitätstest wurde angewendet, um 
Substrat- und Kofaktorkonzentrationen simultan innerhalb der Matrix einer 96-well Platte 
zu variieren. Dabei wurden rekombinant exprimierte Wildtyp- und variante PAH jeweils mit 
Substrat präaktiviert, anschließend wurden Substrat und Kofaktor in unterschiedlichen Ver-
hältnissen zugegeben. Die bioinformatikgestützte Darstellung der Enzymaktivität als drei-
dimensionale Funktion von L-Phenylalanin und BH4 in Form von activity landscapes erlaub-
te eine Bestimmung des optimalen Arbeitsbereichs der PAH. Hierbei zeigte sich, dass vari-
ante PAH nicht nur eine Reduktion der Restaktivität aufweist, sondern es auch zu Verschie-
bungen der für die maximale Aktivität notwendigen Substrat- und Kofaktorkonzentrationen 
kommen kann. Aus diesen Daten lässt sich die Hypothese ableiten, dass eine individuelle 
Anpassung des metabolischen Status, d.h. der therapeutisch angestrebten Phenylalanin-
konzentration im Blut, die Enzymrestfunktion verbessern kann. Dies konnte für zwei der 
häufigsten Mutationen, die mit BH4-Sensitivität assoziiert sind (R261Q und Y414C), durch 
die retrospektive Auswertung von BH4-Belastungstests am Patienten bestätigt werden. Die-
se in vitro und in vivo erhobenen Ergebnisse bilden die Basis für ein Modell, bei dem die 
Funktion der PAH sowohl vom Genotyp als auch vom metabolischen Status in Bezug auf die 
Phenylalaninkonzentration im Blut und von der therapeutischen Einstellung der BH4-
Konzentration abhängt.  
Diese Daten sind für den Patienten von Bedeutung, da sie belegen, dass bei unterschiedli-
chen zugrunde liegenden Mutationen unterschiedliche therapeutisch angestrebte Phe-
nylalaninkonzentrationen und Dosierungen des pharmakologischen Chaperons BH4 mit 
einer optimierten Enzymfunktion und damit Stoffwechseleinstellung einhergehen. 
 
Eigener Beitrag zum Artikel 
In dieser Arbeit wurde der neu etablierte Enzymaktivitätstest angewendet und in einem 
weiteren Schritt automatisiert, um Substrat- und Kofaktorkonzentrationen simultan inner-
halb der Matrix einer 96-well Platte zu variieren. Die dabei gemessene Enzymaktivität wur-
de in Form von activity landscapes dargestellt, um die Funktion der PAH im physiologi-
schen und pathologischen Substratbereich sowie im therapeutischen Kontext der Kofak-
tortherapie zu visualisieren. Dies ermöglichte Aussagen darüber, bei welcher Phenylalanin-
konzentration, also bei welchem metabolischen Status und bei welcher BH4-Konzentration 
bzw. bei welcher Dosierung des Pharmakons die optimale Enzymaktivität erreicht werden 
kann. 
Die dabei erhobenen Ergebnisse wurden in zwei unterschiedliche in vivo Systeme, ein eu-
karyotes Zellkultursystem mit stabiler Expression des PAH-Wildtyps und varianter PAH-
Proteine und die Situation beim Patienten, übersetzt. Dazu wurden zunächst stabil transfi-
zierte Zellen zur Proteinexpression des Wildtyp-Proteins und varianter PAH Proteine herge-
stellt. Anschließend wurde die Enzymaktivität unter dem Einfluss verschiedener Phenylala-
nin- und BH4-Konzentrationen bestimmt. In einem nächsten Schritt wurde eine eingehende 
Literaturrecherche mit retrospektiver Auswertung von BH4-Belastungstests zur Bestim-
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mung des Einflusses verschiedener Phenylalanin- und BH4-Konzentrationen auf die BH4-
Responsivität in Abhängigkeit des Patienten-Genotyps durchgeführt. 
Diese erhobenen Daten und die Translation der Ergebnisse auf in vivo Systeme führten zu 
klinisch relevanten neuen Erkenntnissen.  
 
3.2 Zusätzliche Arbeiten, die im Rahmen der Promotionsarbeit entstanden sind 
Gersting, S. W., Lagler, F. B., Eichinger, A., Kemter, K. F., Danecka, M. K., Messing, D. D.,       
Staudigl, M., Domdey, K. A., Zsifkovits, C., Fingerhut, R., Glossmann, H., Roscher, A. A. 
and Muntau, A. C. (2010) Pah
enu1
 is a mouse model for tetrahydrobiopterin-responsive 
phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological 
chaperone mechanism in vivo. Human Molecular Genetics 19(10): 2039-2049.  
Lagler, F. B., Gersting, S. W., Zsifkovits, C., Steinbacher, A., Eichinger, A., Danecka, M. K.,      
Staudigl, M., Fingerhut, R., Glossmann, H. and Muntau, A. C. (2010) New insights into 
tetrahydrobiopterin pharmacodynamics from Pah
enu1/2
, a mouse model for compound 
heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. 
Biochemical Pharmacology 80(10): 1563-1571.  
 
 4. Schlussbetrachtungen und Ausblick 
Im Rahmen der hier vorgelegten kumulativen Promotionsarbeit haben wir uns eingehend 
mit der Enzymologie der PAH, einem Enzym mit hoher Krankheitsrelevanz beim Menschen, 
beschäftigt. 
Zunächst wurde der weltweit eingeführte state of the art assay zur Bestimmung der PAH-
Aktivität im eigenen Labor etabliert. Er wurde verwendet, um die enzymkinetischen Para-
meter der rekombinant in E. coli exprimierten PAH zu bestimmen. Hierbei wurden das 
Wildtyp-Protein und zehn variante Proteine, die sich von missense Mutationen ableiten, die 
mit dem neuen klinischen Phänotyp der BH4-responsiven PAH assoziiert sind, detailliert 
charakterisiert. Unsere Hypothese, dass es sich bei der PKU um eine Proteinfaltungser-
krankung handeln könnte, wurde durch die Beobachtung gestärkt, dass die o.g. Mutationen 
nahezu ausnahmslos allosterische Parameter verändern, also zu globalen Konformationsän-
derungen des PAH-Proteins führen. 
Obwohl sich das bisherige Testverfahren jahrzehntelang bewährt hat, ist es bezüglich des 
methodischen und zeitlichen Aufwandes und im Hinblick auf den limitierten Bereich an 
Substrat- und Kofaktorkonzentrationen, bei denen die Messung erfolgen kann, mit signifi-
kanten Nachteilen behaftet. Eingehende Kenntnisse zur enzymatischen Funktion der PAH 
bei unterschiedlichen Substrat- und Kofaktorkonzentrationen sind eine wichtige Vorausset-
zung für das Verständnis des fehlfaltungsbedingten Funktionsverlustes der PAH einerseits 
und der pharmakologischen Korrektur der Enzymfunktion andererseits. Um uns diesen Zie-
len zu nähern, haben wir eine neue fluoreszenzbasierte Methode entwickelt und etabliert, 
die eine direkte kontinuierliche Messung der Enzymaktivität erlaubt. So konnte die PAH-
Aktivität in einem 4-fach erweiterten Konzentrationsbereich an Substrat- und Kofaktorkon-
zentrationen als bisher bestimmt werden, um den optimalen Arbeitsbereich des rekombi-
nanten Proteins zu vermessen und den wechselseitigen Einfluss von Substrat (aktivierend) 
und Kofaktor (inhibierend) auf das Enzym zu analysieren. Die Methode wurde automati-
siert, wodurch der Durchsatz (96 Messungen pro Stunde) im Vergleich zum früheren Test-
verfahren (30 Messungen pro 48 Stunden) erheblich erhöht werden konnte. 
Die Anwendung dieser neuen Technologie hat zu drei wesentlichen Ergebnissen geführt. i) 
Wir konnten erstmalig den tatsächlichen optimalen Arbeitsbereich der PAH in Bezug auf 
Substrat- und Kofaktorkonzentration bestimmen; dieser lag in einem deutlich anderen Be-
reich als durch die weniger gut auflösenden bisher verfügbaren Testverfahren vermutet. 
Hierbei konnte die Ratio aus Phenylalanin und BH4, die einerseits Reaktanten sind, ande-
rerseits aber gegenläufig regulierende Effekte auf das Enzym ausüben, als Schlüsselfaktor 
der Funktion identifiziert werden. ii) Die kontinuierliche Messung hat die Analyse des Bin-
dungsverhaltens des Kofaktors an das Protein ermöglicht. Hierdurch konnte erstmalig ge-
zeigt werden, dass zwei unterschiedliche strukturelle Konformationen der PAH mit unter-
schiedlicher Funktion existieren, die den Kofaktor BH4 einmal kooperativ und einmal nicht-
kooperativ binden. iii) Mit Hilfe bioinformatischer Methoden wurden zur dreidimensionalen 
Kartierung der PAH-Aktivität (Wildtyp und variante Proteine) bei unterschiedlichen Sub-
strat- und Kofaktorkonzentrationen activity landscapes erstellt und somit die Funktion der 
PAH im physiologischen und pathologischen Substratbereich sowie im therapeutischen 
Kontext der Kofaktortherapie visualisiert. Hieran lässt sich ablesen, bei welcher Phenylala-
ninkonzentration, also bei welchem metabolischen Status und bei welcher BH4-
Konzentration bzw. bei welcher Dosierung des Pharmakons, bei Vorliegen einer spezifi-
schen Mutation die optimale Enzymaktivität erreicht werden kann. 
In einem weiteren Schritt wurden die an rekombinanten PAH-Proteinen erhobenen Ergeb-
nisse auf zwei unterschiedliche in vivo Systeme, ein eukaryotes Zellkultursystem mit stabi-
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 ler Expression des PAH-Wildtyps und varianter PAH-Proteine und die Situation beim Pati-
enten, übertragen. Wesentliche, klinisch relevante neue Erkenntnisse hieraus waren, dass 
einerseits der Genotyp, andererseits die Phenylalaninkonzentration, also der metabolische 
Status des Patienten, in erheblichem Maße die PAH-Enzymaktivität und das Ansprechen auf 
pharmakologische Dosen des Chaperons BH4 beeinflussen. So kann beispielsweise ein BH4-
Belastungstest beim gleichen Patienten bei unterschiedlichen initialen Phenylalaninkon-
zentrationen zu völlig verschiedenen Ergebnissen (Reduktion der Phenylalaninkonzentrati-
on 0% bzw. 80%) und damit Interpretationen im Hinblick auf die BH4-Responsivität füh-
ren, woraus sich die folgenschwere Festlegung eines lebenslangen Therapieregimes (Diät 
oder pharmakologische Therapie) für den Patienten ergibt. Die hier gewonnenen Ergebnis-
se haben daher sehr dazu beigetragen, dass die Notwendigkeit individualisierter diagnosti-
scher und therapeutischer Konzepte bei der Betreuung von Patienten mit Defekt der PAH 
nun international anerkannt wird. 
Zusammenfassend konnten im Rahmen der hier vorliegenden Promotionsarbeit erhebliche 
technologische Fortschritte auf dem Gebiet der PAH-Enzymologie erreicht werden. In An-
betracht von mehr als 600 Mutationen im PAH-Gen ist es hierdurch möglich geworden, in 
Zukunft die Funktion einer Vielzahl von varianten Proteinen vollständig zu erfassen. Die 
Übertragung der neuen Erkenntnisse auf in vivo-Systeme und der translationale Ansatz mit 
Rückübertragung neuer Sichtweisen auf die Situation bei unseren Patienten hat zu konkre-
ten, weltweit akzeptierten Änderungen in Bezug auf die diagnostischen und therapeuti-
schen Vorgehensweisen geführt. Die Anwendung der hier entwickelten Technologie zur 
Generierung neuer Erkenntnisse bzgl. einer Vielzahl weiterer Mutationen und die system-
biologische Analyse und Aufbereitung dieser Daten wird in Zukunft in erheblichem Maße 
zur Realisierung individualisierter Diagnostik- und Therapiekonzepte beitragen. 
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 5. Zusammenfassung 
Die Phenylketonurie ist seit vielen Jahrzehnten der Prototyp der behandelbaren angebore-
nen Stoffwechselerkrankung. Der Funktionsverlust des Enzyms Phenylalaninhydroxylase 
(PAH) durch Mutationen im PAH-Gen führt zu einem der schwersten neurologischen Phä-
notypen mit nahezu vollständigem Intelligenzverlust. Diese gravierenden Symptome kön-
nen durch eine lebenslange phenylalaninarme Diät fast vollkommen verhindert werden. In 
den letzten Jahren haben neue klinische und wissenschaftliche Erkenntnisse zu einem Pa-
radigmenwechsel bei der Behandlung dieser Erkrankung geführt. Eine Therapie mit Tetra-
hydrobiopterin (BH4), dem natürlichen Kofaktor der PAH, führt in pharmakologischen Do-
sen bei einer signifikanten Subpopulation der Patienten zu einer Normalisierung des bio-
chemischen Phänotyps und der PAH-Enzymaktivität in vivo und wurde 2008 als orphan 
drug zugelassen. Der Wirkungsmechanismus war jedoch zum Zeitpunkt der Zulassung 
noch unklar. Wir und andere stellten die Hypothese auf, dass es sich bei der BH4-
responsiven Phenylketonurie um eine Proteinfaltungserkrankung mit loss of function, also 
Verlust des funktionellen Proteins, handelt. Hierdurch entstand erheblicher neuer For-
schungsbedarf auf dem Gebiet einer Erkrankung, die Ende der 1990er Jahre als vollständig 
erforscht und umfassend verstanden galt. 
Die hier vorliegende Promotionsarbeit befasst sich mit den enzymologischen Aspekten zur 
Phenylketonurie. Wir etablierten zunächst den weltweit anerkannten Standardtest zur Akti-
vitätsbestimmung der PAH und nutzten diesen zur eingehenden Charakterisierung der en-
zymkinetischen Parameter der rekombinanten Wildtyp-PAH und zehn varianter BH4-
responsiver PAH. Die Beobachtung, dass sämtliche Mutationen zu einer Veränderung der 
allosterischen Parameter der PAH, also zu globalen Konformationsänderungen im Enzym 
führen, war ein erster Beleg für die Richtigkeit der Proteinfehlfaltungshypothese, die im 
Rahmen anderer Projekte der Arbeitsgruppe weiter verfolgt wurde.  
In einem zweiten Teil der Arbeit wurde ein neues fluoreszenzbasiertes Verfahren zur direk-
ten kontinuierlichen Messung der Enzymaktivität entwickelt, etabliert und automatisiert. 
Hierdurch konnte die Funktionsweise des Enzyms, insbesondere in Abhängigkeit von Sub-
strat und Kofaktor, erschöpfend untersucht und ihr Funktionsoptimum bestimmt werden. 
Die Ergebnisse wurden mit Hilfe bioinformatischer Methoden als dreidimensionale activity 
landscapes visualisiert. 
Der abschließende Projektanteil beschäftigt sich mit der Übertragung der experimentellen 
Ergebnisse auf ein stabil transfiziertes eukaryotes Zellkultursystem und die Anwendung der 
gewonnenen Sichtweisen beim Patienten. Wesentliche neue Erkenntnisse hieraus waren, 
dass der Genotyp, der metabolische Status des Patienten, also die Phenylalaninkonzentrati-
on im Blut, und die Dosis des verabreichten Medikaments BH4 einen wechselseitigen Ein-
fluss auf die enzymologische Funktion des PAH-Proteins ausüben. 
Heute gilt die Phenylketonurie als Prototyp der genetisch bedingten Proteinfaltungserkran-
kung mit loss of function und BH4 ist das erste pharmakologische Chaperon auf dem Markt. 
Unsere grundlagenorientierten Untersuchungen am rekombinanten PAH-Protein und die 
translationale Sichtweise mit Übertragung der Ergebnisse auf geeignete in vivo-Systeme 
und auf den Patienten haben zu international sichtbaren Veränderungen in Bezug auf indi-
vidualisierte diagnostische und therapeutische Konzepte beim Patienten mit BH4-
responsiver Phenylketonurie geführt. 
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 6. Summary 
For many years, phenylketonuria has been the prototype of a treatable inborn error of me-
tabolism. Mutations in the phenylalanine hydroxylase (PAH) gene with a loss-of-function 
molecular phenotype  result in severe neurological symptoms with near to complete loss of 
intelligence. A lifelong diet can prevent this severe phenotype almost completely. Recent 
clinical and experimental findings have led to a paradigm shift in the treatment of this dis-
ease. In a significant number of patients, pharmacological doses of tetrahydrobiopterin 
(BH4), which is the natural cofactor of the enzyme, lead to a normalization of the biochemi-
cal phenotype and PAH enzyme activity in vivo. In 2008, BH4 was approved as an orphan 
drug in the treatment of phenylketonuria. Yet at the time of approval, the molecular mode of 
action had not been elucidated. We and others hypothesized that BH4-responsive phenylke-
tonuria is a protein misfolding disorder leading to a loss of the functionally active enzyme. 
Consequently, new research projects were needed and had to evolve on a disease that was 
thought to be completely understood already by the end of the 90’s.  
The doctoral thesis presented here covers aspects of basic research on enzyme function in 
phenylketonuria. First, a standard PAH activity assay was established to determine enzyme 
kinetic parameters of recombinant wild-type PAH and ten variant PAH proteins associated 
with BH4-responsiveness. Initial observations, that most mutations lead to changes in en-
zyme allostery and thus to global conformational changes in the enzyme, corroborated the 
hypothesis that phenylketonuria is a protein misfolding disorder with loss-of-function. Se-
cond, a new fluorescence-based method for the direct continuous measurement of enzyme 
activity was developed, established and automated. It was thus possible to analyze sub-
strate- and cofactor-dependent enzyme function as well as the range of substrate and cofac-
tor concentrations leading to optimal enzyme function. The results were visualized as three-
dimensional activity landscapes by means of bioinformatics.  
Finally, these experimental results were translated into a stably transfected eukaryotic cell 
line and compared with data from patients with BH4-responsiveness. The finding of an im-
pact of genotype, metabolic state with respect to blood phenylalanine, and BH4-dosage pro-
vided substantial new insight into diagnostics and therapy of PAH deficiency. 
Today, phenylketonuria is the prototype of a genetic disease leading to protein misfolding 
with loss-of-function. Furthermore, BH4 is the first pharmacological chaperone available on 
the market. Our basic research on the recombinant PAH protein and its translation into in 
vivo-systems as well as to the patient has paved the way for a personalized medicine ap-
proach for this monogenic trait. 
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ARTICLELoss of Function in Phenylketonuria
Is Caused by Impaired Molecular Motions
and Conformational Instability
Søren W. Gersting,1 Kristina F. Kemter,1 Michael Staudigl,1 Dunja D. Messing,1 Marta K. Danecka,1
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A signiﬁcant share of patients with phenylalanine hydroxylase (PAH) deﬁciency beneﬁts from pharmacological doses of tetrahydrobiop-
terin (BH4), the natural PAH cofactor. Phenylketonuria (PKU) is hypothesized to be a conformational disease, with loss of function due to
protein destabilization, and the restoration of enzyme function that is observed in BH4 treatment might be transmitted by correction of
protein misfolding. To elucidate the molecular basis of functional impairment in PAH deﬁciency, we investigated the impact of ten PAH
gene mutations identiﬁed in patients with BH4-responsiveness on enzyme kinetics, stability, and conformation of the protein (F55L,
I65S, H170Q, P275L, A300S, S310Y, P314S, R408W, Y414C, Y417H). Residual enzyme activity was generally high, but allostery was dis-
turbed in almost all cases and pointed to altered protein conformation. This was conﬁrmed by reduced proteolytic stability, impaired
tetramer assembly or aggregation, increased hydrophobicity, and accelerated thermal unfolding—with particular impact on the regula-
tory domain—observed in most variants. Three-dimensional modeling revealed the involvement of functionally relevant amino acid
networks that may communicate misfolding throughout the protein. Our results substantiate the view that PAH deﬁciency is a pro-
tein-misfolding disease in which global conformational changes hinder molecular motions essential for physiological enzyme function.
Thus, PKU has evolved from a model of a genetic disease that leads to severe neurological impairment to a model of a treatable protein-
folding disease with loss of function.Introduction
Deﬁciency of phenylalanine hydroxylase (PAH; EC
1.14.16.1) causes phenylketonuria (PKU [MIM 261600])
and is themost common inborn error of amino acidmetab-
olism in European-descended populations. Since the intro-
duction of a dietary treatment ﬁfty years ago, PKU has been
the prototype for a treatable genetic disease and, later, for
genetic screening inhumanpopulations.1 The recent recog-
nition of a new pharmacologically treatable phenotype of
PAH deﬁciency challenged the classical view of hereditary
diseases that result in loss of enzyme function. We previ-
ously showed that a signiﬁcant share of PKU patients re-
sponds to oral administration of the natural PAH cofactor
(tetrahydrobiopterin, BH4) although these individuals do
not display biochemical evidence of BH4 deﬁciency. The
treatment reduces blood phenylalanine concentrations,
restores enzyme activity in vivo, and signiﬁcantly increases
dietary-protein tolerance.2 Some authors proposed that
restoration of enzyme function observed under treatment
with pharmacological doses of BH4 is transmitted by correc-
tion of PAH misfolding.2–5
About 80% of all mutations in the PAH gene are
missense, and experimental data on the conformational
impact of single amino acid replacements on allostery, sta-
bility, and folding of the PAH protein is scarce. Because the
crystal structure of full-length PAH has not yet been com-
pletely solved,6–8 a composite model is commonly usedfor 3D structural analysis.9 PAH is a homotetrameric
enzyme, with each subunit composed of three functional
domains: the N-terminal regulatory domain (residues
1–142); the catalytic domain (residues 143–410), which
includes binding sites for substrate and cofactor; and the
oligomerization domain at the C terminus (residues 411–
452). There is a high degree of structural interplay between
the single domains and the subunits, respectively.6–8,10–13
Substrate (L-phenylalanine) and cofactor binding induce
conformational changes, which are transmitted through
networks of side-chain interactions.14,15 This is the basis
for homotropic allostery that allows for ﬁne-tuned regula-
tion of PAH enzyme activity comprising substrate activa-
tion, modulation of oligomerization, and the afﬁnity to
substrate and cofactor.3,4,12,15 We hypothesized that the
structural ﬂexibility of PAH permits gross conformational
changes required for enzyme function and thus renders
the enzyme susceptible to protein misfolding. This view
was supported by previous studies demonstrating dis-
turbed oligomerization and accelerated degradation of
some variant PAH proteins.3,4,16–19 However, only little is
known about the structural mechanisms leading to loss
of function in phenylketonuria and in other inherited
diseases that exhibit loss-of-function pathogenesis.
The aim of this study, therefore, was to elucidate the
molecular basis of loss of function in PKU. The impact of
single side-chain replacements associated with BH4-re-
sponsiveness on function and conformational stability of1Department of Molecular Pediatrics, Children’s Research Center, Dr. von Hauner Children’s Hospital, Ludwig Maximilians University, 80337 Munich,
Germany; 2Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, 6020 Innsbruck, Austria; 3Department
of Clinical Chemistry and Clinical Biochemistry, Surgical Clinic, Ludwig Maximilians University, 80337 Munich, Germany
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the PAH protein was analyzed on the basis of enzyme
kinetics, oligomerization, limited proteolysis, thermal in-
activation, thermal unfolding, and 3D structural model-
ing. The mutations analyzed in this study caused pleiotro-
pic effects. Residual enzyme activity was generally high,
but allostery was disturbed in almost all cases and pointed
to altered protein conformation. Reduced proteolytic
stability of most variants, impaired tetramer assembly or
aggregation, increased hydrophobicity, and accelerated
thermal unfolding with particular impact on the regula-
tory domain corroborated the hypothesis of protein mis-
folding. To explain the remote effects on structure and
function that were observed, we propose a model of pro-
tein misfolding as communicated throughout the protein
by disruption of functional networks due to single amino
acid replacements.
In the past twenty years, scientists have made signiﬁcant
efforts to identify a consistent relationship between the
PAH genotype, in vitro residual enzyme activities, and
the clinical phenotype.20–22 A recent report from Pey and
colleagues in this journal marked a breakthrough by open-
ing the view on global conformation of PAH.23 Using com-
putational analyses, they predicted conclusive correlations
between the mutational energetic impact on the protein
and the clinical phenotype. Our results now provide exper-
imental evidence and new insights into how PAHmissense
mutations induce conformational protein destabilization
and loss of PAH function.
Material and Methods
Subjects and Mutations
In a previous study, we identiﬁedﬁve unrelatedpatients bearing six
mutations in the PAH gene that have not yet been characterized in
vitro.2 Three individualswere classiﬁedashavingmildPKU(plasma
phenylalanine concentrations in the absence of treatment ex-
ceeded 600 mmol/l but do not reach values higher than 1200
Figure 1. Structural Localization of PAH Missense
Mutations Analyzed
The PAH monomer, shown as a ribbon representation, is com-
posed of three functional domains: the N-terminal regulatory
domain (residues 19–142, blue), the central catalytic domain
(residues 143–410, red), and the C-terminal oligomerization
domain (residues 411–452, green). The active-site iron (silver
sphere) and the cofactor (orange stick model) are shown.
Amino acid residues affected by mutations are shown as stick
models.
mmol/l): patient 1, a Turkish girl born to consanguineous par-
ents; patient 2, a German girl born to nonconsanguineous
parents; andpatient5, aTurkishboyborntoconsanguineouspar-
ents. Patient 3, a German girl, and patient 4, a female German
newborn, were classiﬁed as having mild hyperphenylalanine-
mia, with plasma phenylalanine concentrations consistently
below 600 mmol/l on an unrestricted diet. In all patients, hyper-
phenylalaninemia had been detected by newborn-screening
programs, and BH4-responsiveness was subsequently demon-
strated in an extended BH4-loading test.
2 BH4 deﬁciency due to ge-
netic disorders of biosynthesis or regeneration of the cofactor had
been ruled out in all cases by the determination of urinary pterins
and the activity of dihydropteridin reductase in erythrocytes. We
obtained written informed consent for genotyping from the fami-
lies. Mutations and clinical phenotypes of the individual patients
are summarized in Table S1. The structural localization of muta-
tions characterized in this study was mapped to the composite
model of a PAH monomer (Figure 1). The mutations were located
in the regulatory domain (F55L, I65S), in the catalytic domain
(H170Q, P275L, A300S, S310Y, P314S, R408W), or in the dimeriza-
tion motif of the oligomerization domain (Y414C, Y417H).
Plasmid Constructs and Site-Directed Mutagenesis
The cDNA of human phenylalanine hydroxylase (ESTclone obtained
from imaGenes, formerly RZPD, Germany) was cloned into the
pMAL-c2E expression vector (New England Biolabs) encoding an
N-terminal MBP (maltose-binding protein) tag and an enteroki-
nase cleavage site. PAH mutants were constructed with the use
of the QuikChange site-directed mutagenesis kit (Stratagene). Au-
thenticity of the mutagenesis was veriﬁed by DNA sequencing.
Expression and Puriﬁcation
Expression plasmids were transformed into E. coli DH5a. Bacteria
were grown to midexponential phase at 37C, and overexpression
of wild-type and variant MBP-PAH fusion proteins was induced
with 0.3 mM isopropylthio-b-D-galactoside (IPTG). MBP-PAH
fusion proteins were more prone to form high-molecular-weight
aggregates at two hours of induction than they were at longer in-
duction periods, but the relative recovery of the tetrameric and the
dimeric form was similar (own and previous observations24). To
avoid artiﬁcial formation of aggregated PAH, we chose an induc-
tion time of 20 hr. Proteins were puriﬁed on A¨KTAxpress (GE
Healthcare) at 4C by afﬁnity chromatography (amylose resin,
New England Biolabs) as described previously,25 followed by
size-exclusion chromatography with a HiLoad 16/60 Superdex
200 column (GE Healthcare). The isolated tetrameric fusion pro-
teins were collected, and protein concentrations were determined
spectrophotometrically with the use of the absorption coefﬁcient
A280,
25 or the dye-binding Bradford assay.6 The American Journal of Human Genetics 83, 5–17, July 2008
It was previously shown that the MBP tag does not signiﬁcantly
affect PAH enzyme activity, kinetic parameters, or the oligomeric
state of the protein.16,17,25–27 Moreover, a comparative analysis
of limited proteolysis, thermal inactivation, and thermal denatur-
ation with the fusion protein and the cleaved PAH protein
revealed no signiﬁcant difference (data not shown).
Analysis of Oligomerization
Oligomerization proﬁles were obtained by size-exclusion chroma-
tography, and peaks corresponding to aggregated forms, tetramers,
dimers, and monomers were determined with the use of LMW
and HMW gel-ﬁltration calibration kits (GE-Healthcare). Relative
amounts of the different oligomeric states were calculated by
deconvolution of the chromatograms with the use of the ACD/
ChromManager software (Advanced Chemistry Development).
Blue dextran was used for determination of the void volume
(V0, 45.3 ml).
PAH-Activity Assay
PAH activity was determined as previously described.25,28 Tetra-
meric wild-type or variant MBP-PAH (0.01 mg/ml) was preincu-
bated with the L-phenylalanine (L-Phe) substrate for 5 min at
25C in a standard reaction buffer containing 15 mM Na HEPES,
pH 7.3 and 1 mg/ml catalase. After the addition of 10 mM ferrous
ammonium sulfate and an additional incubation of 1 min, the
reaction was initiated with BH4 (6[R]-L-erythro-5,6,7,8-tetrahydro-
biopterin, Cayman Chemicals) stabilized in 2 mM dithiothreitol
(DTT). Kinetic parameters were determined at standard L-Phe con-
centration (1 mM) with variable cofactor concentrations (0–704.1
mM BH4) or at standard BH4 concentration (75 mM) and variable
L-Phe concentrations (0–1 mM), respectively. Because of early sub-
strate inhibition, L-Phe concentrations were restricted to 0–250 mM
for P314S and to 0–500 mM for Y414C and Y417H, respectively. To
determine the level of substrate activation, a preincubation with
the substrate was omitted and the reaction was triggered by simul-
taneous addition of 1 mM L-Phe and 75 mM BH4. All concentra-
tions mentioned refer to the ﬁnal concentration in a 100 ml
reaction mixture. The amount of the L-tyrosin (L-Tyr) product
formed after 1 min was measured by HPLC and assayed as tripli-
cates. Steady-state kinetic parameters of three independent exper-
iments were calculated by nonlinear regression analysis with the
use of GraphPad Prism 4.0c (GraphPad Software). Enzyme kinetic
parameters at variable substrate concentrations displayed cooper-
ativity and were calculated with the Hill equation. Enzyme kinetic
parameters at variable cofactor concentrations were calculated
with theMichaelis-Menten equation or with themodiﬁedMichae-
lis-Menten equation29 in the case of cofactor inhibition (WT,
F55L, I65S, P314S, Y417H). All experimental data were conﬁrmed
by repeated analyses of different protein puriﬁcations.
Limited Proteolysis by Proteinase K
The puriﬁed tetramericMBP-PAH fusion proteins of wild-type PAH
and its variant forms were digested with proteinase K at 37C
in a buffer containing 20 mM Na HEPES, 200 mM NaCl, and
38.4 mM DTT at pH 7.0. Stocks of proteinase K and MBP-PAH
were prepared in 20 mM Na HEPES, 200 mM NaCl, pH 7.0 at ﬁnal
concentrations of 1 mg/ml and 1 mg/ml, respectively, and mixed
at protease to substrate ratio of 1:5000 by weight. Proteolysis was
terminated at 5, 10, 15, 20, 30, 60, 90, and 120 min time points
by addition of the inhibitor phenylmethylsulphonyl ﬂuoride
(PMSF) at a ﬁnal concentration of 4 mM. The reaction mixtureswere subjected to SDS-PAGE under reducing conditions with
4%–12% gradient polyacrylamide gels (Invitrogen). The pattern
of proteolysis was monitored by immunoblotting. MBP-PAH
fusion proteins and their proteolytic fragments were detected by
mouse monoclonal anti-phenylalanine hydroxylase IgG1 (PH8,
Calbiochem, 1:2000 dilution) and alkaline phosphatase conju-
gated anti-mouse IgG (Promega, 1:7500 dilution). Bound anti-
bodies were visualized by chemiluminescence with the CDP-Star
substrate (Roche) for alkaline phosphatase. Chemiluminescence
was monitored with the DIANA III imaging system, and the result-
ing protein bands were quantiﬁed by AIDA-software (Raytest). The
densitometry data of quadruplicate assays of one protein puriﬁca-
tion were normalized to the band corresponding to intact MBP-
PAH fusion protein and analyzed by nonlinear curve ﬁtting of
single exponential function in the case of the fusion protein.
The formation of the PAH fragment upon cleavage of the fusion
protein and subsequent degradation of the PAH fragment was
determined by nonlinear curve ﬁtting of a double exponential
‘‘Bateman function’’:
Y ¼ C3 Ki
Ki  Ke3

eKe 3 t  eKi 3 t
in which Y is the amount of the PAH protein; C is the theoretical
amount of the MBP-PAH fusion protein; Ki and Ke are the rate
constants for invasion and elimination of the PAH fragment,
respectively; and t is the incubation time.
Thermal Inactivation
Thermal inactivation of wild-type and variantMBP-PAHwas deter-
mined by analysis of the decay of enzyme activity as a function
of temperature. Aliquots of protein (1 mg/ml) were incubated in
20mMNaHEPES, 200mMNaCl, pH 7.0 for 10 min at 22 different
temperatures ranging from 20C to 75C and then chilled on ice.
PAH enzyme activity was subsequently measured as described
above. Residual activities were normalized to initial enzyme activ-
ity without incubation. Data points were subjected to nonlinear
regression analysis, and midpoints of thermal inactivation (Tm)
at 50% residual activity observed in three independent experi-
ments were calculated with the use of GraphPad Prism 4.0c with
the Boltzmann sigmoidal ﬁt (GraphPad Software).
Thermal Denaturation
Fluorescence measurements were performed on a Cary Eclipse
ﬂuorescence spectrophotometer equipped with a temperature-
controlled Peltier multicell holder (Varian). Samples contained
MBP-PAH fusion proteins (6 mM PAH subunit) in 20 mM Na
HEPES, 200 mM NaCl, pH 7.0, 10 mM ferrous ammonium sulfate,
and 1 mM DTT. Thermal denaturation was monitored by the fol-
lowing of changes in 8-anilino-1-naphtalenesulfonic acid (ANS;
Sigma Aldrich)-ﬂuorescence emission (excitation at 395 nm and
emission at 500 nm, 5.0/10.0 nm slit widths). Thermal denatur-
ation was performed at a rate of 1.2C/min in a 25–85C range.
Thermal denaturation curves were obtained by the plotting of
ﬂuorescence intensities against temperature. The phase transitions
observed in three independent experiments were determined, and
the respective transition midpoints were calculated by differentia-
tion of the increasing part of the curves. Signiﬁcances for the
differences between the wild-type and the variants were calculated
by two-tailed Student’s t test. Thermal denaturation of the MBP
protein occurs at temperatures above 62C, as previously shown30
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denaturation did not interfere with the unfolding curves of the
PAH protein for ANS ﬂuorescence.
Structural Analyses and Figure Preparation
A composite model of the 3D structure (PDB codes 1PAH, 1PHZ,
2PHM, 2PAH, 3PAH, 1J8T, and 1J8U) of tetrameric PAH was
constructed with the use of the DeepView/Swiss-PdbViewer.31 In
the presence of hydrogen atoms, H bonds were computed with
the following constraints: 1.2–2.76 A˚ distance, 120 angles.
When hydrogen atoms were absent, H bonds were computed
with the following constraints: 2.35–3.2 A˚ distance, 90 angles.
Figures were prepared with the use of Visual Molecular Dynamics
software.32
Figure 2. PAH Mutations in All Three Domains Can Lead to
Aggregation or Impaired Tetramer Assembly
Oligomerization profiles of wild-type and variant PAH were
determined by size-exclusion chromatography. Chromatograms
of variant PAH were normalized to the tetramer peak of the
wild-type. Arrows mark the elution volumes of soluble aggre-
gates (45 to 47 ml), tetramers (56 ml), dimers (63 ml), and
monomers (71 ml).
(A) Profiles of variants arising from mutations located in the
regulatory domain (R). I65S showed increased amounts of di-
mers, whereas F55L was almost exclusively eluted as tetramers.
(B) Profiles of variants arising from mutations located in the
catalytic domain (C). S310Y and R408W eluted as high-molec-
ular-weight aggregates without any detectable tetramers. The
variants H170Q, P275L, A300S, and P314S eluted mainly in
the tetrameric form. For P275L, two additional peaks of higher
molecular weight were detected.
(C) Profiles of variants arising from mutations mapping to the
dimerization motif of the oligomerization domain (O). Y417H
showed significant amounts of monomers and increased
amounts of dimers, whereas Y414C showed only tetramers.
Results
Disturbed Oligomerization Manifests
as Aggregation or Impaired Tetramer Assembly
Wild-type PAH and ten variant forms of PAH were puri-
ﬁed by afﬁnity chromatography with subsequent size-
exclusion chromatography, and oligomeric states were
quantiﬁed by deconvolution analysis (Figure 2 and
Table 1). Wild-type PAH was eluted mainly in the tetra-
meric form (86.2%), with a small amount of dimers
(13.8%). Five variant PAH proteins (F55L, H170Q,
A300S, P314S, Y414C) that mapped to all three
domains showed elution proﬁles similar to that of
wild-type with minor changes of the dimer-tetramer
equilibrium. The remaining variants displayed dis-
turbed oligomerization, with only one mutant residue
(Y417H) mapping to the oligomerization domain.
Impaired tetramer assembly was observed for the I65S
mutation located in the regulatory domain and the
Y417H mutation located in the dimerization motif
of the oligomerization domain. The I65S mutation
showed increased amounts of dimers (28.5%). This is
in line with previously reported observations for the I65T
substitution showing a shifted equilibrium of tetramers
and dimers and proneness to aggregation.18,33,34 For the
Y417H variant we observed an oligomerization proﬁle pre-
viously not described for recombinant variant PAH.We de-
tected a signiﬁcant amount of monomers (11.1%), with an
increased amount of dimers (17.7%) in relation to tetra-
mers (63.7%), and some aggregates (7.5%). Although the
residue Y414 is in close proximity to Y417, the variant
Y414C showed an oligomerization pattern resembling
that of the wild-type protein. This is in contrast to previous
studies that reported aggregate formation for Y414C.35
Two mutations located in the catalytic domain (S310Y,8 The American Journal of Human Genetics 83, 5–17, July 2008
R408W) resulted in formation of high-molecular-weight
aggregates (100%) without the occurrence of any tetra-
meric PAH, suggesting a severe folding defect. In addition,
the variant P275L also formed some aggregates (13.2%), of
which the largest fraction (82.2%) was the tetrameric form.
In summary, we observed disturbed oligomerization not
only for mutations located in the oligomerization domain
but also for mutations located in the two other domains.
Our results conﬁrm that PAHmutations can lead tomisfold-
ing, with aggregation and/or disturbed tetramer assembly.
Residual Enzyme Activity of Variant PAH is High,
but Allostery is Disturbed
Detailed analyses of steady-state kinetic parameters were
performed for all puriﬁed tetrameric PAH proteins (Table
2). Enzyme activity of variant PAH was reduced in compar-
ison to wild-type with respect to Vmax determined at vari-
able L-Phe concentrations. However, the reduction in activ-
ity was generally moderate (R50% residual activity), with
the exception of P314S (22% residual activity). For most of
the variant proteins analyzed, the afﬁnity of variant PAH to
its cofactor BH4 or to its substrate L-Phe was not reduced.
Only P275L showed decreased cofactor afﬁnity, with
a threefold increase in Km (65 mM). By contrast, the Km
values for A300S (17 mM) and Y414C (16 mM) were slightly
decreased. The afﬁnity to the substrate was not reduced but
was even increased for P275L and P314S, as shown by
decreased values for S0.5 (76 and 49 mM, respectively).
Tetrameric wild-type PAH displayed positive cooperativ-
ity for L-Phe binding (Hill coefﬁcient [h], 3.0) and substrate
activation (activation fold, 3.0). Notably, all but one of
the PAH variants showed alterations in allostery. Positive
cooperativity was reduced for all variant proteins except
H170Q. Most variants showed reduced substrate activa-
tion, ranging from a mild decrease (P275L and Y414C; ac-
tivation fold 2.3 and 2.0, respectively) to a near-complete
loss (F55L, I65S, P314S, and Y417H; activation fold 1.5,
1.0, 1.3, and 1.5, respectively).
Table 1. Quantitative Analysis of Wild-Type and Variant PAH
Oligomerization Profiles
Missense Mutation Aggregates Tetramers Dimers Monomers
WT 86.2 13.8
F55L 94.1 5.9
I65S 71.5 28.5
H170Q 94.8 5.2
P275L 13.2 82.2 4.6
A300S 2.4 87.0 10.6
S310Y 100
P314S 83.2 16.8
R408W 100
Y414C 92.5 7.5
Y417H 7.5 63.7 17.7 11.1
Relative amounts of the eluted fractions corresponding to different oligo-
meric states of wild-type (WT) and variant PAH proteins are given as per-
centages. The relative amounts were calculated by deconvolution analysis
of the size-exclusion chromatograms.Taken together, the results show that reduction in en-
zyme activity was moderate for most variant PAH proteins,
and only one variant showed reduced afﬁnity to the cofac-
tor. However, allostery was severely affected by mutations
in all three domains. This indicates that side-chain replace-
ments can induce global conformational changes, with
remote effects on PAH enzyme function.
Susceptibility to Proteinase K is Increased
Misfolded subunits and incorrectly assembled oligomeric
forms of proteins are more susceptible to degradation by
proteases in mammalian cells.5 Previous studies using a
transcription and translation system or the protease tryp-
sin showed that mutations in the PAH gene can lead to
decreased protein stability.3–5,18
In this study, we probed protein conformation of PAH by
limited proteolysis with proteinase K. Here, the proteolytic
event is predominantly governed by the stereochemistry
and ﬂexibility of the protein substrate and not by the spec-
iﬁcity of the protease.36 Because MBP was fused to the
N-terminal regulatory domain of PAH, we hypothesized
that altered folding of this domain could lead to increased
susceptibility of the linker region to proteolytic cleavage.
This was conﬁrmed by the ﬁnding that the half-life of
the fusion protein was decreased by R 50% for six out of
eight MBP-PAH variants. Stability of the PAH fragment
was also decreased in most cases (Table 3). Mutations in
the regulatory domain and the oligomerization domain
led to minor reductions of PAH half-life, whereas severe
destabilization was detected for three mutations of the
catalytic domain (H170Q, P275L, A300S; 60%, 55%, and
50% of the wild-type, respectively). Interestingly, one cat-
alytic mutation (P314S) did not lead to destabilization
but even induced marked stabilization of both the fusion
protein (167%) and the PAH fragment (143%) in compari-
son to that of the wild-type.
The increased susceptibility to proteinase K observed
here is in line with the hypothesis that PAH destabilization
is due to partial protein unfolding.
Protein Unfolding Predominantly Affects
the Regulatory Domain of the Protein
To directly investigate whether variant PAH is prone to
aberrant folding, we analyzed conformational alterations
in the ground state and upon thermal denaturation. Two
distinct transitions were previously described for the
denaturation of wild-type PAH. These form the basis for
a three-stage model of thermal PAH denaturation: (i) a
low-temperature transition representing unfolding of the
four regulatory domains, (ii) a high-temperature transition
representing unfolding of two catalytic domains, and (iii)
irreversible protein denaturation.37
Thermal protein denaturation was analyzed by ANS ﬂuo-
rescence (Figures 3A, 3B, and 3C). Transition midpoints are
summarized in Table 4. The usage of the hydrophobic ﬂuo-
rophoreANSallowedus tomonitoroverall unfoldingevents
because it binds to hydrophobic groups of the denaturingThe American Journal of Human Genetics 83, 5–17, July 2008 9
Table 2. Enzyme Kinetic Parameters
L-Phea BH4
b
Missense Mutation Vmax
e (nmol L-Tyr/min 3 mg protein) [S]0.5
e (mM) h Activation Fold Vmax
e (nmol L-Tyr/min 3 mg protein) Km
e (mM)
WT 3470575 15556 3.0 3.0 34255 139 245 3
F55L 2088566 12859 1.5 1.5 24085 112 225 3
I65S 22145130 168520 1.4 1.0 37625 152 295 3
H170Q 2174537 12554 3.1 3.6 21975 43 255 2
P275L 1706525 7653 1.6 2.3 32165 67 655 4
A300S 2990564 14856 2.4 3.7 33205 58 175 2
P314Sc 780522 4952 1.9 1.3 7605 39 255 4
Y414Cd 1877551 104540 2.2 2.0 18705 50 165 2
Y417Hd 2258554 135540 2.5 1.5 28665 188 315 4
Steady-state kinetic parameters of wild-type (WT) and variant tetrameric MBP-PAH fusion proteins. Activation fold represents the substrate activation as
the ratio of specific activity with and without prior incubation with L-Phe. Apparent affinities for L-Phe ([S]0.5) and BH4 (Km) and the Hill-coefficient (h) as
a measure of cooperativity are shown.
a Enzyme kinetic parameters determined at variable L-Phe concentrations and standard BH4 concentration in three independent experiments.
b Enzyme kinetic parameters determined at variable BH4 concentrations and standard L-Phe concentration in three independent experiments.
c
L-Phe concentrations restricted to 0–250 mM.
d
L-Phe concentrations restricted to 0–500 mM.
e Values are given as means5 SEM.protein and shows a high quantum yield in its bound state
butnotwhensolved in aqueousbuffers.38ANS-ﬂuorescence
analysis of tetrameric wild-type PAH fusion proteins re-
vealed a low-temperature transitionandahigh-temperature
transition, with their respective midpoints at 47.3C and
55.0C. This is in agreement with previous results obtained
by differential scanning calorimetry.37
The two mutations located in the regulatory domain
(F55L, I65S) induced alterations in unfolding patterns.
An elevated ﬂuorescence signal for I65S in comparison to
wild-type was detected in the ground state at 25C. This in-
dicates an increased hydrophobicity due to partial protein
unfolding. The same was true to a minor extent for F55L.
Table 3. Proteolytic Stability of Wild-Type and Variant PAH
Missense
Mutation
t1/2 FP
(% of WT) SEM p Value
t1/2 PAH
(% of WT) SEM p Value
WT 100 100
F55L 71 7 0.039 75 15 ns
I65S 34 7 0.001 85 17 ns
H170Q 26 5 0.001 60 12 0.003
P275L 40 4 0.001 55 16 0.002
A300S 31 9 0.001 50 16 0.001
P314S 167 10 0.013 143 16 0.019
Y414C 47 13 0.004 70 16 0.017
Y417H 52 4 0.003 86 18 ns
Stability of wild-type (WT) and variant PAH against limited proteolysis by
proteinase K. Degradation of the MBP-PAH fusion protein and formation
with subsequent degradation of the PAH fragment were probed by west-
ern-blotting analyses. Densitometry data were normalized to intact
MBP-PAH fusion protein and the resulting data points were fitted by single
exponential function (MBP-PAH fusion proteins) and by double exponential
Bateman function (PAH fragment). The calculated half-lives of fusion pro-
teins (t1/2 FP) and of PAH fragments (t1/2 PAH) are given in percent5 SEM
of n ¼ 4 independent experiments. Significances for the differences
between wild-type and the variants were calculated by two-tailed Student’s
t test.10 The American Journal of Human Genetics 83, 5–17, July 2008During thermal unfolding, F55L showed a left-shift of
the low-temperature transition in comparison with the
wild-type protein (tm1/2 43.7
C), whereas a complete loss
of the low-temperature transition was observed for I65S.
By contrast, neither F55L nor I65S signiﬁcantly affected
the high-temperature transition. These ﬁndings indicate
that the two mutations located in the regulatory domain
inducedmisfolding and facilitated unfolding of the respec-
tive domain but did not inﬂuence the conformational
stability of the catalytic domain.
Thermal unfolding of variant PAH was also affected by
the four mutations located in the catalytic domain. All var-
iants but P275L showed elevated ground-state levels of
ANS ﬂuorescence. All residue substitutions in the catalytic
domain induced a left-shift of the low-temperature transi-
tion that reached statistical signiﬁcance for A300S (tm1/2
44.6C) and P275L (tm1/2 44.1C). Interestingly, none of
the mutations located in the catalytic domain signiﬁcantly
altered the high-temperature transition, indicating that
these mutations did not affect unfolding of the catalytic
domain itself but induced a loss of structural integrity of
the regulatory domain.
Distinct alterations of thermal-unfolding parameters
were observed for the two mutations located in the oligo-
merization domain (Y414C, Y417H). In contrast to other
variants exhibiting accelerated thermal unfolding, the
ground-state ANS ﬂuorescence of Y414C and Y417H re-
mained unchanged. However, the low-temperature transi-
tion was considerably left-shifted for Y414C (tm1/2 43.1
C)
and for Y417H (tm1/2 41.9
C), whereas no effect on the
high-temperature transition was detected. The residues
Y414 and Y417 are located close to the site of interaction
between the oligomerization domain and the regulatory
domain within one PAH subunit. This might explain the
effect of these side-chain replacements on the stability of
the regulatory domain.
To assess the impact of thermal stress on PAH enzyme
activity, we performed thermal-inactivation assays (Fig-
ure 3D). A reduction of the thermal-inactivationmidpoints
at 50% residual activity (Tm) in comparison to the wild-
type protein (48.8C) was observed for three variants
(I65S, P314S, Y417H, Tm; 46.2, 44.5, and 45.0
C, respec-
tively), whereas thermal inactivation of the other variants
was not altered (Table 4). The affected residues mapped to
all protein domains, demonstrating that mutations located
outside the catalytic domain can also disturb enzyme
function.
In summary, the results of thermal denaturation show
that mutations in the PAH gene lead to substantial distor-
tion of the protein’s conformation, with particular impact
on the regulatory domain.
Local Amino Acid Replacements Can Affect Networks
of Amino Acid Interactions
We constructed a composite 3D model of the full-length
PAH tetramer and performed 3D structural modeling.
Side-chain interactions in the local environment of amino
acid residues affected by mutations in our patients were
analyzed in order to investigate whether these amino
acid residues are directly or indirectly involved in networks
of side-chain interactions with functional and conforma-
tional impact. Our observations indicate that local amino
acid replacements can induce global conformational
changes, with remote effects on enzyme function and
stability of the PAH.
Figure 3. PAH Mutations Lead to Accelerated Thermal
Unfolding and Early Thermal Inactivation for Some Variants
(A–C) Thermal-unfolding profiles of wild-type and variant PAH
monitored by ANS fluorescence. Intensities of the fluorescent
dye ANS, which binds to hydrophobic groups of the protein
presented upon unfolding, are plotted as a function of increasing
temperatures. Error bars represent the mean5 SEM of three inde-
pendent experiments. The resulting denaturation curves consist of
three segments: a native baseline and two partially overlapping
phase transitions corresponding to unfolding of the regulatory
domain (first transition) and of the catalytic domain (second tran-
sition), respectively. Ground-state ANS fluorescence was markedly
elevated for I65S and A300S, indicating increased protein areas
available for dye binding. I65S lacked the first transition; all other
variants showed a left-shift of the first transition, indicating a
destabilization of the regulatory domain in comparison to the
wild-type. The second transition was not affected. R denotes reg-
ulatory domain; C denotes catalytic domain; O denotes oligomeri-
zation domain.
(D) Time course of thermal inactivation of wild-type and variant
PAH. Proteins were incubated at increasing temperatures, and
the residual enzyme activities were determined. Data points of re-
sidual activities were normalized to the initial enzyme activity and
subjected to nonlinear regression analysis. For three variants that
mapped to all domains (I65S, P314S, and Y417H), curves were left-
shifted in comparison to the wild-type. The remaining five variants
showed inactivation profiles comparable to that of wild-type PAH.The American Journal of Human Genetics 83, 5–17, July 2008 11
Table 4. Transition Midpoints and Midpoints of Thermal Inactivation for Thermal Denaturation of Wild-Type and Variant PAH
ANS Fluorescence Thermal Inactivation
Protein Domain Affected Missense Mutation tm1/2 SEM p Value tm2/3 SEM p Value Missense Mutation Tm SEM p Value
- WT 47.0 0.03 54.8 0.30 WT 48.85 0.52
R F55L 43.7 0.57 0.004 54.5 0.03 ns F55L 47.96 0.72 ns
R I65S - - - 53.9 0.30 ns I65S 46.17 0.56 0.042
- WT 47.0 0.52 55.1 0.30
C H170Q 46.1 0.00 ns 55.4 0.52 ns H170Q 48.92 0.20 ns
C P275L 44.1 0.52 0.029 54.6 0.05 ns P275L 48.40 0.76 ns
C A300S 44.6 0.30 0.016 54.5 0.03 ns A300S 49.46 0.61 ns
C P314S 44.9 0.60 ns 54.5 0.03 ns P314S 44.50 1.05 0.021
- WT 47.9 0.52 55.1 0.30
O Y414C 43.1 0.30 0.001 54.5 0.03 ns Y414C 48.42 0.43 ns
O Y417H 41.9 0.30 0.001 55.4 0.03 ns Y417H 44.99 0.21 0.011
- WT (mean) 47.3 0.26 55.0 0.16
Transition midpoints and midpoints of thermal inactivation obtained by thermal denaturation of wild-type PAH were compared to variants arising from
mutations in the regulatory (R), catalytic (C), and the oligomerization (O) domain. For ANS-fluorescence three sets of experiments covering the mutations
of different domains were carried out separately. The transition midpoints of the first (tm1/2) and the second transitions (tm2/3) were calculated by dif-
ferentiation of the increasing part of the curves and are given in C as means5 SEM of n ¼ 3 independent experiments. For thermal inactivation residual
activities were subjected to nonlinear regression analysis and the midpoints of thermal inactivation (Tm) were calculated. Tm-values representing the
temperature at 50% residual activity are given in C as means 5 SEM of quadruplicate assays in n ¼ 2 independent experiments. Significances for the
differences between wild-type and the variants were calculated by two-tailed Student’s t test.F55 and I65 are part of the hydrophobic core of the reg-
ulatory domain.Whereas F55L showed no impact on tetra-
mer assembly, I65S displayed disturbed oligomerization,
with increased amounts of dimeric protein in comparison
to the wild-type (Figure 2). The assembly of dimers to tetra-
meric PAH is promoted by coiled-coil interactions of the
C-terminal ahelices,7 which are preceded by two antiparallel
strands forming a b ribbon that comprises the dimerization
motif (residues 411–427).15,17 This b ribbon interacts with
the regulatory domain in the same subunit and with the
catalytic domain in the adjacent subunit within the dimer
(Figures 4A–4D). The electrostatic interactions of D415 and
E422 with R71 located in the prominent loop 68–75 play
a pivotal role for the proper position of the dimerization
motif, resulting in the right orientation of the a-helical
tetramerization motif for correct tetramer assembly. A dis-
tortion of the hydrophobic packing in the regulatory do-
main due to a substitution of the hydrophobic isoleucine
by the polar serine at position 65 is supposed to lead to
a displacement of the loop 68–75.10 Hence, an alteration
of the interaction of this loop with the dimerization motif
might lead to dislocation of the a-helical tetramerization
motif and result in altered oligomerization with increased
amounts of dimers.
Two of the PAH variants located in the catalytic domain
(S310Y and R408W) were exclusively puriﬁed as high-
molecular-weight aggregates lacking all residual enzyme ac-
tivity (Table 1 and Figure 2). Formation of aggregates was
previously described for R408W and structurally explained
by potential disruption of hydrogen bonding to L308 and
L311.7,8 The S310 residue builds a hydrogen bond to G307,
which interacts with L311. We thus inferred that both
S310 and R408 are part of a hydrogen-bonding network
formed by G307, L308, S310, L311, and R408 (Figures 4B12 The American Journal of Human Genetics 83, 5–17, July 2008and 4C). The R408 residue is located between two proline
residues, which deﬁne a sharp turn preceding the dimeriza-
tion motif. This hinge region anchors the oligomerization
domain to the catalytic domain and thereby ensures its
proper orientation. A disruption of the network by the
nonconservative substitutions S310Y and R408W could
therefore well induce severe distortion of the protein’s
oligomeric state.
P314 adopts a central position in a network that com-
prises residues of the regulatory and the catalytic domain
(Figure 4C). There is only one direct interaction between
the backbone carbonyl of P314 and the backbone amide
of Y317. However, the P314 residue is located in a loop (res-
idues 311–314) connecting a helices Ca8 and Ca9 that
deﬁne the active site. The neighboring residues D315 and
A313 form a network of interactions with R252 near the
pterin-binding loop (residues 248–251), with K113 in the
regulatory domain, and with D27 in the autoregulatory
sequence. Thus, local changes of the protein conformation
in the neighborhood of P314 could induce structural
changes at the active site, at the pterin-binding site, and
in the regulatory domain. This is in line with the observa-
tion that the variant P314S affected various enzyme kinetic
parameters with low residual activity, loss of activation,
and reduced cooperativity.
Y414C and Y417H, the variants arising from mutations
mapping to the oligomerization domain, surprisingly ex-
hibited clearly different oligomerization patterns although
they are located in close proximity to each other. Both res-
idues are part of the dimerization motif (Figure 4D). Y414
interacts with the catalytic domain of the same subunit,
whereas Y417 is located at the interface of monomer-
monomer interactions in the dimer, where it builds a net-
work with T238, R261, and Q304 of the adjacent subunit.
Figure 4. Amino Acid Residues Affected by PAH Mutations Are Involved in Functional Networks of Side-Chain Interactions
Selected parts of subunit backbones are shown as ribbon representations, and selected residues are depicted as stick models with carbon
atoms in white, oxygen atoms in red, and nitrogen atoms in blue. Hydrogen bonds are shown as golden dotted lines.
(A) Residues F55 and I65 are located in the hydrophobic core of the regulatory domain (subunit A, blue) followed by the prominent loop
68–75. Upon substrate activation, R68 builds a hydrogen bond to C237 in the catalytic domain of the adjacent monomer (subunit D, red).
R71 establishes electrostatic interactions with D415 and E422 in the dimerization motif, followed by coiled-coil interaction of the
tetramerization motif with the adjacent dimer (subunit B, yellow). The electrostatic interactions are supposed to hold the b-ribbon
in its proper spatial position resulting in the right orientation of the a-helical tetramerization motif.
(B) Residues S310 and R408 are both part of a hydrogen-bonding network that anchors the entire oligomerization domain to the catalytic
domain within one subunit. The coiled-coil interaction of subunits A (blue) and B (yellow) of both dimers contributes to tetramer
assembly. R408 builds hydrogen bonds to the main-chain carbonyl oxygens of L308 and L311 located in the active-site helix Ca8.
S310 contributes to this network through interaction with G307 that builds a hydrogen bond to the main-chain amide of L311.
(C) P314 is part of the loop 311–314 connecting a helices Ca8 and Ca9 that define the bottom of the active site. The network of R252,
A313, P314, D315, and Y317 contributes to the correct spatial orientation of the active site and the pterin-binding loop 248–251. It is
expanded via interaction with residues D27, located in the intrinsic autoregulatory sequence (1–33), and K113, located in a hinge-bend-
ing region (111–117) connecting the catalytic to the regulatory domain. This area is in close proximity to the network comprising
residues S310 and R408 (B), which constitutes the connection of the whole region with the dimerization motif of the oligomerization
domain. BH4 at the active site is shown as an orange stick model.
(D) Y414 and Y417 are located in a loop connecting two antiparallel b strands forming the dimerization motif. Y417 joins a network
comprising residues Q304, R261, and T238, which tightly links the dimerization motif to the catalytic domain of the adjacent subunit
(subunit A, blue; subunit D, red). The hydroxyl group of Y417 builds a hydrogen bond to Q304, and the aromatic ring of Y417 stacks
with the positively charged guanidinium group of R261. Q304 and T238 are connected to R261 via hydrogen bonds. Y414 is localized
in close proximity to residue Y417 but does not contribute to the monomer-monomer interaction.The American Journal of Human Genetics 83, 5–17, July 2008 13
Y417H is supposed to disrupt the hydrogen bond to Q304
and to damage the polar p stacking due to repulsions
between the histidine and the positively charged guanidi-
nium group of R261. This would result in hindrance of
dimer formation with the appearance of monomers, and,
as a consequence, disturbed tetramerization.
Taken together, the results of the in silico structural
analysis of this subset of variants support the notion that
local replacement of an amino acid at one site can disturb
amino acid networks and, as a consequence, induce global
changes in conformation that also affect remote parts of
the protein at the functional level.
Discussion
Despite the severe clinical phenotype of PKU, many
missense mutations in the PAH gene have previously
been shown to be associated with surprisingly high resid-
ual enzyme activities in vitro. It therefore has to be antici-
pated that mutations lead to loss of function through
mechanisms other than impaired catalysis. Previous stud-
ies reported on PAH protein aggregation and rapid degra-
dation,3,4,18,39 raising the hypothesis that aberrant folding
is a consequence of PAH mutations. Recent work substan-
tiated this hypothesis, providing predictions about the
effect of PAHmutations on native-state-protein stability.23
Here, we present several lines of experimental evidence
that support the hypothesis that PAH missense mutations
associated with the newly recognized clinical phenotype of
BH4-responsive PAH deﬁciency lead to protein misfolding.
Two mutations (S310Y and R408W) caused severe struc-
tural distortion, with protein aggregation and complete
loss of enzyme function. The others showed milder alter-
ations of conformation but were associated with impaired
enzyme-kinetic parameters, oligomerization, and protein
stability at different degrees. Moreover, we showed that
PAHmutations not only have an impact on the local struc-
tural environment of the affected side chain but rather
induce alterations consistent with distortion of the
enzyme’s global conformation.
Interestingly, all variant PAH proteins analyzed in our
study showed disturbed regulation. Allostery in general
and PAH allostery in particular are complex events in
which numerous side-chain interactions transmit struc-
tural changes throughout the whole oligomer. Extensive
previous work has deﬁned speciﬁc sites that are involved
in PAH allostery.12,15,34 Allosteric conformational changes
in substrate binding result not only in positive cooperativ-
ity but also in activation of the enzyme. We observed that
all but one variant led to reduced cooperativity, and six
mutations that mapped to all three domains induced a
loss of substrate activation. This led us to assume that
mutations affecting sites involved in allostery cause a cas-
cade of structural consequences, with alteration of confor-
mational ﬂexibility. As a result, remote functional units of
side-chain interactions could be disturbed. Indeed, we ob-14 The American Journal of Human Genetics 83, 5–17, July 2008served a negative impact of the I65S mutation located in
the regulatory domain on the tetramer-dimer equilibrium.
On a structural level, this can be explained by the multiple
interactions required for PAH oligomerization that are not
limited to the oligomerization domains but also involve
allosteric contacts of all domains.
Additional evidence for protein misfolding arose from
results demonstrating destabilization of variant PAH
against proteolytic attack by proteinase K. In general, mis-
folded or partly unfolded proteins show enhanced back-
bone ﬂexibility and thus facilitate proteolytic attack.36
Results from limited proteolysis pointed to altered folding
of the N-terminal regulatory domain. Moreover, mutations
located on the protein surface (H170Q, P275L) were shown
to be particularly prone to proteolytic attack, whereas
mutations buried in the core of the protein (F55L, I65S,
Y417H) were not. Direct experimental evidence for alter-
ations in global protein conformation arose from the anal-
ysis of PAH hydrophobicity in the ground state and during
thermal denaturation. Presentation of hydrophobic groups
at the variant protein’s surface caused by protein misfold-
ing facilitates binding of the ANS ﬂuorophore. Indeed, an
increase in ANS ﬂuorescence in the ground state was
observed for the two mutations in the regulatory domain
and for most mutations in the catalytic domain. Interest-
ingly, all variant PAH showed accelerated thermal unfold-
ing. Furthermore, our investigations revealed that inde-
pendent of the position of the affected residue, PAH
mutations had the most impact on the unfolding of the
regulatory domain. This was conﬁrmed by analysis of the
inactivation of enzyme function by thermal stress. Only
three mutations led to accelerated thermal inactivation
(I65S, P314S, Y417H); among these, just one mapped to
the catalytic domain. Altogether, data from stability assays
indicate that the structural conformation of the PAH regu-
latory domain is particularly unstable. This observation
can be explained by the structural characteristics of this
domain. Recently, Liberles et al. provided strong evidence
that the regulatory domain of PAH comprises an evolu-
tionary mobile regulatory module, the ACT domain.12 It
facilitates allosteric regulation via transmission of ﬁnely
tuned conformational changes, a process that appears to
be set by the regulatory domains’ interactions with the
partner domains. These interactions require a high degree
of conformational ﬂexibility. For PAH isolated from a cold-
adapted organism, it was shown that an increase in confor-
mational ﬂexibility is accompanied by an increase in ther-
molability.40 Thus, the mobility of the regulatory domain
that allows for complex regulation of activity and the olig-
omeric state might on the other hand cause reduced stabil-
ity against thermal stress and proteolytic attack. Moreover,
the extensive networking of the regulatory domain with
other parts of the protein could account for the adoption
of misfolding from remote sites. By contrast, missense
mutations, if not structurally disruptive, hardly affected
the integrity of the catalytic domain. This was shown by
unchanged patterns of thermal unfolding of the catalytic
domain and further supported by the variant’s high resid-
ual enzyme activity and minor changes in thermal-inacti-
vation experiments. The domain’s dense tertiary structure
with few ﬂexible regions could be the reason for these
observations.
Taken together, the results presented here indicate that
PAH missense mutations can lead to protein misfolding
and conformational destabilization at different degrees.
Our ﬁndings are in agreement with recent results from
computational analyses using the FoldX algorithm. This
study showed that a signiﬁcant share of a large set of
PAHmutations is predicted to provoke protein misfolding.
Moreover, the authors raised the hypothesis that residues
buried in the 3D structure, unlike those in ﬂexible regions,
are particularly prone to severe misfolding.23 Our ﬁndings
conﬁrm this at the experimental level for a subset of ten
mutations identiﬁed in patients with BH4-responsive
PAH deﬁciency. Mutations at the center of the protein
structure (S310Y, R408W) were shown to lead to severe ag-
gregation and complete disruption of structural integrity.
Conversely, mutations in ﬂexible regions of the protein
(H170Q, P275L, P314S, Y417H) did not primarily show
severe protein misfolding. However, they can indeed cause
milder conformational changes, which still exert deleteri-
ous effects on enzyme function. Features like oligomeriza-
tion, allostery, activation, and cooperativity need complex
conformational rearrangements, which are communicated
through ﬂexible regions of the protein via networks of
amino acid interactions. Our observations imply that mu-
tations, even those in ﬂexible protein regions, can severely
affect enzyme function and stability if they directly or in-
directly disrupt these networks. In addition to our results
from naturally occurring mutations, this was previously
shown by analysis of artiﬁcial mutations of amino acid res-
idues in ﬂexible hinge-bending regions. These are involved
in substrate-triggered molecular motions, and the corre-
sponding proteins showed a reduced conformational sta-
bility in comparison to that of wild-type PAH.13 Finally,
two observations exemplify that there also appears to be
no general rule for missense mutations of buried residues
leading to severe misfolding with protein destabilization
and impaired enzyme function. Both A300 and P314 are
located in the active center of the protein; A300 is part of
helix Ca8, which together with helix Ca9 deﬁnes the
catalytic core, whereas P314 lies in a ﬂexible loop between
helices Ca8 and Ca9. A300S led to conformational desta-
bilization, with distinct proneness to proteinase K and
elevated ground-state ANS ﬂuorescence. Nonetheless, en-
zyme function remained virtually unaffected. Conversely,
P314S showing a clear stabilization toward proteinase K
led to a marked reduction in enzyme activity and to accel-
erated thermal inactivation.
The results from our experimental work revealed that
PAH misfolding is probably communicated throughout
the protein by disruption of functionally crucial networks
of amino acid interactions. Thus, the classical domain-as-
sociated view of mutational effects on the protein mightbe insufﬁcient for understanding of the molecular pheno-
type, and it disregards the well-known complexity in
structure and regulation of the PAH protein.15,37 We there-
fore propose a view of PAH that not only considers three
primary-structure domains but takes into account that
the PAH enzyme is an entity of functional units that arise
from the tertiary and quaternary protein structure. If this
holds true, mutations in the PAH gene exert their effects
by disturbance of these functional units.
PKU has evolved from a model of a genetic disease that
leads to severe neurologic impairment to amodel of a treat-
able protein-folding disease with loss of function. The new
insights into molecular mechanisms of protein misfolding
are a prerequisite for the unraveling of how the natural co-
factor BH4 corrects the biochemical consequences of PAH
gene mutations and will help treatment of patients on an
individually tailored basis.
Supplemental Data
One supplemental table is available with this article online at
http://www.ajhg.org/.
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Protein misfolding with loss-of-function of the enzyme phe-
nylalanine hydroxylase (PAH) is themolecular basis of phenylk-
etonuria inmany individuals carryingmissensemutations in the
PAH gene. PAH is complexly regulatedby its substrate L-Phenylal-
anine and its natural cofactor 6R-L-erythro-5,6,7,8-tetrahydro-
biopterin (BH4). Sapropterin dihydrochloride, the synthetic
form of BH4, was recently approved as the first pharmacological
chaperone to correct the loss-of-function phenotype. However,
current knowledge about enzyme function and regulation in the
therapeutic setting is scarce. This illustrates the need for com-
prehensive analyses of steady state kinetics and allostery beyond
single residual enzyme activity determinations to retrace the
structural impact of missense mutations on the phenylalanine
hydroxylating system. Current standard PAH activity assays are
either indirect (NADH) or discontinuous due to substrate and
product separation before detection. We developed an auto-
mated fluorescence-based continuous real-time PAH activity
assay that proved to be faster and more efficient but as precise
and accurate as standardmethods.Wild-type PAHkinetic anal-
yses using the newassay revealed cooperativity of activatedPAH
toward BH4, a previously unknown finding. Analyses of struc-
turally preactivated variants substantiated BH4-dependent
cooperativity of the activated enzyme that does not rely on the
presence of L-Phenylalanine but is determined by activating
conformational rearrangements. These findings may have
implications for an individualized therapy, as they support the
hypothesis that the patient’s metabolic state has a more signifi-
cant effect on the interplay of the drug and the conformation
and function of the target protein than currently appreciated.
Phenylalanine hydroxylase (PAH4; EC 1.14.16.1) is a non-
heme iron monoxygenase that catalyzes the hydroxylation of
the substrate L-Phe to L-Tyr in the presence of its natural cofac-
tor 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) and molec-
ular dioxygen. Mutations in the PAH gene can lead to protein
misfolding with loss of function and subsequently to phenylke-
tonuria ([MIM 261600]), the most common inborn error of
amino acidmetabolism in European-descended populations (1,
2). Pharmacological doses of BH4 can correct protein misfold-
ing in a significant number of patientswith PAHdeficiency, and
sapropterin dihydrochloride, the synthetic form of the natural
PAH cofactor, was recently approved as the first pharmacolog-
ical chaperone to treat phenylketonuria patients (3–5).
The enzyme is a homotetramer built as a dimer of dimers
with each subunit consisting of an N-terminal regulatory
domain (residues 1–142), a catalytic domain (residues 143–
410), and a C-terminal oligomerization domain (residues 411–
452). Elaborate functional and kinetic studies have revealed
complex enzyme regulation by its substrate and cofactor as well
as by phosphorylation (6–8). Binding of the substrate induces a
catalytically competent (activated) enzyme, whereas binding of
BH4 leads to formation of an inactive dead-end PAH-BH4 com-
plex (9–12). These regulatory mechanisms require reversible
conformational changes that are transmitted throughout the
enzyme upon binding of BH4 and L-Phe (13). Structural analy-
ses of BH4 binding revealed that the cofactor interacts with the
N-terminal autoregulatory sequence and the pterin binding
loop, leading to stabilizing hydrogen bonds and to formation of
a binary enzyme-BH4 complex (14). The largest conformational
changes were observed upon binding of L-Phe, where local
changes at the active site are propagated globally through
hinge-bending motions in the catalytic domain, also altering
the position and orientation of bound BH4 (13, 15) and of the
regulatory domain (16).
Analyses of the effects of missense mutations in the PAH
gene on PAH enzyme kinetic properties have shown that resid-
ual enzyme activity generally is high, yet allostery is often dis-
turbed (17–19), with reduced cooperativity for substrate bind-
ing, decreased substrate activation, or altered affinity to the
substrate and the cofactor. Thus, the evaluation of kinetics and
allostery can help to assess to which extent local single amino
acid replacements lead to global conformational alterations
compromising enzyme function. In this context, comprehen-
sive steady state kinetic analyses beyond single determination
of residual enzyme activity are needed to retrace the structural
impact of missense mutations on the phenylalanine hydroxy-
lating system.Yet, the current standard activity assays requiring
substrate and product separation before L-Tyr detection by
radioactivity or fluorescence signals (20–22) are laborious and
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time consuming. In addition, designed as end-point measure-
ments, these discontinuous assays assume a linear range of
activity for the time period chosen, although variations of tem-
perature and pH aswell as concentrations of enzyme, substrate,
and cofactor can dramatically change the linearity of a reaction
over the fixed time window (23). Therefore, we aimed to
develop an automated continuous real-time assay of PAHactiv-
ity. Our new fluorescence-based multi-well assay has given rise
to the possibility of evaluating PAH kinetics and allostery faster
and more efficiently but as precisely and accurately as the
standard methods. Surprisingly, by application of this tech-
nique, the data obtained for BH4-dependent PAH kinetics did
not fit to thewell acceptedmodel of a single hyperbolic function
(Michaelis-Menten kinetic model). Instead, a good fit was
found using a sigmoidal binding curve (Hill kinetic model).
Although positive cooperativity for the binding of L-Phe has
been extensively studied (24, 25), cooperativity toward BH4 has
not been described to date. However, cofactor-dependent
kinetic studies were routinely performed using the non-acti-
vated PAH enzyme (19, 26), whereas an L-Phe preincubated
(activated) enzyme was applied in our experiments.
Thus, we aimed to characterize BH4-dependent PAH kinet-
ics in more detail and to investigate whether activation of PAH
is a prerequisite for the positive cooperativity observed. Real-
time fluorescence kinetic analyses using L-Phe-activated and
non-activated PAH were performed. Furthermore, genetic
variants of PAH, which are structurally preactivated by single
amino acid replacements, were analyzed. To discriminate
between non-cooperative and cooperative enzyme kinetics, in-
depth model comparisons by nonlinear regression analysis
were conducted with fitting of the data to the Michaelis-Men-
ten or the Hill kinetic model.
EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant PAH Enzymes—
The cDNA of human phenylalanine hydroxylase (EST clone
obtained from Imagines, formerly RZPD,Germany) was cloned
into the pMAL-c2E and pMAL-c2X expression vectors (New
EnglandBiolabs) encoding anN-terminalmaltose-binding pro-
tein (MBP) tag and enterokinase or Factor Xa cleavage sites,
respectively. PAH mutants were constructed by site-directed
mutagenesis as described (17). Escherichia coli DH5 were
transformed with the expression vector for wild-type and
mutant MBP-PAH fusion proteins. Proteins were purified by
affinity chromatography (MBP Trap, GE Healthcare) followed
by size-exclusion chromatography using aHiLoad 26/60 Super-
dex 200 column (GE Healthcare) on an A¨KTAxpress system as
previously described (17). The isolated tetrameric fusion pro-
teins were collected, and protein concentrations were deter-
mined spectrophotometrically using 280 (1 mg/ml)  1.63. Tet-
rameric fusion protein was cleaved by factor Xa (10 units of
factor Xa:1mg of fusion protein) at 4 °C for 16 h and isolated by
size-exclusion chromatography using aHiLoad 16/60 Superdex
200 prep grade column (GE Healthcare). Protein concentra-
tions of the cleaved tetrameric PAH were determined spectro-
photometrically using 280 (1 mg/ml) 1.0.
Verifying Direct Fluorescence Detection of Enzymatic L-Tyr
Production—To verify the spectral separation needed for the
direct in-well fluorescence detection of enzymatic L-Tyr pro-
duction, L-Tyr (0–150 M) (Sigma) in 17 mMNaHepes, pH 7.3,
was added to all wells of a 96-well plate (NUNCF96) containing
a reaction mixture with 1 mg/ml catalase (Sigma), 10 M fer-
rous ammonium sulfate (Fe2) (Fluka), and L-Phe (0–1000M)
(Sigma) yet lacking the apoenzyme andBH4. L-Tyr fluorescence
intensity was subsequentlymeasured using a fluorescence pho-
tometer (FLUOstar OPTIMA, BMG Labtech) at an excitation
wavelength of 274 nm and an emission wavelength of 304 nm.
Individual experiments were assayed as triplicates. All concen-
trations mentioned refer to a final volume of 204 l.
Quantification of L-Tyr Production—For the quantification
of L-Tyr production, standards consisting of L-Tyr (0–463 M)
and L-Phe (547 M) in 17 mM NaHepes, pH 7.3, 1 mg/ml cata-
lase, and 10 M ferrous ammonium sulfate were measured
before each experiment using the fluorescence photometer
(excitation 274 nm, emission 304 nm). Individual experiments
were assayed as triplicates before enzyme kinetic measure-
ments on each experimental day. All concentrationsmentioned
refer to a final volume of 204 l.
Analysis of the Inner Filter Effect (IFE) of BH4—A 96-well
plate was prepared with L-Tyr (0–150 M) in 17 mM NaHepes,
pH 7.3, and a standard reaction mixture containing the stan-
dard concentration of 1mM L-Phe in 17mMNaHepes, pH 7.3, 1
mg/ml catalase, 10 M ferrous ammonium sulfate, and 15 mM
NaHepes, pH 7.0. Subsequent to injection of BH4 (0–125 M)
(6R-L-erythro-5,6,7,8-tetrahydrobiopterin, Schircks Laborato-
ries) stabilized in 2 mM dithiothreitol (DTT) (Fluka), L-Tyr
fluorescence intensity was measured using the fluorescence
photometer (excitation 274 nm, emission 304 nm). The IFE of
BH4 was corrected by defining a correction factor for each BH4
concentration added to the reaction mixture: q  f (at each
[BH4])/f (fluorophore alone), where f is the fluorescence inten-
sity, and q is the correction factor for the substrate concentra-
tion (27, 28). All measurements were assayed as triplicates
before enzyme kinetic measurements on each experimental
day. All concentrations mentioned refer to a final volume of
204 l.
Time-dependent Enzyme Activity Measurement—For time-
dependent enzyme activity measurements, the assay was per-
formed with and without preincubation of the enzyme with 1
mML-Phe.A reaction buffer containing 1mg/ml catalase, 10M
ferrous ammonium sulfate, and the tetrameric MBP-PAH
fusion protein (0.01 mg/ml) was prepared. After preincubation
with 1 mM L-Phe in 22.35 mM NaHepes, pH 7.3, for 5 min at
25 °C, the reaction was initiated by the addition of 75 M BH4
stabilized in 2 mM DTT. For enzyme activity measurements
without L-Phe preincubation, the reaction was initiated by
simultaneous injection of 1 mM L-Phe and 75 M BH4.
Time-dependent substrate production was assessed by
detection of the increase in L-Tyr fluorescence intensity at an
excitationwavelength of 274 nmand an emissionwavelength of
304 nm using a fluorescence spectrophotometer (Cary Eclipse,
Varian). All concentrations mentioned refer to the final con-
centration in a 204-l reaction mixture.
PAH Cooperativity for BH4
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Multiwell Enzyme Activity Assay with and without L-Phe
Preactivation—For PAH activity measurement, L-Phe in 22.35
mM NaHepes, pH 7.3, was added to 12 wells of a 96-well plate
with varying L-Phe concentrations (0–1000 M) or at a con-
stant L-Phe concentration (1 mM) using the injection system of
a fluorescence photometer. A reaction buffer containing 1
mg/ml catalase, 10 M ferrous ammonium sulfate, and the tet-
rameric MBP-PAH fusion protein (0.01 mg/ml) was prepared
and injected in all 12 wells. After preincubationwith L-Phe for 5
min at 25 °C, the reaction was initiated by the addition of BH4
stabilized in DTT for a final concentration of 75 M BH4 with
varying L-Phe concentrations (0–1000M) or varying BH4 con-
centrations (0–125 M) at 1 L-Phe concentration (1 mM) and 2
mM DTT.
For enzyme activitymeasurementswithout L-Phe preincuba-
tion, the reaction buffer was prepared and injected to 12 wells.
The reaction was initiated by simultaneous injection of varying
L-Phe concentrations (0–1000 M) and 1 BH4 concentration
(75 M) or 1 L-Phe concentration (1 mM) and varying BH4 con-
centrations (0–125 M).
Steady state kinetics of PAH were determined at 25 °C and
a 60-s measurement time per well. Substrate production was
assessed by detection of the increase in L-Tyr fluorescence
intensity at an excitation wavelength of 274 nm and an emis-
sion wavelength of 304 nm using a fluorescence photometer
(FLUOstar OPTIMA, BMG Labtech) and assayed as dupli-
cates on 3 consecutive days. Fluorescence intensity signals
were corrected for the quenching effect of BH4. All concen-
trations mentioned refer to the final concentration in a
204 l reaction mixture.
For all enzyme activitymeasurements, fluorescence intensity
was recorded and, after subtraction of the blank reaction, con-
verted to enzyme activity units (nmol Tyr/min  mg protein)
using the standard curve obtained by L-Tyr concentration
measurements. Data were analyzed by nonlinear regression
analysis using the single hyperbolic model (Michaelis-Menten
kinetic model),
v 
VmaxS
Km S
(Eq. 1)
where v is the observed rate of enzyme catalysis, Vmax is the
maximum rate of enzyme catalysis, [S] is the substrate concen-
tration, and Km is the substrate concentration at which Vmax/2
is reached and the sigmoidal kineticmodel (Hill kineticmodel),
v 
Vmax
1 EC50S 
h (Eq. 2)
where v is the observed rate of enzyme catalysis, Vmax is the
maximum rate of enzyme catalysis, [S] is the substrate concen-
tration, EC50 is the substrate concentration at which Vmax/2 is
reached, and h is the Hill coefficient (GraphPad Prism 4.0c).
Values are given as themean S.E. of three independent exper-
iments. The coefficient of variation was determined as the ratio
of the S.D. to the mean value. Comparison of model fitting was
performed using the F-test (GraphPad Prism QuickCal), resid-
uals of values, the S.D. of the residuals (Sy.x), the runs test, and
the square of residuals (R2) (see supplemental Tables S1
and S2 and Fig. S2) (29–34).
Tryptophan Fluorescence Measurements—For tryptophan
fluorescence emission scans, wild-type PAH, dimeric PAH
103–427, and variant PAHR68Swere diluted to 11Msubunits
PAH (0.6 g/l) in 20 mM NaHepes and 200 mMNaCl, pH 7.0,
containing 10 M ferrous ammonium sulfate and 2 mM DTT.
Fluorescence measurements were performed using a fluores-
cence spectrophotometer (Cary Eclipse, Varian) at an excita-
tionwavelength of 295 nmwith excitation and emission slits set
to 2.5 and 5 nm, respectively.
Differential Scanning Fluorimetry—Differential scanning
fluorimetry analyses were performed on a Cary Eclipse fluores-
cence spectrophotometer equipped with a temperature-con-
trolled Peltier multicell holder (Varian). Denaturation of 6 M
MBP-PAH subunits diluted in 20 mM NaHepes and 200 mM
NaCl, pH 7.0, containing 2 mM DTT was performed by scan-
ning a temperature range of 25 to 70 °C at a rate of 1.2 °C/min.
In the cases indicated, L-Phe was added to a final concentration
of 1 mM. Changes in 8-anilino-1-naphtalenesulfonic acid fluo-
rescence emission (Sigma) were monitored at 500 nm (excita-
tion 395 nm, slit widths 5.0/10.0 nm). The phase transitions of
three to eight independent experiments were determined, and
the respective transition midpoints were calculated using the
Boltzmann sigmoidal equation. Transition midpoints for wild-
type and variant PAHwith and without L-Phe were plotted and
compared using a paired t test.
RESULTS
Direct Fluorescence Detection of Enzymatic L-Tyr Production—
To date measurement of PAH activity is routinely performed
using a standard reaction mixture containing the apoenzyme,
Fe2, L-Phe, and BH4 followed by time-consuming chromato-
graphic separation of substrate and product. Yet differences in
the fluorescence properties of the aromatic amino acids L-Phe
and L-Tyr, such as emission and excitation wavelengths as well
as the quantum yield, would allow for spectral separation of
these substances even in a mixed solution.
To determine spectral separation of the two substances, we
assessed fluorescence signal intensities of varying L-Tyr con-
centrations at 304 nm (35), the L-Tyr emission wavelength, as a
function of increasing L-Phe concentrations. We showed that
direct in-well detection of L-Tyr was unaffected by the various
L-Phe concentrations used in our assay (Fig. 1A and sup-
plemental Fig. 1A). This was true for all L-Tyr concentrations
expected in the following enzyme kinetic measurements. How-
ever, L-Tyr fluorescence signal intensities decreased with
increasing BH4 concentrations (supplemental Fig. 1B), suggest-
ing an IFE of BH4 on L-Tyr excitation and emission. Therefore,
we determined specific correction factors on the basis of the
factorial decrease of signal intensity for every BH4 concentra-
tion added to account for the IFE (Fig. 1B) (27, 28). Evaluation of
the IFE of BH4 and calculation of the correction factor for each
BH4 concentration added to the reaction mixture was per-
formed before each enzyme kinetic measurement (Fig. 1B).
The analysis of steady state enzyme kinetics using direct in-
well detection of L-Tyr production revealed a time-dependent
change of enzyme activity upon the addition of BH4, with an
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initial high activity burst phase (Fig. 1C and Fig. 1D, top) fol-
lowed by a linear steady state rate of catalysis for the L-Phe
preincubated (activated) enzyme (Fig. 1C and Fig. 1E, top). In
contrast, the non-activated enzyme showed an initial lag-phase
(Fig. 1C and Fig. 1D, bottom) before a linear phase of L-Tyr
production (Fig. 1C and Fig. 1E, bottom).
In addition, time-dependent initial velocity measurements
require substrate turnover to remain less than 10% that of the
FIGURE 1.Anovel continuous assay for themeasurementof PAHactivity.A, fluorescence intensity (I304) of L-Tyr concentrations (0–150M)with increasing
L-Pheconcentrations (0, 243, 490, and958M) is shown. L-Tyr fluorescence intensitywasnot influencedby increasing L-Pheconcentrations, confirming spectral
separation of the two substances in one mixed solution. Values are given as the mean  S.E. of three independent measurements. B, quenching of L-Tyr
fluorescence intensity by BH4 is shown.Measurement of L-Tyr (0–150M) subsequent to the addition of increasing BH4 concentrations (0, 25, 75, and 125M),
revealedan inner filter effect of BH4on L-Tyr excitationandemission (left panel). For eachBH4 concentrationused in theassay, a correction factorwas calculated
according to the factorial decrease in signal intensity to account for the inner filter effect (right panel). Values are given as themean S.E. of three independent
measurements. C, continuous measurement of time-dependent wild-type PAH kinetics with and without preincubation of the enzyme with 1 mM L-Phe are
shown. D, L-Phe preincubation (activation) led to burst-phase kinetics within the first 30 s of the reaction (top) followed by a linear phase of L-Tyr production.
Without L-Phepreincubation, an initial lag-phasebefore steady state enzymekineticswas found (bottom, a red linewasused toguide the eye). E, the time frame
chosen for the measurement of steady state enzyme kinetics between 30 and 120 s showed a linear rate of reaction (top, with L-Phe preincubation; bottom,
without L-Phe preincubation). F, a 96-well plate for sequentialmeasurement of PAH enzyme kinetics is shown. Direct in-wellmeasurements of enzyme kinetics
of up to four different PAHenzymes (numbers 1–4)wereperformedby the sequential analysis of 2 rows, consistingof 24wells (red box). Each rowcontained the
PAH enzyme varying substrate concentrations (0–1 mM) and one cofactor concentration (75 M) or varying cofactor concentrations (0–125 M) and one
substrate concentration (1 mM). Repeated cycles allowed kinetic measurements of 24 wells over a time period of 60 s.
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substrate concentrations added to the reaction mixture (23). A
time frame of 60 s for measurement of steady state enzyme
kinetics starting 30 s after the addition of BH4 proved to best
fulfill the criteria of linearity and limited substrate turnover.
To allow for an accurate and efficient performance of the
enzyme kinetic assay, liquid handling and signal detection were
automated using a multi-well fluorescence detection device
with an integrated injection system. Various substrate or cofac-
tor concentrations were injected for L-Phe or BH4-dependent
kinetics, respectively, and process automation enabled sequen-
tial duplicate measurements of up to four different PAH
enzymes, resulting in reduced time for experimental prepara-
tion and procedure (Fig. 1F).
Thus, real-time measurement of PAH product formation
revealed that direct in-well detection of L-Tyr during the cata-
lytic reaction without prior separation of substrate and product
is feasible when BH4 quenching is taken into account. In addi-
tion, real-time kinetics give more insights into both pre-steady
state and steady state kinetics of phenylalanine hydroxylation,
allowing thorough analysis of PAH enzyme kinetics.
A Continuous PAH Activity Assay Reveals BH4-dependent
Cooperativity—The newly developed continuous assay was
used to determine enzyme kinetic parameters at varying sub-
strate concentrations (L-Phe, 1–1000 M) and a constant
cofactor concentration (BH4, 75 M) or at varying cofactor
concentrations (BH4, 0–125 M) and a constant substrate
concentration (L-Phe, 1 mM).
Measurement of L-Phe-dependent PAH kinetics showed sig-
moidal behavior for the activated enzyme (Fig. 2A) as previ-
ously described (24, 36–38). Enzyme kinetic parameters were
calculated by nonlinear regression analysis using the Hill equa-
tion, accounting for substrate cooperativity and comparedwith
the results of a standard discontinuous PAH activity assay
(Table 1) (17). Values for Vmax were substantially higher when
determined by the continuous assay (6598 nmol Tyr/minmg
protein) as compared with the discontinuous assay (3470 nmol
Tyr/minmg protein). However, apparent affinity to the sub-
strate (S0.5 156 M), cooperativity (Hill coefficient, hPhe 3.0),
and substrate activation (activation-fold 2.8) showed virtually
identical results in both experiments (discontinuous assay; S0.5
155 M, hPhe 3.0, activation-fold 3.0). As expected from previ-
ous studies using recombinant human PAH (26, 37) and the rat
enzyme (36), enzyme kinetic parameters obtained without
L-Phe preincubation gave different results (Table 1). Vmax was
markedly lower (2533 nmol Tyr/min  mg protein), and the
apparent affinity of the enzyme to L-Phe (Km 318 M) was
reduced. In addition, binding of L-Phe to the non-activated
enzyme was found to be non-cooperative (hPhe 1.0). This is in
concordance with studies using surface plasmon resonance
(25). The enzyme kinetic parameters determined for both acti-
FIGURE 2. Measurements of wild-type PAH kinetics. A, reaction rates at variable L-Phe concentrations (0–1 mM) and one BH4 concentration (75 M) are
shown. Before initiationof the reactionbyBH4, theenzymewaspreincubated for 5minat 25 °Cwith L-Phe toactivate theenzyme.Nonlinear regressionanalysis
wasperformedusing theHill equation.B andC, reaction rates at variable BH4 concentrations (0–125M) andone L-Phe concentration (1mM) are shown.B, data
obtained for the L-Phepreincubated (activated) enzymewereevaluatedusing theMichaelis-Mentenequation (dashed line) and theHill equation (solid line).C, a
comparison of enzyme kinetics measured using the non-activated (F) and the activated (E) wild-type PAH is shown. The non-activated enzyme showed
non-cooperative binding of BH4. The activated enzyme indicated positive cooperativity for the binding of BH4. D, enzyme kinetics of non-activated and
activated PAH at variable BH4 concentrations (0–50M) and one L-Phe concentration (1 mM) are shown. Data obtained for the non-activated enzymewere fit
to the Michaelis-Menten equation (left panel). Data of the activated enzyme followed Hill kinetics (right panel). For all enzyme activity measurements, fluores-
cence intensity was recorded and after subtraction of the blank reaction converted to enzyme activity units (nmol L-Tyr/minmgprotein) using the standard
curve obtained by L-Tyr concentration measurements. Values are given as the mean S.E. of three independent experiments.
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vated and non-activated PAH were well comparable with the
data found in previous studies (Table 1) (17, 37).
Surprisingly, the data obtained for BH4-dependent PAH
kinetics did not fit to the well accepted Michaelis-Menten
kinetic model. Instead, the data showed a sigmoidal behavior,
indicating BH4-dependent cooperativity (Fig. 2B). Although
BH4-dependent kinetics was as yet mainly determined using
the non-activated enzyme (19, 26), we conducted the assay uti-
lizing the L-Phe-preincubated (activated) enzyme. To examine
whether the Hill kinetic model describing BH4-dependent
kinetic parameters depends on the activation state of the
enzyme, the assay was runwith andwithout prior incubation of
the enzyme by L-Phe, and the results were compared with data
from the literature (Table 2). Similar to L-Phe-dependent
enzyme kinetics, Vmax of the activated enzyme was markedly
lower in the discontinuous assay (3425 nmol Tyr/min  mg
protein) when compared with the continuous assay (7288 nmol
Tyr/minmg protein), but the values for the apparent affinity
to the ligand were comparable for both methods used (Km 24
M; C0.5 33 M) (Table 2). Although the analysis of the non-
activated enzyme showed a reduction in Vmax (2277 nmol Tyr/
minmg protein), an increased apparent affinity to BH4 (Km 8
M) was observed. In addition, steady state kinetic analysis of
activated PAH indicated BH4-dependent-positive cooperativ-
ity (Hill coefficient, hBH4 2.2), whereas Michaelis-Menten
kinetics for the non-activated PAHwas confirmed (Fig. 2C). To
obtain a better resolution of the range that best discriminates
between both kinetic models, the assay was repeated in the
limits of 0–50 M BH4 (Fig. 2D). The data obtained for the
activated enzyme clearly followed Hill kinetics (hBH4 2.0). This
was in contrast to the non-activated enzyme, where nonlinear
regression analysis showed hyperbolic kinetics following the
Michaelis-Menten kinetic model (hBH4 1.0).
The enzyme kinetic parameters determined for L-Phe- and
BH4-dependent enzyme kinetics were well comparable with
previous studies using the standard discontinuous assay (17,
19), confirming the accuracy of our newly developed continu-
ous assay. Furthermore, we aimed to determine the assay pre-
cision and calculated the coefficient of variation for all enzyme
kinetic parameters of the activated enzyme, comparing the
standard discontinuous with the continuous assay. The coeffi-
cients of variation for both L-Phe- and BH4-dependent kinetic
parameters were similar for the two assays, revealing equal pre-
cision in enzyme kinetic measurements (Tables 1 and 2).
In conclusion, allosteric parameters obtained using the
newly developed PAH activity assay were well comparable with
results from standard discontinuous assays. The assay accuracy
as well as precision confirmed the suitability of this method for
the evaluation of enzyme kinetic parameters of PAH. In addi-
tion, PAH kinetic analysis using the continuous assay gave evi-
dence for BH4-dependent cooperativity with PAH activation as
a prerequisite.
BH4-dependent Cooperativity Relies on an Activated Struc-
tural Conformation of PAH—Three variant PAH enzymes,
R68S, V106A, and the dimeric double-truncated form 103–427
(19, 37, 39, 40), were used to characterize the interrelation of
enzyme activation and BH4-dependent cooperativity in more
detail. In particular, we aimed to investigatewhether the shift in
enzyme kinetics from Michaelis-Menten to the Hill kinetic
model depends on the presence of the L-Phe substrate itself or
on structural attributes of the activated enzyme. It is known
that substrate activation induces conformational changes (16,
TABLE 1
Comparison of L-Phe-dependent enzyme kinetic parameters obtained by standard PAH activity assay and direct in-well detection of L-Tyr
production
Steady state kinetic parameters of WT MBP-PAH fusion protein are shown. Apparent affinities for L-Phe (S0.5, Km, and the Hill-coefficient (hPhe) as a measure of
cooperativity are shown. Measurements were performed with () and without () L-Phe preincubation of the enzyme. Enzyme kinetic parameters were determined at
variable L-Phe concentrations (0–1000 M) and standard BH4 concentrations (75 M). CV, coefficient of variation, defined as the ratio of the S.D. to the mean value.
L-Phe preincubation Vmax CV S0.5 CV Km hPhe Activation folda
nmol L-Tyr/minmg protein % M % M
WTb  495c 318c 1.5c —
 1550c 154c 2.2c 3.1c
 3470 75d 2 155 6d 4 3.0d 3.0d
WTe  2533 217 — 318 68 1.0 —
 6598 190 3 156 9 6 3.0 2.8
aFold increase in PAH activity by L-Phe preincubation calculated at the standard L-Phe (1 mM) and BH4 (75 M) concentrations.
bMeasurement by standard discontinuous PAH activity assay (HPLC and fluorimetric detection). Values are given as the mean S.E. of three independent experiments.
cFrom Knappskog et al. (37); activation fold was calculated from Vmax.
dFrom Gersting et al. (17).
eMeasurement by continuous PAH activity assay (direct in-well fluorescence detection). Values are given as the mean S.E. of four independent experiments.
TABLE 2
Comparison of BH4-dependent enzyme kinetic parameters obtained by standard PAH activity assay and direct in-well detection of L-Tyr
production
Steady state kinetic parameters of WTMBP-PAH fusion protein are shown. Apparent affinities for BH4 (C0.5) and the Hill-coefficient (hBH4) as a measure of cooperativity
are shown. Measurements were performed with () and without () L-Phe preincubation of the enzyme. Enzyme kinetic parameters were determined at variable BH4
concentrations (0–125 M) and standard L-Phe concentrations (1 mM). CV, coefficient of variation, defined as the ratio of the S.D. to the mean value.
L-Phe preincubation Vmax CV Km CV C0.5 CV hBH4
nmol L-Tyr/minmg protein % M % M %
WTa  3425 139b 4 24 3b 12.5 — 1.0
WTc  2277 84 8 1 — 1.0
 7288 282 4 — 33 2 6 2.2
aMeasurement by standard discontinuous PAH activity assay (HPLC and fluorimetric detection). Values are given as the mean S.E. of three independent experiments.
bFrom Gersting et al. (17).
cMeasurement by continuous PAH activity assay (direct in-well fluorescence detection). Values are given as mean S.E. of four independent experiments.
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37, 41–45) that convert the enzyme from a low activity T-state
to a high activity R-state (Monod Wyman Changeux model)
(46, 47). This is accompanied by an increase in quantum yield
and a red-shifted emission maximum of the Trp-120 residue
(48, 49). To determine the level of preactivation, structural
attributes of the variants were compared with wild-type PAH.
Spectral differenceswith andwithout preincubation by the sub-
strate were utilized to assess the activation state.
Tryptophan emission scans of wild-type PAH and the vari-
ants R68S and 103–427 were performed. As expected, wild-
type PAH revealed a red shift in the emissionmaximum (340 to
351 nm) and an increase in intrinsic tryptophan fluorescence
(247–296 arbitrary units) upon the addition of L-Phe (Fig. 3A)
(Table 3). Both variants showed a red-shifted emission maxi-
mum in the absence of L-Phe, which was more pronounced for
the dimeric variant.Upon L-Phe preincubation, R68S yielded an
emission maximum of the activated wild-type (351 nm),
whereas the emission maximum of the dimeric PAH remained
unchanged (350 nm). Both variants showed an increase in
quantumyield but to a lesser extent than observed forwild-type
PAH. Furthermore, we determined activation-induced struc-
tural rearrangements for all three variants by thermal unfolding
using temperature-dependent differential scanning fluorimetry
(Fig. 3B). Although the addition of L-Phe induced a highly sig-
nificant increase in the transition midpoint for wild-type PAH
(p 0.0006), no significant increase was found for the variants
R68S and V106A (Fig. 3B) (Table 4). These variants already
showed increased transition midpoints at the activated wild-
type level even without L-Phe preincubation. The dimeric PAH
103–427, although showing markedly decreased transition
midpoints in general, revealed a significant increase when
L-Phe was added (p 0.0345). Taken together, all variants dis-
played structural characteristics that are indicative of muta-
tion-induced conformational preactivation but to different
extents.
According to the results on structural preactivation, evalua-
tion of the activation-fold determined by the continuous assay
(Fig. 3C) (Table 5) confirmed functional preactivation of the
variants without L-Phe preincubation (R68S, 0.9; V106A, 1.0;
103–427, 1.3). Nonlinear regression analysis of BH4-dependent
kinetics of all three preactivated variants followed the Hill
model as shown for activated wild-type PAH. Although dis-
tinctly positive, the Hill-coefficients ranging from 1.6 to 2.1
were lower than that determined for activated wild-type PAH
(h, 2.2). The dimeric variant 103–427 showed a Vmax (1980
nmol Tyr/minmg protein) comparable with that of the non-
activated wild-type PAH, which did not change markedly upon
L-Phe preincubation (2421 nmol Tyr/minmg protein). This
is in contrast to an increase by 3.2-fold observed for wild-type
PAH preincubated with L-Phe. However, for the variants R68S
and V106A, a Vmax comparable with the activated wild-type
PAH was found without L-Phe preincubation, and no further
increase was measured when the substrate was present. R68S
and V106A without L-Phe preincubation showed lower cofac-
tor affinities than the non-activated wild-type PAH; however,
the values were at the same level as determined for the L-Phe
preincubatedwild-type PAH.C0.5 of the dimeric PAH103–427
was 2-fold higher as compared with the non-activated wild-
type PAH. Notably, no marked changes in sigmoidal behavior
and kinetic parameters were observed for all variants irrespec-
tive of whether they were preincubated by L-Phe (Fig. 3C)
(Table 5). In summary, analyses of structurally preactivated
variants substantiated BH4-dependent positive cooperativity of
FIGURE 3. Determining the activated structural and functional conformation. A, intrinsic tryptophan fluorescence emission spectra of the Factor Xa
cleavedwild-type PAH, variant PAHR68S, and 103–427 are shown. Fluorescence emission spectrawere acquired in the absence (dashed line) or presence (solid
line) of 1mML-Phe. Theexcitationwavelength for Trp fluorescencemeasurementswas295nm,withanexcitationandemission slit of 2.5 and5nm, respectively.
a.u., arbitraryunits.B, differential scanning fluorimetryof thewild-typePAHandvariant PAHR68S, V106A, and103–427 fusionprotein are shown.Denaturation
of PAH was monitored by scanning a temperature range of 25 to 70 °C at a rate of 1.2 °C/min. Changes in 8-anilino-1-naphtalenesulfonic acid fluorescence
emissionweremonitored at 500 nm (excitation 395nm, slit widths 5.0/10.0 nm). The fraction unfoldedof three to four independent experiments forwild-type,
R68S, and 104–427 and seven to eight independent experiments for V106Awithout L-Phe (solid line) and with 1mM L-Phe (dashed line) were determined (top
panel; wild-type (black), R68S (blue), V106A (green), and 103–427 (red)), and the respective transitionmidpointswere calculatedusing theBoltzmann sigmoidal
equation. For comparison of the transition midpoints, a paired t test, two-tailed, was used. Transition midpoints for wild-type and variant PAH, with (E) and
without (F) L-Phe preincubation were plotted and compared (bottom panel) (ns, not significant; *, p 0.05; **, p 0.01; ***, p 0.001). C, enzyme activity
measured for thewild-typePAHand thepreactivated variants R68S, V106A, and103–427without preincubation (F) andwithpreincubationof the enzyme (E)
with 1mM L-Phe before initiation of the reaction by the addition of BH4. Data obtained for the non-preincubated and preincubated enzymes followed the Hill
kineticmodel as shown for the activatedwild-typePAH. For all enzymeactivitymeasurements, fluorescence intensitywas recordedandafter subtractionof the
blank reaction converted to enzyme activity units (nmol of L-Tyr/minmgprotein) using the standard curve obtained by L-Tyr concentrationmeasurements.
Values are given as the mean S.E. of three independent experiments.
TABLE 3
Trp emission scans of PAH cleaved by factor Xa
Tryptophan fluorescence emission spectra were obtainedwith andwithout L-Phe (1
mM) preincubation of the cleavedWTPAH and preactivated variants. Fluorescence
measurements were performed using a fluorescence spectrophotometer at an exci-
tation wavelength of 295 nm with excitation and emission slits set to 2.5 and 5 nm,
respectively. a.u., arbitrary units.
Without L-Phe
preincubation
With L-Phe
preincubation
Wavelength Fluorescenceintensity Wavelength
Fluorescence
intensity
nm a.u. nm a.u.
WT 340 247 351 296
R68S 345 266 351 304
103–427 350 288 350 310
TABLE 4
Mean transition midpoints of thermal denaturation assays
Calculation of transition midpoints from differential scanning fluorimetry of WT
PAH and preactivated variants with and without 1 mM L-Phe. Transition midpoints
were calculated using the Boltzmann sigmoidal equation. Transition midpoints are
given as themean S.E. of three to four for V106A eight independent experiments.
Mean transition midpoints with and without L-Phe were compared using a paired t
test, two-tailed. NS, not significant.
Tm
p valueWithout L-Phe
preincubation
With L-Phe
preincubation
°C
WT 47.49 0.46 50.90 0.38 p 0.0006
R68S 49.28 0.78 50.15 0.64 NS
V106A 49.63 1.40 51.11 0.21 NS
103–427 37.68 0.32 40.99 0.54 p 0.0345
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the activated enzyme, where the kinetic model does not rely on
the presence of L-Phe but is determined by activating confor-
mational rearrangements.
Evaluation of Model Fitting—To validate the experimental
data on conditions that determine PAH cooperativity, an
extended evaluation of model fitting by nonlinear regression
analysis of BH4-dependent kinetics was performed. The test
parameters goodness of fit (R2), root mean square (Sy.x), runs
test, and residuals of values were compared, and an F-test was
run to discriminate between the two nested kinetic models
Michaelis-Menten and Hill for activated and non-activated
PAH, respectively.
First we analyzed non-activated PAH.A simple calculation of
goodness of fit (R2) did not allow for distinction between the
two models used for data analyses (R2MM 0.97; R2H 0.97)
(supplemental Table 1). The residuals of values (supplemental
Fig. 2) and, thus, the S.D. of the residuals also showed no
marked improvement of data description by the more compli-
catedHill equation. Although the runs test showed amarginally
significant deviation of the data from the Michaelis-Menten
model (p  0.048), the F-test proved the simpler Michaelis-
Menten kinetics to be the correct model for data analysis of
BH4-dependent kinetics of non-activated PAH (F ratio 2.86;
p 0.125) (Table 6). This was confirmed by refined analysis of
BH4-dependent kinetics in the limits of 0–50M. As before,R2,
Sy.x, and the residuals of values did not allow for a clear distinc-
tion between the twomodels (supplemental Table 1). However,
no significant deviation of the data from any of the two equa-
tions could be determined by the runs test. Yet again, the F-test
revealed that the data were best described by the simpler
Michaelis-Menten kinetic model (F ratio 0.58; p  0.463)
(Table 6).
In contrast to non-activated PAH, enzyme activation by
L-Phe now resulted in marked differences of the two models
even by goodness of fit (R2MM 0.96; R2H 0.99) (supplemental
Table 1) (Table 6). In addition, evaluation of the data by theHill
equation revealed a decrease of Sy.x by 	2-fold, and the resid-
uals of values showed less fluctuation (supplemental Fig. 2). The
runs test showed no significant deviation from any of the two
models used, but comparison by the F-test resulted in a highly
significant p value (F ratio 274.28; p 0.0001) (Table 6) favor-
ing Hill kinetics. Detailed analysis at low BH4 concentrations
(0–50M) additionally uncovered a significant deviation of the
data from Michaelis-Menten kinetics in the runs test (p 
0.024) (Table 6) (supplemental Table 1 and Fig. 2). Taken
together, the evaluation of model fitting provided clear evi-
dence for BH4-dependent positive cooperativity of activated
PAH,whereas the BH4-dependent kinetics of the non-activated
enzyme followed the non-cooperative Michaelis-Menten
model.
Next, we aimed to learn whether the presence of the L-Phe
substrate has an impact on the kinetic model beyond L-Phe
induced conformational changes upon PAH activation. To val-
idate structural preactivation of R68S, V106A, and of the
dimeric double-truncated 103–427 PAH, we first analyzed
whether BH4-dependent kinetic data would fit significantly
better to the more complex Hill equation even without L-Phe
preincubation. Indeed, we identified an increase in R2, a more
than 2-fold decrease in Sy.x, and a significant deviation of the
Michaelis-Menten model in the runs test for the variants R68S
and V106A (supplemental Table 2). Only the dimeric 103–427
showed a less pronounced reduction in Sy.x and no discrimina-
tion between the two models in the runs test. In all cases fluc-
tuation of the residuals of values was lower using the Hill equa-
tion (supplemental Fig. 2). This was in line with the results
obtained by the F-test (p  0.01) (Table 7). Hence, the kinetic
data fit significantly better to the more complicated Hill equa-
tion, indicating substrate-independent structural preactiva-
tion. Second, model fitting of the structurally activated variants
was compared with and without prior incubation with L-Phe in
the next step. All in all, the presence of L-Phe only negligibly
changed the test results. Only for the dimeric 103–427, Sy.x
was markedly lower upon evaluation by sigmoidal kinetics,
and the runs test classifiedMichaelis-Menten as an incorrect
TABLE 6
Comparison of two nested non-linear regression models
F-test for two nested models after measurement of wild-type PAH kinetics without
and with preincubation of the enzyme with L-Phe. Enzyme kinetics were measured
with L-Phe (1 mM) and BH4 (0–125 M and 0–50 M). The F-test assumes that the
Michaelis-Menten equation is a simpler case of the Hill equation. If the simpler
model is correct, the F ratio is near 1.0. To verify the correctness of the more
complicated model (if the F ratio is
1.0), the p value is calculated. If the p value is
less than the traditional significance level of 5%, it can be concluded that the data do
not randomly fit to the more complicated model but fit significantly better to Hill
than to Michaelis-Menten kinetics.
BH4
F-test
L-Phe preincubation F ratio p value
M
0–125  2.86 0.125
0–125  274.28 0.0001
0–50  0.58 0.463
0–50  62.79 0.0001
TABLE 5
Comparison of BH4-dependent enzyme kinetic parameters of variant PAH proteins with and without L-Phe preincubation
Steady state kinetic parameters of variant MBP-PAH fusion proteins were determined by direct in-well activity measurements. Apparent affinities for BH4 (C0.5) and the
Hill-coefficient (h) as a measure of cooperativity are shown. Enzyme kinetic parameters determined at variable BH4 concentrations (0–125 M) and standard L-Phe
concentrations (1 mM) with and without preincubation of the enzyme with L-Phe (1 mM).
Without L-Phe preincubation With L-Phe preincubation
Vmaxa Km C0.5a hBH4 Vmax
a C 0.5a hBH4 Activation fold
b
nmol L-Tyr/minmg protein M M nmol L-Tyr/minmg protein M
WT 2277 84 8 1 — 1.0 7288 282 33 2 2.2 2.8
R68S 7928 232 — 29 1 1.8 6940 225 34 2 1.8 0.9
V106A 9041 489 — 40 3 1.6 9773 534 43 4 1.8 1.0
103–427 1980 100 — 16 2 2.1 2421 73 19 1 2.6 1.3
aValues are given as the mean S.E. of three independent measurements.
bFold increase in PAH activity by L-Phe preincubation calculated at the standard L-Phe (1 mM) and BH4 (75 M) concentrations.
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model (supplemental Table 2). Again, all data provided evi-
dence for a correct data description by the Hill kinetic model
(supplemental Table 2 and Fig. 2) (Table 7).
In summary, extended analysis and comparison of the two
non-linear regression models Michaelis-Menten and Hill
revealed non-cooperative kinetics of the non-activated enzyme,
whereas activation of the enzyme clearly induced cooperativity.
Moreover, L-Phe preincubation did not have a significant
impact on the kinetic model of structurally activated variant
PAH.
DISCUSSION
In this study we established a newmethod for the evaluation
of PAH kinetic parameters, allowing for real-time detection of
enzyme activity. Continuous assays are the safest means of
determining reaction velocity from the slope of a plot of signal
versus time (23). However, many assays used for the evaluation
of PAH enzyme kinetics are discontinuous due to chromato-
graphic separation of the substrate from the product before
product detection. We aimed to establish the measurement of
L-Tyr production without separation from the substrate L-Phe.
The spectral properties of the aromatic amino acids and differ-
ences in quantum yield allowed for direct detection of L-Tyr
uninfluenced by L-Phe concentrations. However, the IFE of
BH4 at the excitation and emission maxima of L-Tyr (274 and
304nm, respectively) had to be taken into account. By analyzing
the IFE of BH4 on L-Tyr fluorescence in the entire range of
concentrations used in the assay, a concentration-dependent
correction factor was defined (27, 28). This facilitated accurate
and precise quantification of L-Tyr product formation inside
the assay reaction mixture. In addition, all substances required
to perform the activity assay were applied by means of an inte-
grated injection system. Although equally precise, this led to
marked time reduction in sample preparation. Furthermore,
sequential duplicate measurements subsequent to sample
injections of up to four different PAH proteins in a 96-well
format substantially increased the throughput of enzyme kinet-
ics analyses. The addition of various substrate and cofactor con-
centrations as well as their injection at different time-points
proved this method to be very flexible, allowing for numerous
assay conditions in one single run.
By applying the new technique, we observed burst-phase
kinetics of preactivated and lag-phase kinetics of non-activated
PAH. The discontinuous assays used previously measured
product formation from the initiation of the reaction to a
defined end point, and burst- and lag-phase kinetics were not
taken into consideration. However, pre-steady state kinetics
should not be ignored as they may lead to erroneous interpre-
tations regarding the existence of cooperativity (50). A com-
pletemodel describing the enzyme reaction is a prerequisite for
comprehensive understanding of the mechanisms involved in
pre-steady state kinetics. Assumptions to approach such a
model have been made using a prokaryotic monomeric PAH
(51). Yet this enzyme lacks the regulatory properties of the
oligomeric multidomain human protein and is, therefore, not
applicable to human PAH. Therefore, we decided to assess
steady state kinetics at a 1-min time frame after the burst-phase
and provided a linear rate of reaction velocity for the non-acti-
vated and the activated enzyme while remaining within 10% of
substrate turnover.
The data of continuous measurements were compared with
our results obtained previously by the discontinuous assay as
well as to data described in the literature. Differences in Vmax
between the discontinuous and the continuous assay were
found. These variations may be due to the different methods
used, yet additional aspects such as different time frames for
measurement of steady state kinetics and the improvement of
protein purification methods in our laboratory within the last
years play an important role andmay further explain these find-
ings. Notably, large differences in enzyme activities, ranging up
to 7-fold, can also be found in the literature (16, 37, 52, 53).
However, kinetic parameters describing apparent affinity and
enzyme allostery (S0.5, Km/C0.5, Hill coefficient (h), and activa-
tion-fold) were similar to results obtained using discontinuous
assays and to results previously described (17, 37), confirming
the accuracy of our newly developed continuous assay. Further-
more, calculation of the coefficient of variation proved the new
assay to be as precise as the standard discontinuous assays
applied.
Interestingly, data points did not fit to theMichaelis-Menten
kinetic model when themethod was applied to determine BH4-
dependent enzyme kinetics. Instead, a good fit was found apply-
ing the Hill kinetic model. All previous studies using different
methods had shownhyperbolic non-cooperative binding kinet-
ics of the cofactor to PAH (17, 19, 25, 53). When applying the
continuous assay, BH4-dependent kinetics of wild-type PAH
revealed positive cooperativity. However, our experiments
were performed with an L-Phe-preincubated (activated) enzyme,
whereas inmost of the previous studies the non-activated enzyme
had been used. To elucidate whether PAH activation determines
cofactor dependent cooperativity, we compared enzyme kinetics
of non-activated and of activated PAH. In agreement with previ-
ous findings, the continuous assay without L-Phe preincubation
resulted in hyperbolic binding kinetics of BH4. Together with the
observed BH4-dependent cooperativity of activated PAH, these
results suggested that cooperativity of BH4 depends on an acti-
vated state of the enzyme.
Thus, we investigated whether the shift in enzyme kinetics
from Michaelis-Menten to the Hill kinetic model depends on
TABLE 7
Comparison of two nested non-linear regression models with and
without preincubation of preactivated variants
F-test for two nested models after measurement of enzyme kinetics without and
with preincubation of the enzyme with L-Phe. Enzyme kinetics were measured with
L-Phe (1 mM) and BH4 (0–125 M). The F-test assumes that the Michaelis-Menten
equation is a simpler case of the Hill equation. If the simpler model is correct, the F
ratio is near 1.0. To verify the correctness of the more complicated model (if the F
ratio is 
1.0), the p value is calculated. If the p value is less than the traditional
significance level of 5%, it can be concluded that the data do not randomly fit to the
more complicated model but fit significantly better to Hill than to Michaelis-Men-
ten kinetics.
F-test
L-Phe preincubation F ratio p value
R68S  58.02 0.0001
R68S  69.63 0.0001
V106A  24.00 0.001
V106A  35.44 0.001
103–427  10.66 0.01
103–427  40.23 0.001
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the presence of the L-Phe substrate itself or on structural
attributes of the activated enzyme. This was dissected bymeans
of conformationally preactivated genetic variants of PAH
(R68S, V106A, dimeric 103–427). Using two different spectro-
scopic techniques we analyzed local and global effects on pro-
tein structure bymutation/truncation or by L-Phe, respectively,
and correlated this with enzyme kinetic parameters. Preincu-
bation of wild-type PAH with L-Phe leads to a series of struc-
tural and functional changes resulting in enzyme activation (16,
37, 41–45). On the structural level these include a red-shifted
and enhanced tryptophan emission and a right-shifted thermal
denaturation profile. On the functional level an increase in
Vmax, a decreased apparent affinity, and a switch from non-
cooperative to positive cooperative kinetics accounted for acti-
vation. All three variants displayed characteristics of structural
and functional preactivation but to varying degrees. Preactiva-
tion of the variants was reflected by the activation-fold with
values ranging from 0.9 to 1.3. Furthermore, all variants dis-
played clear positive cooperativity without prior incubation
with the substrate. In the presence of L-Phe some selective
structural changes for single variants were observed, i.e. a
minor shift in tryptophan emission for R68S and a significantly
enhanced transition midpoint of the thermal denaturation for
103–427. However, no variant showed decisive changes in
enzyme kinetic parameters upon L-Phe preincubation. This
observation held true irrespective of whether the parameter
was at the same level as activated wild-type PAH. These data
provide evidence that the variants are activated at a struc-
tural level and that L-Phe does not have any additional effect
on their activity and cooperativity. We conclude that the
conformation associated with preactivation accounts for
positive cooperativity where L-Phe induces activating con-
formational changes that in turn lead to allostery. The addi-
tion of the substrate to the assay, however, does not induce
cooperativity by itself.
Mathematical analyses of the data obtained by enzyme
kinetic measurements were used to substantiate our findings
on the comparison of the kinetic models (29, 34, 54–58). A
simple calculation of best-fit parameters for enzyme kinetic
data (R2, root mean square, runs test) did not always allow for a
clear distinction between the Michaelis-Menten and the Hill
model. However, the application of an F-test made evident to
which biological mechanism the kinetic data are linked with
highest probability (29–32). Even though a more complex
model like the Hill equation would always fit the experimental
data better than a simpler model, the F-test revealed that kinet-
ics of non-preincubated wild-type PAHwere not described sig-
nificantly better by this model. However, analysis of the L-Phe-
activated enzyme gave a significant p value in the F-test for the
Hill equation and, thus, proved positive cooperativity. These
findings were corroborated when enzyme kinetic analyses were
focused on the area of distinct sigmoidality, i.e. on the range of
0 to 50 M BH4. Statistical analyses of model fitting for preac-
tivated PAH variants verified BH4-dependent cooperativity
even without prior incubation with L-Phe. Taken together,
mathematical analyses of the cofactor-dependent enzyme
kinetic data confirmed that the non-activated enzyme follows
Michaelis-Menten kinetics, whereas the activated enzyme
shows cooperativity.
Cooperativity of PAH to the L-Phe substrate is reflected by a
Hill coefficient of
3.0 and has previously been described to be
propagated throughout the whole tetramer (59). Alterations in
the orientation of the oligomerization domain transfer cooper-
ative activating conformational changes from one to the other
dimer. This requires a switch between a low affinity “T-state”
conformation to a high affinity “R-state” conformation at ele-
vated L-Phe concentrations following the model proposed by
Monod, Wyman, and Changeux. The Hill coefficients of BH4-
dependent kinetics determined for the L-Phe preincubated
(activated) wild-type PAH and the preactivated variants in this
study were	2.0. The current study may, thus, allow speculat-
ing that enzyme activation leads to positive cooperativity in
BH4 binding. The dissimilar Hill coefficients for substrate and
cofactor binding may also show that cooperative binding of
BH4 follows different conformational alterations propagating
cooperativity than found for L-Phe binding. This may explain
that positive cooperativity was not only observed for the tet-
rameric enzyme but also for the truncated PAH 103–427 that
lacks the regulatory and the oligomerization domain and, thus,
only exists in dimeric form. However, whether there is cooper-
ative behavior of PAH upon BH4 binding in the strict mecha-
nistic sense or hysteresis leading to cooperative kinetics could
not be fully elucidated. Further crystallization andNMRstudies
are needed for a thorough understanding of the impact of L-Phe
and BH4 binding on cooperative allosteric changes in PAH
structure.
In conclusion, the development of a novel method for real-
time measurement of PAH activity provided accurate, fast,
and efficient PAH enzyme kinetic measurements in a 96-well
format. Application of this method for wild-type PAH
revealed BH4-dependent positive cooperativity previously
not described. Spectroscopic assessment of activating confor-
mational changes and statistical evaluation ofmodel-fitting dis-
closed PAH activation as a prerequisite for BH4-dependent
positive cooperativity. BH4 has recently been approved as a
pharmacological chaperone drug in the treatment of phenyl-
ketonuria. We showed that the presence of L-Phe affects the
BH4-dependent kinetic properties of PAH. These findingsmay,
thus, have implications for an individualized therapy, as they
support the hypothesis that patient metabolic state may have a
more significant effect on the interplay of the drug and the
conformation and function of the target protein than currently
appreciated.
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SUPPLEMENTAL MATERIALS AND METHODS 
 
Real-time multi-well kinetic analysis. The application of the enzyme reaction mixture to a 96-well plate 
with varying substrate concentrations was automated using a multi-well fluorescence detection device 
with integrated injection system (FLUOstar OPTIMA, BMG Labtech). The reaction was initiated by 
sequential injection of BH4 with and without simultaneous injection of L-Phe, allowing the determination 
of L-Tyr production in all wells after the following scheme. Following the injection of BH4, L-Phe and a 
final mixture of the samples, 2 rows consisting of 24 wells were measured in repeated cycles over a time 
period of 60 seconds (Fig. 1F), the time frame evaluated to be within the linear range of action for the 
enzyme concentration used (Fig. 1E).  
 
Defining the protein concentration. Enzyme activity was measured using the assay described under 
standard conditions with 1 mM L-Phe and 75 µM BH4, with varying protein concentrations (0.005-3 
mg/ml). Production of L-Tyr was measured directly over a time period of 10 minutes. Initial velocity was 
determined as the time period in which less than 10 % of the substrate is utilized. For all protein 
concentrations, steady state kinetics occurred 30 seconds after initiation of the reaction and burst-phase 
kinetics. With decreasing protein concentrations, steady state kinetics were linear over increasing periods 
of time, yet sensitivity for the measurement of L-Tyr production decreased. All measurements were 
assayed as triplicates and all concentrations refer to a final volume of 204 µl. 
A final protein concentration of 0.01 mg/ml with an optimal time range of 60 seconds for linear range of 
reaction was chosen for all activity assays (Fig. 1E). 
 
 
FIGURE LEGENDS 
 
SUPPLEMENTAL FIGURE 1. Verifying spectral separation and the inner filter effect of BH4. A, To 
verify spectral separation needed for the direct in-well fluorescence detection of enzymatic L-Tyr 
production, 190 µM L-Tyr were measured at the L-Tyr excitation wavelength 304 nm as a function of 
increasing L-Phe concentrations. L-Tyr fluorescence signal intensities uninfluenced by increasing L-Phe 
concentrations are shown. B, A decrease in L-Tyr fluorescence intensity with increasing BH4 
concentrations, as applied in the BH4-dependent enzyme activity assay, is shown. Specific correction 
factors were determined on the basis of the factorial decrease of signal intensity for every BH4 
concentration added to the reaction mixture to account for its inner filter effect. 
 
SUPPLEMENTAL FIGURE 2. Comparison of non-linear regression model fitting by the Michaelis-
Menten and the Hill kinetic model. Residuals of values calculated using the Michaelis-Menten and Hill-
equation for non-linear regression analysis of the enzyme kinetic data obtained for the wild-type PAH, 
R68S, V106A and the dimeric PAH 103-427, without (-) and with (+) preincubation of the enzyme with 1 
mM L-Phe, are shown. Enzyme kinetics were determined with varying BH4 concentrations (0-50 and 0-
125 µM) and one L-Phe concentration (1 mM). The residuals of values were used as the primary criteria 
for selecting one model over the other. In case of indifferent residuals of values, the simpler Michaelis-
Menten kinetic model was chosen for data-fitting because a more complex model like the Hill equation 
would always fit the experimental data better than a simpler model. A good model fitting reduces the 
residuals to zero. The model best describing the enzyme kinetic data obtained is shown in green. While 
BH4-dependent enzyme kinetics of the non-activated wild-type PAH were best described by the 
Michaelis-Menten equation, the activated wild-type PAH and the preactivated variants followed the Hill 
kinetic model.  
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SUPPLEMENTAL TABLE 1. Comparison of two nested non-linear regression models 
  Henri-Michaelis-
Menten-Equation   Hill-Equation   
[BH4] µM 
L-Phe 
preincubation R
2 Sy.x Runs R2 Sy.x Runs 
0-125  - 0.9660 127.5 3§ (P = 0.048) 0.9742 117.8 8 n.s. 
0-125 + 0.9609 559.2 5 n.s. 0.9943 225.6 7 n.s. 
0-50 - 0.9802 46.60 6 n.s. 0.9813 47.75 10 n.s. 
0-50 + 0.9806 287.0 3§ (P = 0.024) 0.9973 112.1 6 n.s. 
Analysis of goodness of fit, Sy.x and runs test for two nested models after measurement of wild-type PAH kinetics 
without and with preincubation of the enzyme with L-Phe. Enzyme kinetics were measured with L-Phe (1 mM) 
and BH4 (0-125 µM and 0-50 µM). 
§ If the data were randomly scattered above and below the curve, there is less than 5% chance of observing so few 
runs. The data systematically deviate from the curve. Most likely, the data were fit to the wrong equation. P < 0.05 
 
 
 
SUPPLEMENTAL TABLE 2. Comparison of two nested non-linear regression models with and without 
preincubation of preactivated variants  
  Henri-Michaelis-
Menten-Equation   
Hill-
Equation   
 L-Phe 
preincubation R
2 Sy.x Runs R2 Sy.x Runs 
R68S  - 0.9788 412.4 3§ (P = 0.048) 0.9972 160.3 5 n.s. 
R68S  + 0.9762 385.1 3§ (P = 0.047) 0.9973 138.2 9 n.s. 
V106A  - 0.9850 341.4 3§ (P = 0.024) 0.9956 195.2 9 n.s. 
V106A  + 0.9790 454.7 3§ (P = 0.024) 0.9954 224.9 7 n.s. 
103-427  - 0.9231 197.4 5 n.s. 0.9628 144.8 7 n.s. 
103-427  + 0.9177 265.0 3§ (P = 0.033) 0.9836 124.6 7 n.s. 
Analysis of goodness of fit, Sy.x  and runs test for two nested models after measurement of enzyme kinetics 
without and with preincubation of the enzyme with L-Phe. Enzyme kinetics were measured with L-Phe (1 
mM) and BH4 (0-125 µM). 
§ If the data were randomly scattered above and below the curve, there is less than 5% chance of observing so 
few runs. The data systematically deviate from the curve. Most likely, the data were fit to the wrong 
equation. P < 0.05 
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The discovery of a pharmacological treatment for phenylketonuria (PKU) raised new questions about func-
tion and dysfunction of phenylalanine hydroxylase (PAH), the enzyme deficient in this disease. To investigate
the interdependence of the genotype, the metabolic state (phenylalanine substrate) and treatment (BH4 cofac-
tor) in the context of enzyme function in vitro and in vivo, we (i) used a fluorescence-based method for fast
enzyme kinetic analyses at an expanded range of phenylalanine and BH4 concentrations, (ii) depicted PAH
function as activity landscapes, (iii) retraced the analyses in eukaryotic cells, and (iv) translated this into
the human system by analyzing the outcome of oral BH4 loading tests. PAH activity landscapes uncovered
the optimal working range of recombinant wild-type PAH and provided new insights into PAH kinetics.
They demonstrated how mutations might alter enzyme function in the space of varying substrate and cofac-
tor concentrations. Experiments in eukaryotic cells revealed that the availability of the active PAH enzyme
depends on the phenylalanine-to-BH4 ratio. Finally, evaluation of data from BH4 loading tests indicated
that the patient’s genotype influences the impact of the metabolic state on drug response. The results
allowed for visualization and a better understanding of PAH function in the physiological and pathological
state as well as in the therapeutic context of cofactor treatment. Moreover, our data underscore the need
for more personalized procedures to safely identify and treat patients with BH4-responsive PAH deficiency.
INTRODUCTION
Phenylketonuria (PKU; OMIM #261600), the most common
inborn error of amino acidmetabolism, is an autosomal recessive
disorder caused by phenylalanine hydroxylase (PAH) deficiency
(PAH; EC 1.14.16.1) (1). Currently, 627 different disease-
causing mutations in the PAH gene are known (www.pahdb.m
cgill.ca; www.hgmd.org) and some of these were shown to
lead to protein misfolding with loss of function (2–4).
Pharmacological doses of 6R-L-erythro-5,6,7,8-tetrahydro-
biopterin (BH4), the enzyme’s natural cofactor, can reduce
blood phenylalanine concentrations (5–10) and increase
phenylalanine oxidation rates in vivo (11) in patients with
PAH deficiency without any evidence of cofactor deficiency.
The compound was shown to rescue the biochemical pheno-
type by correcting PAH misfolding and was thus classified
as a pharmacological chaperone (4,12). Following these
studies, sapropterin dihydrochloride, the synthetic form of
the natural PAH cofactor, was approved as an orphan drug
to alleviate or even replace burdensome dietary treatment in
a significant share of patients with PKU due to PAH deficiency
(13–16).
However, not all patients show BH4 responsiveness. Since
the introduction of sapropterin dihydrochloride as a pharmaco-
logical treatment, many attempts to predict BH4 responsive-
ness from a patient’s genotype were made (17–19).
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Combined evidence seems to support the view that residual
enzyme activity of individual mutations may be a parameter
that—to some extent—allows for discrimination of responders
and non-responders (19–22). In two studies performed on
Croatian and Turkish populations, calculation of mean in
vitro residual enzyme activity of the two PAH variants
arising from both alleles led to the identification of some
responders with high accuracy, whereas patients with two
fully inactive alleles were found to be always non-responders
(19,22). Yet, in many instances, no clear genotype–phenotype
correlation is found pointing to contributing factors such as the
patient’s age or initial blood phenylalanine concentrations
(17,19). Marked inconsistencies as to BH4 responsiveness
were observed for two of the most common PKU mutations
associated with this particular phenotype, R261Q and
Y414C (17) and for R252W, L48S and R241C homozygous
genotypes (22). In addition, interpretation of genotype
effects is hampered by the fact that .80% of BH4 responders
are compound heterozygous (17).
Hydroxylation of the substrate L-phenylalanine to the
product L-tyrosine with the use of the natural cofactor BH4
and molecular oxygen is a complexly regulated catalytic
mechanism. While L-phenylalanine induces activating confor-
mational rearrangements, BH4 leads to the formation of an
inactive dead-end PAH–BH4 complex (23–26). Recent
studies unraveled new aspects concerning the interplay of
phenylalanine and BH4 having an impact on enzyme kinetics
as well as on drug response. Adoption of an enzyme activity
assay using a newly developed fluorescence-based real-time
PAH activity assay revealed cooperativity of recombinant
PAH towards the BH4 cofactor. This was restricted to the
phenylalanine substrate-activated state of the enzyme indicat-
ing that conformational rearrangements of the PAH protein
induce cooperative binding (27). Moreover, investigations of
the BH4 effect in two different mouse models for BH4-
responsive PAH deficiency provided evidence that the
response to BH4 in terms of rescue of enzyme function by
increasing the effective intracellular PAH amount also
depends on phenylalanine concentrations and on the under-
lying genotype (12). These results suggested that the influence
of substrate and cofactor concentrations in the presence of a
certain genotype on enzyme function and on the response to
the pharmacological chaperone BH4 might be of even more
functional and therapeutic relevance than previously esti-
mated. In addition, the BH4 loading test routinely used world-
wide to assess BH4 responsiveness in PAH deficiency (28,29)
was shown to result in a number of inconsistencies that are
still not well understood. In some but not all cases, this may
be due to inadequate BH4 dosage or to initial blood phenyl-
alanine concentrations near to the physiological state. Unfortu-
nately, this may lead to false negative results precluding
cofactor treatment and thus increasing burden of treatment
in some BH4-responsive patients.
To address these issues, (i) we adapted our new
fluorescence-based method for fast enzyme kinetic analyses
to cover an expanded range of phenylalanine and BH4 concen-
trations when compared with previous analytical setups
enabling the investigation of the mutual impact of substrate
and cofactor on PAH enzyme kinetics, (ii) we depicted these
data as activity landscapes uncovering the optimal working
range of recombinant wild-type and mutated PAH, (iii) we
retraced these analyses in a eukaryotic cell culture system,
revealing that the availability of the active PAH enzyme
depends on both the metabolic state and drug dosage, and
(iv) we translated this into the human system by analyzing
the effect of the genotype, phenylalanine concentrations and
the BH4 dosage applied on the results of oral BH4 loading
tests from PAH-deficient patients.
RESULTS
Expanded insights into wild-type PAH kinetics unraveling
the mutual impact of substrate and cofactor concentrations
In order to investigate the interdependence of L-phenylalanine
and BH4 in PAH enzyme kinetics, we adapted a newly devel-
oped fluorescence-based real-time activity assay (27) to simul-
taneously analyze the effect of a wide range of substrate and
cofactor concentrations on PAH activity. Process automation
now allowed for continuous measurement of tyrosine
product formation over time in one single operation consisting
of six sequential runs for all 96 wells (Fig. 1A). The assay was
expanded to cover the space of 0 to 4000 mM L-phenylalanine
and 0–500 mM BH4 (Fig. 1B). First, we validated the data
obtained with the new method by comparison with previous
findings using a standard high-performance liquid chromato-
graphy (HPLC) based discontinuous assay (2). Data points
determined at either varying L-phenylalanine concentrations
(0–1000 mM) and one BH4 concentration (75 mM) or at one
L-phenylalanine concentration (1000 mM) and varying BH4
concentrations (0–125 mM), respectively, were used to calcu-
late enzyme kinetic parameters. Prior to calculation, an F-test
was used to decide whether the Michaelis–Menten or the Hill
kinetic model was more appropriate (27). Both L-phenylalanine
and BH4-dependent PAH enzyme kinetics showed clear data-
fitting to the Hill equation (Fig. 1C), as previously described
for the L-phenylalanine-activated enzyme (27). Although
Vmax values for L-phenylalanine and BH4-dependent kinetics
were higher in the new assay, allosteric parameters, i.e. appar-
ent substrate affinity, the Hill coefficient and apparent cofactor
affinity, were similar in both assays (Table 1).
We depicted the data analyzed by non-linear and poly-
nomial regression fitting as three-dimensional landscapes of
enzyme activity (30). This enabled a visual representation of
the mutual impact of substrate (x-axis) and cofactor concen-
trations (y-axis) on PAH kinetics (color code) representing
functional conditions of the PAH enzyme. Wild-type PAH
showed a peak maximum enzyme activity at 575 mM
L-phenylalanine and 125 mM BH4, respectively (Fig. 1D).
The analysis of PAH enzyme kinetics at BH4 and
L-phenylalanine concentrations extended to supraphysiological
levels led to a number of interesting observations. High PAH
enzyme activity was determined at a surprisingly wide range
of substrate and cofactor concentrations. The optimal
working range reflected by PAH enzyme activity in the bound-
aries of [S]0.5 to Ki for the substrate and [C]0.5 to Ki for the
cofactor spanned from 252 to 2026 mM L-phenylalanine and
from 44 to 306 mM BH4 (Table 2). At L-phenylalanine concen-
trations above 561 mM, we observed the well-known substrate
inhibition of enzyme activity (30,31). Notably, at cofactor
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concentrations above 108 mM cofactor inhibition occurred. In
addition, a mutual interdependence of both inhibitory events
was found. These observations represent previously
unknown findings. Over and above that, at L-phenylalanine
concentrations within the range naturally occurring in the
pathological state (500–1500 mM), the enzyme requires more
BH4 with increasing L-phenylalanine concentrations to main-
tain the same level of enzyme activity.
Taken together, the considerable extension of analysis con-
ditions and the evaluation of data by compiling activity land-
scapes provided new insights into PAH kinetics. It allowed for
a precise evaluation of peak PAH enzyme activity and the
Figure 1. Optimal working range of wild-type PAH activity. (A) Scheme of sequential measurements of PAH enzyme kinetics in a 96-well plate. One sequence
consists of two columns (red box). In each column, cofactor concentrations (0–500 mM) were varied at a fixed substrate concentration (0–4000 mM), respectively.
Repeated cycles allowed for kinetic measurements of 16 wells over a time period of 90 s. (B) Extension of substrate and cofactor concentrations. The range of
L-phenylalanine and BH4 concentrations was expanded from standard conditions (BH4, 75 mM; L-phenylalanine 1000 mM, red box) to 500 mM BH4 and 4000 mM
L-phenylalanine (arrows), respectively. (C) Cooperativity of PAH towards substrate and cofactor. Pre-activated PAH showed sigmoidal behavior for
L-phenylalanine- (upper panel) and BH4-dependent (lower panel) PAH enzyme kinetics. (D) Activity landscape of human wild-type PAH. Data for PAH
enzyme activity assayed at varying L-phenylalanine and BH4 concentrations were interpolated and depicted by a color code. The dot-and-dash line represents
Ki for substrate inhibition at varying cofactor concentrations, the dotted line represents Ki for cofactor inhibition at varying substrate concentrations. With
increasing substrate concentrations, more BH4 is needed to maintain the same level of enzyme activity (solid line).
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optimal working range spanning a wide area of substrate and
cofactor concentrations. Moreover, cofactor inhibition as
well as a mutual impact of substrate and cofactor concen-
trations on PAH activity have been identified.
Activity landscapes: the effect of PAH mutations on PAH
enzyme kinetics
Variant PAH proteins harboring mutations mapping to the
regulatory (F39L, I65T), the catalytic (R216Q, P275L,
P314S, V388M) and the dimerization motif of the oligomeri-
zation domain (Y414C, Y417H) of the enzyme were analyzed.
The results from kinetic measurements were depicted as
activity landscapes and compared with those from wild-type
PAH (Fig. 2). For each variant analyzed, enzyme kinetic par-
ameters and peak enzyme activities with their corresponding
L-phenylalanine or BH4 concentrations were determined
(Tables 2 and 3). The area of optimal enzyme activity
defined as the range [S]0.5 to Ki for the substrate and [C]0.5
to Ki for the cofactor, respectively, was calculated (Table 2).
The variant proteins bearing the mutation F39L or I65T,
both located in the regulatory domain, showed at first glance
a landscape pattern comparable with that of the wild-type.
Besides enzyme activity (F39L, 92%; I65T, 55%), the variants
displayed unaffected enzyme kinetic parameters as well as
similar effects of substrate and cofactor inhibition as found
for the wild-type enzyme. However, a more detailed analysis
revealed that peak PAH activities were found at similar sub-
strate concentrations, but at 1.3-fold higher cofactor concen-
trations when compared with the wild-type. This indicates that
in the presence of these mutations, more cofactor is needed to
achieve optimal PAH function.
All mutations mapping to the catalytic domain induced
marked alterations of activity landscapes. For the variant
R261Q, the area of substantial PAH activity was much
larger than for the wild-type, but residual enzyme activity
was reduced to 42%. The concentrations of substrate and
cofactor needed to achieve peak PAH activity were shifted
to higher values (L-phenylalanine, 1.5-fold; BH4, 1.4-fold).
We observed reduced affinity to the substrate by a factor of
0.5 ([S]0.5 282 mM). Binding of BH4 followed Michaelis–
Menten kinetics representing a loss of cooperativity that
occurred with reduced affinity (Km 66 mM). Broadening of
the landscape resulted from a significant shift of enzyme inhi-
bition. Notably, the variant did not display cooperative binding
of BH4 when activated. Taken together, the unique feature of
Table 2. Peak enzyme activity and range of substrate and cofactor concentrations of wild-type and variant PAH
Peak activity L-phenylalanine BH4
(nmol L-tyrosine/min
× mg protein)
Residual
activity (%)
concentration at
peak activity (mM)
[S]0.5–Ki
§ concentration at
peak activity (mM)
[C]0.5–Ki or Km–Ki
§
WT 6370 100 561 252–2026 108 44–306
F39L 5865 92 622 187–2275 143 35–331
I65T 3533 55 612 254–2075 135 29–322
R261Q 2654 42 842 344–2825 149 41–321
P275L 5215 82 1293 238–1980 334 71–435
P314S 1956 31 612 76–1043 80 42–218
V388M 6355 100 591 201–1933 105 47–296
Y414Ca 3106 49 591 124–1048a 105 43–274
Y417H 5206 82 471 147–1501 92 63–262
Peak enzyme activity of variant tetramericMBP–PAH fusion proteinsmeasured by direct in-well activitymeasurements. The apparent affinities for L-phenylalanine (S0.5)
and BH4 (C0.5/Km) as well as Ki for substrate and cofactor inhibition were calculated based on non-linear regression analysis at L-phenylalanine and BH4 concentrations
of peak enzyme activity.
§Ki calculated at peak L-phenylalanine and BH4 concentrations using the Boltzman-sigmoidal equation.
aCalculation of Ki at a range of L-phenylalanine 0–1624 mM.
Table 1. Comparison of enzyme kinetic parameters of human wild-type MBP–PAH at standard L-phenylalanine (1000 mM) and BH4 (75 mM) concentrations
L-phenylalaninea BH4
b
Vmax (nmol L-tyrosine/min× mg protein) [S]0.5 (mM) hPhe Vmax (nmol L-tyrosine/min × mg protein) [C]0.5 (mM) Km (mM) hBH4
Continuous assay 5407+210 145+11 3.3 5222+286 23+2 2.0
Discontinuous assay 3470+75 155+6 3.0 3425+139 24+3
Steady-state kinetic parameters of wild-type MBP–PAH fusion proteins. Vmax and the apparent affinities for L-phenylalanine (S0.5) and BH4 (C0.5, Km) as well as
the Hill coefficient (h) as a measure of cooperativity are shown. Enzyme kinetic parameters were determined from enzyme activities measured using the newly
developed fluorescence-based continuous assay and compared with enzyme activities measured by the standard HPLC-based discontinuous assay (2). Data were
analyzed using the F-test for model comparison and the kinetic parameters of the best-fitting model (cooperative versus non-cooperative) were calculated. Values
are given as mean+SEM of three independent measurements.
aEnzyme kinetic parameters determined at variable L-phenylalanine concentrations (0–1000 mM) and standard BH4 concentration (75 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
bEnzyme kinetic parameters determined at variable BH4 concentrations (0–125 mM) and standard L-phenylalanine concentration (1000 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
Human Molecular Genetics, 2011, Vol. 20, No. 13 2631
 at Universitaetsbibliothek M
uenchen on June 8, 2011
hm
g.oxfordjournals.org
D
ow
nloaded from
 
the R261Q variant was the right shift of PAH enzyme activity
towards higher L-phenylalanine concentrations indicating a
reduced affinity of this variant to its substrate and that the
enzyme displays low activity at L-phenylalanine concen-
trations below 600 mmol/l. At these substrate concentrations,
even very high BH4 doses would not produce any response
in PAH activity. The presence of the mutation P275L resulted
in an enzyme with overall high residual enzyme activity
(82%), yet with a shift of peak enzyme activity to 2.3-fold
higher L-phenylalanine and 3-fold higher BH4 concentrations
(L-phenylalanine 1293 mM, BH4 334 mM) than the wild-type.
In comparison to the wild-type, the enzyme had a substantially
higher need for BH4 to achieve the optimal working range. As
a consequence, substrate and cofactor inhibition was almost
abolished. The variant protein bearing the mutation P314S
showed a severe loss in residual enzyme activity (31%) with
Figure 2. Activity landscapes of recombinant wild-type and variant PAH. The interpolated specific enzyme activities are color-coded and given as a function of
different L-phenylalanine and BH4 concentrations. Substrate and cofactor inhibition are depicted as a summation line (black dotted line). Positions of S0.5 and Ki
for L-phenylalanine and C0.5 and Ki for BH4, respectively, are indicated at peak enzyme activities (open circles). Marked changes in the activity landscape of
variant PAH when compared with the wild-type (WT) are highlighted (open triangles) and BH4 concentrations needed to maintain the same enzyme activity with
increasing L-phenylalanine concentrations are shown (red dotted line).
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a narrow optimal working range that was shifted towards
lower L-phenylalanine as well as BH4 concentrations. In
addition, enzyme kinetics revealed a significantly increased
apparent affinity to the substrate with marked reduction in
cooperativity. In contrast to previous findings (3,32), where
the variant protein V388M was described as a Km variant
with reduced affinity to the cofactor, we detected high residual
enzyme activity over an expanded range of substrate and
cofactor concentrations. Residual PAH activity was 100%
and peak catalysis (L-phenylalanine 591 mM, BH4 105 mM) as
well as effects of substrate and cofactor inhibition were
similar to that of the wild-type enzyme.
Mutations mapping to the oligomerization domain, Y414C
and Y417H, showed a narrowed optimal working range that
was shifted to lower substrate concentrations. However, this
was less pronounced for the milder mutation Y417H (82%
residual enzyme activity) when compared with Y414C
(49%). On the other hand, Y417H needed less BH4 to
achieve the area of optimal function. Interestingly, different
to all variants analyzed, Y414C showed two peaks of high
enzyme activity.
Taken together, we identified many similarities between the
activity landscapes of the wild-type and variant PAH proteins,
showing generally high residual enzyme activity as well as
substrate and cofactor inhibition. However, these activity land-
scapes also revealed important differences in the regulation of
PAH activity by BH4 and L-phenylalanine and helped to visu-
alize the interdependence of substrate and cofactor concen-
trations on variant PAH enzyme activity.
Cofactor action on PAH function in respect of kinetic
behavior and the chaperone effect
We used two different approaches to analyze different aspects
of cofactor action on the wild-type, R261Q and Y414C PAH
enzyme in HEK293 cells. First, we in part retraced the activity
landscapes analyzing the kinetic behavior by assaying enzyme
activity of cell lysates at different L-phenylalanine
concentrations (0–1000 mM) while keeping the BH4 concen-
tration constant (75 mM) (Fig. 3A). Secondly, we analyzed
the chaperone effect of the BH4 cofactor at different phenyl-
alanine and BH4 concentrations after a 72 h incubation.
As expected, the wild-type protein showed the highest
enzyme activity of all three proteins analyzed with a peak
activity at about 250 mM L-phenylalanine. The latter finding
differed from the peak activity observed for recombinant
PAH at 500 mM. As seen for prokaryotic PAH, a further
increase in L-phenylalanine concentrations resulted in sub-
strate inhibition. The variant R261Q displayed 50% residual
enzyme activity and a lower slope of the curve that leveled off
at a plateau. Reduced enzyme function, which was shifted
toward higher substrate concentrations with a broadened
working range, substantiated results from activity landscapes.
Residual enzyme activity of eukaryotic Y414C was substan-
tially lower than the specific activity of the corresponding
recombinant variant. In addition to peak activity at 180 mM
L-phenylalanine, a second slight incline of activity was
observed at high L-phenylalanine concentrations (1000 mM).
Although generally shifted toward lower substrate concen-
trations, this is in line with the two peaks observed in the
activity landscape.
Next, we aimed to elucidate the long-term chaperone effect
of varying intracellular phenylalanine and BH4 concentrations
on PAH function. The determination of enzyme activity at stan-
dard conditions after previous incubation of cells with different
substrate and cofactor concentrations assays the availability of
functionally active PAH. For this purpose, stably transfected
cells were cultivated with L-phenylalanine concentrations of
91, 500 or 1200 mM and BH4 concentrations of 0, 40 or
75 mM for 72 h. First, cells were cultivated at L-phenylalanine
levels representing the physiological state (91 mM), mild PKU
(500 mM) or classical PKU (1200 mM) without the addition of
BH4 to the medium (Fig. 3B). Wild-type PAH activity
showed a trend towards an increase only at clearly pathological
L-phenylalanine concentrations. For R261Q, a steady but stat-
istically not significant increase in enzyme activity was seen
Table 3. Enzyme kinetic parameters at standard L-phenylalanine (1000 mM) and BH4 (75 mM) concentrations calculated from activity landscapes
L-phenylalaninea BH4
b
Vmax (nmol L-tyrosine/min × mg protein) [S]0.5 (mM) hPhe Vmax (nmol L-tyrosine/min × mg protein) [C]0.5 (mM) Km (mM) hBH4
WT 5407+210 145+11 3.3 5222+286 23+2 2.0
F39L 4961+342 115+15 2.7 5669+311 36+3 1.7
I65T 3166+96 161+10 2.7 3277+196 27+3 1.7
R261Q 3041+128 282+18 3.4 4693+598 66+17
P275L 3204+126 112+8 2.6 3022+179 36+3 2.8
P314S 1650+91 76+9 1.8 991+25 24+1 5.2
V388M 5639+112 140+6 2.7 5895+236 26+2 1.8
Y414C 2895+206 120+17 2.4 2148+203 28+4 2.6
Y417H 4434+247 111+10 3.6 3011+93 23+1 2.5
Steady-state kinetic parameters of variant tetrameric MBP–PAH fusion proteins determined by direct in-well activity measurements. Data were analyzed using the
F-test for model comparison and the kinetic parameters of the best-fitting model (cooperative versus non-cooperative) were calculated. Vmax and the apparent
affinities for L-phenylalanine (S0.5) and BH4 (C0.5, Km) as well as the Hill coefficient (h) as a measure of cooperativity are shown. Values are given as mean+SEM
of three independent measurements.
aEnzyme kinetic parameters determined at variable L-phenylalanine concentrations (0–1000 mM) and standard BH4 concentration (75 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
bEnzyme kinetic parameters determined at variable BH4 concentrations (0–125 mM) and standard L-phenylalanine concentration (1000 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
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upon increasing substrate concentrations in the medium (35+5
to 52+9 pmol L-tyrosine/min × mg total protein). For Y414C,
residual activity was very low without any effect of increasing
L-phenylalanine concentrations.
To further evaluate the mutual impact of the substrate and
the cofactor on enzyme activity in the eukaryotic system, 40
or 75 mM BH4 were added to the medium at L-phenylalanine
concentrations of 91 or 1200 mM, respectively (Fig. 3C).
Figure 3. Cofactor action on PAH function in respect of kinetic behavior and the chaperone effect. (A) Enzyme activity of eukaryotic expressed PAH assayed at
varying substrate concentrations. Enzyme activities in cell lysates of HEK293 cells stably transfected with wild-type PAH, R261Q or Y414C were determined at
varying L-phenylalanine concentrations (0–1000 mM) and a fixed BH4 concentration (75 mM). (B) Effect of varying intracellular phenylalanine concentrations on
functionally active PAH. PAH enzyme activity in HEK293 cell lysates expressing wild-type PAH, R261Q or Y414C was determined at standard assay concen-
trations (1000 mM L-phenylalanine and 75 mM BH4) after prior incubation with different L-phenylalanine concentrations (black, 91 mM; dark gray, 500 mM; white,
1200 mM) for 72 h. (C) Mutual impact of varying substrate and cofactor concentrations on functionally active PAH. Cells stably expressing wild-type PAH,
R261Q or Y414C were cultivated at different phenylalanine (left column, 91 mM; right column, 1200 mM) and BH4 concentrations (white, 0; dark gray,
40 mM; and black, 75 mM). PAH enzyme activities were analyzed at standard assay conditions. PAH activities are given as mean+SEM of three independent
experiments. Significant differences in enzyme activities were calculated using one-way ANOVA and Dunnett’s multiple comparison test (ns, not significant;
∗P , 0.05; ∗∗P , 0.01).
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Interestingly, at physiological L-phenylalanine concentrations
(91 mM), the addition of 40 and 75 mM BH4 induced a trend
towards increased enzyme activity of wild-type PAH (57+
9 to 98+ 22 and 105+ 18 pmol L-tyrosine/min × mg total
protein), whereas the opposite effect was observed at elevated
L-phenylalanine concentrations (1200 mM L-phenylalanine,
108+ 37 to 40+ 7 and 35+ 5 pmol L-tyrosine/min × mg
total protein). For the variant R261Q, the addition of 40 mM
BH4 at physiological L-phenylalanine concentrations resulted
in a significant increase in enzyme activity (35+ 5 to 86+
17 pmol L-tyrosine/min × mg total protein), but the inhibitory
effect at elevated L-phenylalanine concentrations as seen for
the wild-type was not observed. At physiological
L-phenylalanine concentrations, the variant Y414C showed
low residual enzyme activity with only a minor increase
upon the addition of 40 mM BH4. Interestingly, at high
L-phenylalanine concentrations (1200 mM), the addition of 40
but not 75 mM BH4 led to a significant increase in residual
enzyme activity (23+ 4 pmol L-tyrosine/min × mg total
protein) achieving as much as 40% of the wild-type level.
Taken together, findings from the prokaryotic system
depicted by activity landscapes were substantiated in the
eukaryotic environment. Also in this system probing lysates
of cultured cells, the mutual impact of different
L-phenylalanine and BH4 concentrations on enzyme activity
varied among different PAH variants with substrate inhibition
for the wild-type as well as constant activity levels for R261Q
also at very high L-phenylalanine concentrations. Residual
enzyme activity of Y414C was substantially lower in cell
culture when compared with the specific activity of the recom-
binant protein, but enzyme function was rescued by the
addition of BH4. This may point to impaired protein stability
in the eukaryotic environment and a stabilizing pharmacologi-
cal chaperone effect by BH4.
The mutual impact of substrate and cofactor
concentrations on results from BH4 loading tests
performed in PAH deficient patients
So far, data pointed to a simultaneous dependency of PAH func-
tion from available substrate and cofactor concentrations. After
having confirmed results from the prokaryotic system in the
eukaryotic system, we aimed to investigate whether our obser-
vations may be transferred to the human situation by analyzing
data from BH4-loading tests performed in patients with PAH
deficiency. To address this issue, we collected data of patients
homozygous or functionally hemizygous for the mutations
F39L, I65T, R261Q or Y414C, that underwent a BH4-loading
test with a dose of 20 mg/kg body weight and a duration of at
least 24 h from the literature (19,33–37) and from the
BIOPKU database (www.biopku.org). First, we compiled the
course of blood phenylalanine values within 24 h after a single
dose of BH4 as a function of initial blood phenylalanine concen-
trations. For all mutations analyzed, different blood phenyl-
alanine concentrations at the beginning of the test led to
differences in the extent of BH4 responsiveness, i.e. the
percent decrease in blood phenylalanine after drug adminis-
tration. Patients carrying the mutations F39L, I65T and
Y414C showed a peak level of BH4 responsiveness below an
initial blood phenylalanine concentration of 500 mM (Fig. 4A).
In the presence of F39L and I65T increasing initial blood
phenylalanine concentrations were associated with a decrease
in BH4 responsiveness. While patients with F39L still displayed
positive response at 1000 mM phenylalanine (.30% decrease in
blood phenylalanine), those carrying I65T did not show a drug
response when initial blood phenylalanine concentrations
were .800 mM. The mutation Y414C led to inconsistent
response to BH4 with maximum responsiveness at initial
blood phenylalanine concentrations up to 750 mMphenylalanine
and at 1000 mM phenylalanine. In general, patients bearing the
mutation Y414C showed a high degree in BH4 responsiveness
with the lowest response remaining within the range of 30%
decrease in blood phenylalanine.
Patients bearing the mutation R261Q showed strong incon-
sistencies in BH4 responsiveness with some patients display-
ing high levels of responsiveness (.60% decrease of blood
phenylalanine) and others no response at all (Fig. 4B). To
investigate the basis of these inconsistencies, we analyzed
the impact of both the genotype on BH4 response and of
phenylalanine concentrations on different genotypes compris-
ing the R261Q mutation. The decrease in blood phenylalanine
concentrations was significantly stronger in individuals carry-
ing the R261Q mutation in the homozygous state (median,
37.5%) than those carrying it in the functional hemizygous
state (median, 6.5%). However, among homozygous patients,
some were responders and some were not, whereas all func-
tionally hemizygous patients had to be classified as non-
responders. Interestingly, the level of initial blood phenyl-
alanine did not allow differentiating either homozygous
responders from homozygous non-responders or homozygotes
from functional hemizygotes.
In addition to the influence of initial blood phenylalanine
concentrations on BH4 response, we analyzed the impact of
the genotype on BH4 dose response to investigate the
optimal PAH working range in vivo. Literature data providing
information on BH4 dosage revealed clear differences for
patients homozygous for R261Q, patients homozygous for
Y414C and those compound heterozygous for these two
mutations (Fig. 4C). In the presence of the mutation R261Q,
the percent decrease in blood phenylalanine levels remained
nearly unchanged for the range of BH4 dosages between 10
and 30 mg/kg body weight. In contrast, patients bearing the
mutation Y414C showed a gain in BH4 response with increas-
ing BH4 doses (5–20 mg/kg body weight). Interestingly,
patients compound heterozygous for R261Q and Y414C
showed an intermediate response with respect to the BH4
dosage administered (10–20 mg/kg body weight) when com-
pared with patients homozygous for these mutations.
As a conclusion, in vivo PAH activity is a function of the
phenylalanine substrate and the BH4 cofactor as well as the
patient’s genotype. Hence, enzyme function in the individual
patient at a given time point is the resultant of the metabolic
state and the dosage of cofactor treatment both in turn deter-
mined by the underlying mutations.
DISCUSSION
Regulation of PAH activity is essentially governed by the
abundance of the phenylalanine substrate and the BH4
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cofactor. The supply of substrate, e.g. upon food intake,
induces enzyme activation and subsequently full catalytic
activity. In contrast, at low blood phenylalanine levels, e.g.
under fasting conditions, BH4-induced PAH inhibition pre-
vents from undue elimination of the essential amino acid
phenylalanine. Thus, it is the ratio of phenylalanine to BH4
that determines activation and inhibition of the enzyme.
However, the concentration of BH4 in the liver cell is held
rather constant, whereas phenylalanine levels undergo
substantial fluctuations in function of the metabolic state
and—in the presence of PAH deficiency—of the underlying
genotype. While treating patients with BH4 we intervene in
this system without disposing of profound knowledge concern-
ing the effect of shifts of the substrate-to-cofactor ratio. In the
work presented here, we first wanted to apply the newly devel-
oped real-time fluorescence-based PAH enzyme activity assay
to identify the optimal working range of the enzyme with
respect to these substances. Secondly, we aimed to analyze
Figure 4. Evaluation of BH4 responsiveness in PAH-deficient patients. (A) The impact of the genotype and of initial blood phenylalanine concentrations on BH4
response. The graphs show the percent decrease in blood phenylalanine levels 24 h after a single dose of BH4 (20 mg/kg bw) in patients homozygous or func-
tional hemizygous for the mutations F39L (n ¼ 3), I65T (n ¼ 5) or Y414C (n ¼ 10) as a function of different blood phenylalanine values at the beginning of the
test. The horizontal dashed line indicates 30% decrease in blood phenylalanine concentrations, the arbitrary criterion of BH4 responsiveness. The vertical dashed
line shows the initial blood phenylalanine concentration, above which BH4 leads to a blood phenylalanine decrease of ,30%. (B) BH4 responsiveness in patients
carrying the mutation R261Q (n ¼ 28). (Left) Percent decrease in blood phenylalanine 24 h after a single dose of BH4 (20 mg/kg bw) as a function of initial
blood phenylalanine values in patients homozygous or functional hemizygous for the R261Q mutation. (Middle) Percent decrease in blood phenylalanine
24 h after a single dose of BH4 (20 mg/kg bw) in patients carrying the R261Q mutation in the homozygous state (n ¼ 22) in comparison to functional hemi-
zygotes (n ¼ 6). The boxes show the interquartile ranges (25th to 75th percentiles), the horizontal black bars represent the median, the bars indicate the
range. Significance is indicated (∗∗P, 0.01, unpaired Student’s t-test). (Right) Percent decrease in blood phenylalanine concentrations in function of initial
blood phenylalanine values in homozygous responders (n ¼ 13) and non-responders (n ¼ 9) as well as functional hemizygous patients (n ¼ 6) displaying the
mutation R261Q. (C) The impact of the genotype on BH4 dose response. Percent decrease in blood phenylalanine 24 h after a single application of BH4 in
different dosages in patients homozygous for R261Q (n ¼ 24) (left), homozygous for Y414C (n ¼ 10) (middle) or compound heterozygous for R261Q/
Y414C (n ¼ 3) (right).
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the influence of changes in the phenylalanine-to-BH4 ratio on
PAH function of the wild-type and variant enzymes.
Analyses of wild-type PAH revealed two interesting new
findings. In addition to the well-known enzyme inhibition by
the substrate, cofactor inhibition was identified by the exten-
sion of the enzyme activity assay to much higher cofactor con-
centrations. Moreover, we learned that with increasing
phenylalanine concentrations, more BH4 is needed to maintain
the same level of PAH activity. Still, it has to be considered
that the full range of substrate and cofactor concentrations
applied in our novel assay provided new insights into theoreti-
cal aspects of PAH enzymology, but it is well beyond physio-
logical levels. However, our approach allowed for detailed
visualization and better understanding of conditions corre-
sponding to those occurring at the edges of classical pathologi-
cal situations in PKU patients and in the therapeutic context
upon cofactor treatment.
The optimal working range of the wild-type enzyme
occurred at phenylalanine concentrations of 250–500 mM.
From a physiological point of view, this appears reasonable,
since upon food intake liver phenylalanine concentrations
are expected to reach levels up to 500 mM rather than around
1000 mM, the phenylalanine concentration at which standard
PAH enzyme activity assays are performed (2,38). Our
results showed that the optimal BH4 concentration for PAH
enzyme activity is 100 mM, while standard PAH activity
assays are run at 75 mM BH4 (2,38). In any case, the physio-
logical cellular BH4 concentration in the liver is by far
lower (8.5 mM) (26), implying that the cell has always to
be considered BH4 deficient in view of the enzymatic task.
Yet, in light of the inhibitory potential of BH4 on the
enzyme, a cellular cofactor concentration significantly below
the Km value of 23 mM reduces inhibition when activity is
needed, i.e. at phenylalanine concentrations above the physio-
logical range. The trade-off between these two tasks is
balanced by a 6-fold higher affinity of the enzyme toward
the cofactor (Km, 23 mM) than toward the substrate (S0.5,
145 mM). As a consequence, PAH binds BH4 and phenyl-
alanine at a ratio of 0.5 at 100 mM blood phenylalanine (inhi-
bition) when compared with 0.09 at 561 mM blood
phenylalanine (no inhibition). These theoretical assumptions
are corroborated by previous in vivo 13C-phenylalanine oxi-
dation tests performed in a PKU mouse model (39). In the
euphenylalaninemic state, a hypothetical BH4 deficiency is
overruled by an inhibitory effect following the application of
BH4 in wild-type animals. However, in hyperphenylalanine-
mia phenotypes, the administration of BH4 leads to an
immediate increase in 13C-phenylalanine oxidation. In view
of a time to effect of ,5 min, this has to be considered inde-
pendent of a pharmacological chaperone effect and rather
points to compensation of BH4 deficiency in this metabolic
state. Comparable studies in humans addressing phenylalanine
concentrations, BH4 concentrations, the effect of BH4 in
healthy individuals, time to onset of action and effect duration
would be of interest, but have not yet been performed.
Next, we investigated the effect of selected missense
mutations in the PAH gene on the optimal working range of
the enzyme. In general, activity landscapes of the wild-type
and variant PAH proteins displayed comparable patterns
with rather high residual enzyme activity and a limited area
of maximum activity. More detailed analyses, however,
revealed various alterations with respect to the extension and
position of the optimal working range in the coordinates of
substrate and cofactor concentrations. Most variant proteins
were in need of more BH4 to achieve peak activity (F39L,
I65T, R261Q, P275L, Y417H, Y414C). For two variants
(R261Q and P275L), maximum activity was determined at
markedly higher phenylalanine concentrations (842 and
1293 mM). In contrast, three variants (P314S, Y414C and
Y417H) presented a narrowed optimal working range that
was shifted to lower phenylalanine concentrations when com-
pared with the wild-type.
Two of these mutations, R261Q and Y414C, are frequent,
but inconsistently associated with BH4 responsiveness
(17,34–37). The analysis of activity landscapes provided
first evidence for an impact of the metabolic state on variant
PAH function. R261Q displayed marked reduction in
enzyme activity at phenylalanine concentrations in the thera-
peutic range below 240 mM giving rise to the hypothesis that
patients bearing this mutation in the homozygous or functional
hemizygous state would not benefit from a restrictive dietary
regime. On the other hand, the mutation Y414C that induces
a shift of activity to lower phenylalanine concentrations
would require a rather strict metabolic adjustment with low
blood phenylalanine values to achieve optimized PAH
activity. Thus, observations from the analysis of activity land-
scapes could be of importance for a deeper understanding of
inconsistent results from BH4 loading tests or some disap-
pointing experiences upon BH4 treatment of our patients. To
perform a further step in this direction, we carried out cell
culture experiments and analyzed data from BH4 loading
tests performed in PKU patients.
Data extracted from activity landscapes were reproduced in
the setting of stably transfected cells. Having gained insights
into the mutual impact of varying substrate and cofactor con-
centrations on PAH activity, we were then interested in
answering the question of how changes in the metabolic
state would affect the effective PAH concentration, that is,
the intracellular amount of functional PAH enzyme available
for phenylalanine conversion. Since BH4 has been classified
as a pharmacological chaperone, i.e. a stabilizing compound
that helps to overcome PAH degradation in the cell, it is
expected to raise the amount of PAH in cell culture. In
addition, we had previously shown that the effective PAH con-
centration is influenced by changes in the
phenylalanine-to-BH4 ratio in the mouse (12). To address
these issues in cell culture, we mimicked physiological
(euphenylalaninemic) and pathologic (hyperphenylalanine-
mic) conditions representing classical PKU. The supplemen-
tation of BH4 induced diverse results in the presence of
R261Q and Y414C, respectively. BH4 was beneficial for cat-
alytic PAH function of the R261Q variant particularly at low
phenylalanine levels, whereas a significant increase in PAH
enzyme activity reflecting an increase in the effective PAH
amount was observed for Y414C under PKU conditions. Inter-
estingly, the therapeutic range for BH4 was narrow for Y414C,
a finding confirming the observations from the activity land-
scapes.
As a next step, we aimed to verify the clinical relevance
of our findings and analyzed the effect of different substrate
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and cofactor concentrations on the outcome of single dose
BH4-loading tests in individuals carrying different PAH gen-
otypes. In clinical routine, the initial phenylalanine concen-
tration at the beginning of the BH4-loading test is not
expected to significantly affect the outcome of the test. In
general, only a minimum phenylalanine concentration of
400 mM is considered to be required for reliable test
results. Surprisingly, data from BH4 loading tests available
in the BIOPKU database and in the literature (19,33–
37,40) does not confirm this view. We learned that patients
carrying one of the mutations F39L, I65T or Y414C in
either a homozygous or a functional hemizygous state
show substantially different responses to the BH4-loading
test in function of the phenylalanine concentration at the
beginning of the test. For example, in presence of the
mutation I65T, the response may vary from 60% at
500 mM phenylalanine to 0% at 1500 mM blood phenyl-
alanine. This is a new finding that may undermine our
trust in current BH4-loading test protocols. Our results
may, for instance, allow for the hypothesis that patients car-
rying the I65T mutation are at risk to show false negative
test results at phenylalanine concentrations .750 mM. In
the case of the R261Q mutation, phenylalanine concen-
trations did not significantly influence test results
(Fig. 4B). However, the kind of genotype significantly
affected BH4 responsiveness with carriers of the R261Q
mutation in the homozygous state showing a higher
response (37.5% decrease in phenylalanine after BH4
loading) than individuals with the mutation in the functional
hemizygous state (6.5% decrease). Further analysis revealed
that none of the patients carrying the R261Q mutation in
combination with a null mutation met the criterion of BH4
responsiveness of 30% decrease of phenylalanine concen-
trations, whereas 12 out of 21 patients with a homozygous
genotype did and 9 out of 21 patients did not. Similar
observations were recently reported in 27 Turkish PKU
patients with a homozygous R261Q genotype and variable
clinical phenotypes (11% mild hyperphenylalaninemia,
67% mild PKU, 22% classic PKU), from which only
39.1% were BH4 responsive (22). Taken together, our
results show that the outcome of a BH4-loading test may
much more vary in function of individual test circumstances
than previously assumed. Unfortunately, it has to be
expected that this is true for a number of mutations and
in view of the lifelong consequences for our patients
arising from the initial classification of being a responder
or not it has to be emphasized that with the knowledge
available today results from single-loading tests are not suf-
ficient to determine BH4 responsiveness in patients with
PAH deficiency.
Last, we analyzed the effect of BH4 dosage on the results of
single BH4-loading tests. Since 10 years, a dosage of 20 mg/
kg body weight is internationally recommended (11,28,29,41).
However, in some centers and countries, this recommendation
may not be followed. In homozygous R261Q patients, the
dosage of BH4 (10, 20 and 30 mg/kg body weight) did not
seem to influence test results (26, 27 and 25% decrease,
respectively). In presence of the Y414C mutation, increasing
BH4 dosages increased BH4 responsiveness in terms of
percent decrease of blood phenylalanine after BH4 application.
Interestingly, compound heterozygous patients carrying both
the R261Q and the Y414C mutation also showed a dose
dependency of response, but to a lower extent than homozy-
gous Y414C patients.
In summary, we developed a rapid PAH enzyme activity
assay allowing for a much higher throughput than previous
assays and for detailed analysis of a broad range of substrate
and cofactor concentrations on PAH enzyme kinetics. This
enabled new insights into optimal PAH working range at phys-
iological, pathological and therapeutic conditions. As to
enzyme kinetics, two main conclusions can be drawn from
our experimental work: phenylalanine concentrations for
optimal working range of PAH are lower, whereas BH4 con-
centrations for optimal PAH activity are higher than pre-
viously assumed. The validity of our observations was
substantiated and expanded by the fact that we were able to
translate data from the prokaryotic system into the eukaryotic
cell culture system and into patient data. Of relevance for the
clinical context, we revealed a significant impact of the geno-
type, substrate concentrations and BH4 dosage on the assess-
ment of BH4 responsiveness.
Since the discovery of the pharmacological effect of BH4 in
patients with PAH deficiency (5), the scientific community
discusses possible mechanisms of BH4 responsiveness in
PKU. The initial concept was kinetic action, in particular the
hypothesis that PAH gene mutations lead to decreased affinity
of the variant protein to the cofactor, that is overcome by the
administration of pharmacological doses of BH4. Kinetic
studies using the recombinant PAH protein revealed that this
is true only in rare instances (2,32,42). Subsequent work
moved the concept away from kinetic effects toward the
view of BH4 acting as a molecular chaperone by increasing
the stability of partially misfolded PAH proteins and by this
the effective intracellular concentration of functional PAH
enzyme (3,4,12). A deeper view into PAH enzyme kinetics
using a technology that allows for the analysis of a broad
range of substrate and cofactor concentrations on PAH activity
now showed that besides the indubitable chaperone effect,
kinetic aspects also have to be taken into account. Thus, we
may now put forward the view of both concepts being of rel-
evance for the diagnosis and the treatment of patients with
PAH deficiency. The diagnostic loading test with BH4 or long-
term BH4 treatment has to be seen in the light of the fact that
short-term supply of BH4 can compensate for latent BH4
deficiency as to optimal catalytic function (kinetic effect),
whereas long-term treatment with pharmacological doses of
BH4 increases the stability of PAH and by this the amount
of metabolically active enzyme (chaperone effect). In
addition, individual mutations may shift the impact of one or
the other therapeutic effect.
For daily clinical routine, this underscores the need for even
more standardized and at the same time individualized test
procedures including detailed documentation of phenylalanine
concentrations before the BH4 load and the awareness that the
metabolic status of the patient will influence the outcome of
the test. In non-responders with suggestive genotypes, re-
petition of the loading test at different initial phenylalanine
concentrations may help rule out false negative results. More-
over, we suggest to combine short-term BH4 loading tests
(assessment of kinetic effects) and long-term BH4 treatment
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tests (assessment of chaperone effects) with in vivo 13C-
phenylalanine oxidation tests (assessment of the effect of
BH4 on in vivo PAH enzyme activity) (11,43). The test is non-
invasive, innocuous, easy to perform and may add important
information about an individual’s response to the drug at a
functional level.
In conclusion, our work pinpoints the importance of geno-
typing PKU patients even in clinical routine and underscores
the need for more personalized testing procedures addressing
individual patient characteristics, the metabolic state and the
dosage of the test compound to safely identify BH4 respon-
siveness in PAH-deficient patients.
MATERIALS AND METHODS
Patients and mutations
Mutations previously identified in BH4 responsive patients
(4,11) were analyzed in terms of the effect of various substrate
(L-phenylalanine) and cofactor (BH4) concentrations on PAH
enzyme activity. The mutations mapped to the regulatory
domain (F39L, I65T), the catalytic domain (R261Q, P275L,
P314S, V388M) or to the dimerization motif of the oligomer-
ization domain (Y414C, Y417H). Forty-six patients homozy-
gous and functional hemizygous for the mutations F39L
(n ¼ 3), I65T (n ¼ 5), R261Q (n ¼ 28) and Y414C (n ¼ 10)
were identified performing a comprehensive literature survey
and by extracting data from the BIOPKU database (www.
biopku.org). Patients were included in the analysis, when
data on a BH4-loading test using 20 mg/kg body weight and
blood phenylalanine concentrations over a period of at least
24 h were available. In addition, the effect of different BH4
dosages, ranging from 5 to 30 mg/kg body weight, on the
course of blood phenylalanine concentrations was analyzed
(16,19,34,35,37).
Expression and purification of recombinant PAH proteins
The cDNA of human PAH (EST clone obtained from ima-
Genes, formerly RZPD, Germany) was cloned into the prokar-
yotic expression vector pMAL-c2E (New England Biolabs)
encoding an N-terminal maltose-binding protein (MBP) tag.
PAH mutants were constructed by site-directed mutagenesis
as previously described (2). Expression plasmids containing
the wild-type PAH and variants were transformed to Escheri-
chia coli DH5a. Expressed proteins were purified by affinity
chromatography (MBPTrap, GE Healthcare) followed by
size-exclusion chromatography using a HiLoad 26/60 Super-
dex 200 column (GE Healthcare) on an A¨KTAxpress system
(2). Obtained tetramers of the fusion proteins were collected
and protein concentrations were determined spectrophotome-
trically using 1280 (1mg/ml) ¼ 1.63.
PAH activity assay
Enzyme activity of the recombinantly expressed PAH. The
multi-well PAH activity assay and data evaluation were per-
formed as previously described (27) with modifications.
L-phenylalanine and 22.35 mM Na HEPES, pH 7.3, were
added to all wells of a 96-well plate with different volumes.
This resulted in 12 columns of varying L-phenylalanine con-
centrations (0–4000 mM). A reaction buffer containing 1 mg/
ml catalase (Sigma-Aldrich), 10 mM ferrous ammonium
sulfate (Sigma-Aldrich) and the tetrameric MBP–PAH
fusion protein (0.01 mg/ml) was prepared and injected in all
96 wells. After pre-incubation with L-phenylalanine for 5–
20 min, the reaction was initiated by the addition of variable
concentrations of BH4 (6R-L-erythro-5,6,7,8-tetrahydrobiop-
terin, Cayman Chemical) (0–500 mM) stabilized in 100 mM
dithiothreitol (DTT; Fluka Chemie). PAH activity was deter-
mined at 258C and 90 s measurement time per well. Using
sets of 16 wells and 10 measurement cycles per set, total
measurement time for all 96 wells was 22 min. Substrate pro-
duction was measured by the detection of the increase in
L-tyrosine fluorescence intensity, at an excitation wavelength
of 274 nm and an emission wavelength of 304 nm, using a flu-
orescence photometer (FLUOstar OPTIMA, BMG Labtech)
and assayed as triplicates. Measured fluorescence intensity
signals were corrected by the inner filter effect of BH4 for
every BH4 concentration added. Enzyme activity measure-
ments were quantified by the measurement of L-tyrosine stan-
dards (0–200 mM) before each experiment, and fluorescence
intensity was converted to enzyme activity units (nmol
L-tyrosine/min × mg protein). Data were analyzed by non-
linear regression analysis using the Michaelis–Menten or the
Hill kinetic model after comparison of model-fitting using
the F-test (GraphPad Prism 4.0c) (27). All concentrations
mentioned refer to the final concentration in a 202 ml reaction
mixture.
Standard PAH activity assay of eukaryotic expressed PAH.
PAH enzyme activity was determined as previously described
(2,39) with modifications. Twenty microliters of total lysates
obtained from cell culture were pre-incubated with 1000 mM
L-phenylalanine and 1 mg/ml catalase (Sigma-Aldrich) for
5 min (258C) in 15 mM Na HEPES pH 7.3, followed by
1 min incubation with 10 mM ferrous ammonium sulfate
(Sigma-Aldrich). The reaction was initiated by the addition
of 75 mM BH4 stabilized in 2 mM DTT, carried out for
60 min at 258C and stopped by acetic acid followed by
10 min incubation at 958C. All concentrations mentioned
refer to the final concentration in a 100 ml reaction mixture.
The amount of L-tyrosine production was measured and quan-
tified by HPLC, assayed as duplicates. Three independent
experiments were performed.
PAH activity landscapes
The data set of multi-well enzyme activity assayed in a 12 × 8
matrix corresponding to 12 different L-phenylalanine concen-
trations ranging from 0 to 4000 mM (columns) at 8 BH4 con-
centrations ranging from 0 to 500 mM (rows) was loaded into
non-linear regression analysis software (GraphPad Prism
4.0c). A non-linear regression analysis was performed for
each column of the data matrix in order to extend the sparse
data set for BH4 concentrations from 8 measured to 400
newly calculated values following a substrate inhibition
curve. This resulted in a 12 × 400 matrix of activity values.
For further calculation of the data and for the creation of land-
scapes, this data matrix was exported to the free software
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package R (www.r-project.org). In order to draw a smooth
surface of the landscape, we used the function interp.loess
from additional R package tgp (http://cran.r-project.org/
web/packages/tgp/index.html), which interpolates between
two data points by using local polynomial regression fitting
to find a function between them. This resulted in an increase
in data from an originally measured 12 × 8 (96-well format)
over a 12 × 400 to a 400 × 400 data set. This grid was
then depicted as a smooth landscape plot using the function
image.plot from package fields (http://cran.r-project.org/
web/packages/fields/index.html). To facilitate calculation of
landscapes, a script was written accepting comma-separated
files and automatically coloring landscapes depending on the
measured and interpolated fluorescence intensities.
Stable expression of PAH in HEK293
Stably transfected cells were generated using the Flp-In
system (Invitrogen) according to the manufacturer’s protocol.
The Flp-In-293 cell line was maintained in basic DMEM
(PAA Laboratories) supplemented with L-glutamine, high
glucose (4.5 g/l), 10% fetal bovine serum (GIBCO), 1% anti-
biotics (Antibiotic-Antimycotic; PAA) and 100 mg/ml Zeocin
(Invitrogen). Cells were stably transfected with pEF5/FRT/
V5-DEST cDNA constructs coding for the wild-type, R261Q
or Y414C PAH, respectively. Positive clones were selected
and maintained in medium containing 150 mg/ml hygromycin
B (Invitrogen).
For all further experiments, cells were cultured for 72 h
under three different conditions: (i) basic RPMI 1640
medium (91 mM phenylalanine, PAA Laboratories) sup-
plemented with stable glutamine, 10% fetal bovine serum
(GIBCO), 1% antibiotics (Antibiotic-Antimycotic; PAA) and
150 mg/ml of hygromycin B, (ii) basic medium (as described
above) with 500 mM phenylalanine, and (iii) basic medium
with 1200 mM phenylalanine. Additionally, culture conditions
were modified by adding 40 or 75 mM BH4, respectively.
Culture medium was changed every 24 h. Cells were harvested
and lysed by three freeze-thaw cycles in a Tris–KCl lysis
buffer (0.03 M Tris, 0.2 M KCl, pH 7.2) containing protease
inhibitors (Roche), followed by 20 min centrifugation at
3000 rcf, 48C. Recovered supernatants were subsequently
used for activity assays.
Statistics
Group mean values were compared by Student’s unpaired
two-tailed t-test. Eukaryotic PAH activities following BH4
treatment were analyzed by one-way ANOVA and Dunnett’s
post-test. Statistical analyses were performed using GraphPad
Prism 4.0c (GraphPad Software).
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